Mitch Report

date generated: 2022-05-10

Background

Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch

Input profiles

Here is the first few lines of the input profile.

##                   KO        drug
## 5_8S_rRNA -0.4520464  13.3743116
## 7SK       -2.2982399   8.2273688
## A1BG      -3.3008939   6.5686329
## A1BG-AS1   0.3211569   2.0364019
## A1CF      -0.7352419  -0.3353024
## A2M       30.2687300 -19.6842209

Here are some metrics about the input data profile:

Profile metrics

	Profile metrics
num_genes_in_profile	24473
duplicated_genes_present	0
num_profile_genes_in_sets	8850
num_profile_genes_not_in_sets	15623
profile_pearson_correl	0.06908
profile_spearman_correl	0.09129

Here is a plot of the input profiles. Note the dynamic ranges.

Here is the contour plot of the profile including all detected genes.

Input genesets

Here are some metrics about the gene sets used: GMT file of genesets: ReactomePathways.gmt

Gene sets metrics

	Gene sets metrics
num_genesets	2512
num_genesets_excluded	1047
num_genesets_included	1465

Gene sets by quadrant

Number of significant gene sets (FDR<0.05)= 928

Interactive enrichment scatterplot

All sets with FDR<0.05. Try hovering over the points.

Top N sets irrespective of FDR. Try hovering over the points.

A heatmap of S values for top results

A plot of effect size versus significance

Significance is the -log2(p.adjustMANOVA) and effect size is the s.dist which is the hypotenuse of the s scores.

Results table

Top N= 50 gene sets

set	setSize	pMANOVA	p.adjustMANOVA	s.dist	s.KO	s.drug	p.KO	p.drug
CLEC7A (Dectin-1) induces NFAT activation	11	3.38e-06	1.31e-05	0.897	-0.308	-0.842	7.70e-02	1.30e-06
Cohesin Loading onto Chromatin	10	1.94e-05	6.18e-05	0.865	-0.196	-0.842	2.83e-01	3.98e-06
MET activates RAP1 and RAC1	11	1.26e-05	4.27e-05	0.856	-0.399	-0.758	2.20e-02	1.35e-05
Syndecan interactions	19	5.07e-10	4.45e-09	0.844	0.216	-0.816	1.04e-01	7.21e-10
Peptide chain elongation	87	2.79e-43	3.40e-41	0.830	-0.422	0.715	9.35e-12	8.26e-31
Viral mRNA Translation	87	3.07e-43	3.46e-41	0.830	-0.420	0.715	1.17e-11	7.10e-31
APC truncation mutants have impaired AXIN binding	14	1.34e-06	5.64e-06	0.828	-0.348	-0.752	2.43e-02	1.10e-06
AXIN missense mutants destabilize the destruction complex	14	1.34e-06	5.64e-06	0.828	-0.348	-0.752	2.43e-02	1.10e-06
Signaling by AMER1 mutants	14	1.34e-06	5.64e-06	0.828	-0.348	-0.752	2.43e-02	1.10e-06
Signaling by APC mutants	14	1.34e-06	5.64e-06	0.828	-0.348	-0.752	2.43e-02	1.10e-06
Signaling by AXIN mutants	14	1.34e-06	5.64e-06	0.828	-0.348	-0.752	2.43e-02	1.10e-06
Truncations of AMER1 destabilize the destruction complex	14	1.34e-06	5.64e-06	0.828	-0.348	-0.752	2.43e-02	1.10e-06
Laminin interactions	23	1.23e-11	1.39e-10	0.827	0.269	-0.782	2.58e-02	8.23e-11
ERKs are inactivated	13	4.26e-06	1.60e-05	0.821	-0.333	-0.751	3.74e-02	2.76e-06
Receptor Mediated Mitophagy	11	2.63e-05	8.10e-05	0.819	-0.776	-0.263	8.30e-06	1.31e-01
S33 mutants of beta-catenin aren’t phosphorylated	15	7.71e-07	3.45e-06	0.811	-0.260	-0.768	8.08e-02	2.62e-07
S37 mutants of beta-catenin aren’t phosphorylated	15	7.71e-07	3.45e-06	0.811	-0.260	-0.768	8.08e-02	2.62e-07
S45 mutants of beta-catenin aren’t phosphorylated	15	7.71e-07	3.45e-06	0.811	-0.260	-0.768	8.08e-02	2.62e-07
Signaling by CTNNB1 phospho-site mutants	15	7.71e-07	3.45e-06	0.811	-0.260	-0.768	8.08e-02	2.62e-07
Signaling by GSK3beta mutants	15	7.71e-07	3.45e-06	0.811	-0.260	-0.768	8.08e-02	2.62e-07
T41 mutants of beta-catenin aren’t phosphorylated	15	7.71e-07	3.45e-06	0.811	-0.260	-0.768	8.08e-02	2.62e-07
Mucopolysaccharidoses	11	1.36e-05	4.58e-05	0.799	0.756	-0.258	1.41e-05	1.38e-01
Defective EXT1 causes exostoses 1, TRPS2 and CHDS	13	1.43e-06	5.93e-06	0.799	0.358	-0.714	2.55e-02	8.23e-06
Defective EXT2 causes exostoses 2	13	1.43e-06	5.93e-06	0.799	0.358	-0.714	2.55e-02	8.23e-06
Establishment of Sister Chromatid Cohesion	11	5.26e-05	1.53e-04	0.795	-0.298	-0.737	8.65e-02	2.30e-05
Eukaryotic Translation Termination	91	2.19e-41	1.89e-39	0.794	-0.402	0.684	3.27e-11	1.32e-29
Eukaryotic Translation Elongation	92	1.82e-41	1.67e-39	0.790	-0.412	0.674	8.16e-12	4.97e-29
Formation of a pool of free 40S subunits	99	1.26e-44	1.68e-42	0.789	-0.444	0.652	2.03e-14	3.21e-29
Signaling by Hippo	20	1.90e-08	1.19e-07	0.781	-0.162	-0.764	2.09e-01	3.23e-09
Synthesis of PIPs at the early endosome membrane	16	1.36e-06	5.69e-06	0.773	-0.298	-0.713	3.91e-02	7.87e-07
Synthesis of PIPs at the late endosome membrane	11	1.09e-04	2.94e-04	0.771	-0.383	-0.670	2.78e-02	1.20e-04
HDMs demethylate histones	22	1.14e-08	7.46e-08	0.771	-0.358	-0.683	3.61e-03	2.94e-08
Unwinding of DNA	12	5.50e-05	1.60e-04	0.770	0.603	0.479	2.99e-04	4.02e-03
Activation of RAC1	13	2.04e-05	6.47e-05	0.770	-0.340	-0.690	3.36e-02	1.63e-05
Selenocysteine synthesis	91	1.38e-38	8.77e-37	0.768	-0.355	0.681	4.60e-09	2.66e-29
Cell-extracellular matrix interactions	16	2.20e-06	8.89e-06	0.766	-0.418	-0.642	3.77e-03	8.63e-06
MET activates PTK2 signaling	18	6.80e-08	3.72e-07	0.765	0.155	-0.749	2.56e-01	3.71e-08
Signaling by PDGFRA extracellular domain mutants	12	4.81e-05	1.41e-04	0.763	-0.263	-0.716	1.14e-01	1.74e-05
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants	12	4.81e-05	1.41e-04	0.763	-0.263	-0.716	1.14e-01	1.74e-05
Beta-catenin phosphorylation cascade	17	8.19e-07	3.66e-06	0.762	-0.273	-0.711	5.12e-02	3.79e-07
tRNA processing in the mitochondrion	20	6.21e-08	3.42e-07	0.755	0.160	0.738	2.16e-01	1.09e-08
Response of EIF2AK4 (GCN2) to amino acid deficiency	99	6.60e-41	5.37e-39	0.755	-0.423	0.625	3.36e-13	5.07e-27
ERK/MAPK targets	22	2.93e-08	1.77e-07	0.751	-0.352	-0.663	4.27e-03	7.08e-08
Non-integrin membrane-ECM interactions	41	1.27e-16	2.25e-15	0.751	0.200	-0.724	2.68e-02	1.00e-15
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)	93	6.86e-38	4.02e-36	0.749	-0.424	0.617	1.55e-12	6.83e-25
Complex I biogenesis	57	8.21e-22	2.23e-20	0.740	-0.123	0.729	1.09e-01	1.49e-21
Defective B4GALT7 causes EDS, progeroid type	18	1.10e-07	5.83e-07	0.739	0.371	-0.639	6.44e-03	2.71e-06
Formation of the ternary complex, and subsequently, the 43S complex	50	7.28e-20	1.67e-18	0.731	-0.501	0.532	8.83e-10	7.23e-11
Signaling by PDGFR in disease	19	5.53e-07	2.59e-06	0.726	-0.198	-0.698	1.35e-01	1.36e-07
MET promotes cell motility	29	1.04e-10	1.03e-09	0.725	-0.011	-0.725	9.19e-01	1.37e-11

---

Results (complete table)

Click HERE to show results for all gene sets

Complete results

set	setSize	pMANOVA	p.adjustMANOVA	s.dist	s.KO	s.drug	p.KO	p.drug
CLEC7A (Dectin-1) induces NFAT activation	11	3.38e-06	1.31e-05	0.8970	-3.08e-01	-0.842000	7.70e-02	1.30e-06
Cohesin Loading onto Chromatin	10	1.94e-05	6.18e-05	0.8650	-1.96e-01	-0.842000	2.83e-01	3.98e-06
MET activates RAP1 and RAC1	11	1.26e-05	4.27e-05	0.8560	-3.99e-01	-0.758000	2.20e-02	1.35e-05
Syndecan interactions	19	5.07e-10	4.45e-09	0.8440	2.16e-01	-0.816000	1.04e-01	7.21e-10
Peptide chain elongation	87	2.79e-43	3.40e-41	0.8300	-4.22e-01	0.715000	9.35e-12	8.26e-31
Viral mRNA Translation	87	3.07e-43	3.46e-41	0.8300	-4.20e-01	0.715000	1.17e-11	7.10e-31
APC truncation mutants have impaired AXIN binding	14	1.34e-06	5.64e-06	0.8280	-3.48e-01	-0.752000	2.43e-02	1.10e-06
AXIN missense mutants destabilize the destruction complex	14	1.34e-06	5.64e-06	0.8280	-3.48e-01	-0.752000	2.43e-02	1.10e-06
Signaling by AMER1 mutants	14	1.34e-06	5.64e-06	0.8280	-3.48e-01	-0.752000	2.43e-02	1.10e-06
Signaling by APC mutants	14	1.34e-06	5.64e-06	0.8280	-3.48e-01	-0.752000	2.43e-02	1.10e-06
Signaling by AXIN mutants	14	1.34e-06	5.64e-06	0.8280	-3.48e-01	-0.752000	2.43e-02	1.10e-06
Truncations of AMER1 destabilize the destruction complex	14	1.34e-06	5.64e-06	0.8280	-3.48e-01	-0.752000	2.43e-02	1.10e-06
Laminin interactions	23	1.23e-11	1.39e-10	0.8270	2.69e-01	-0.782000	2.58e-02	8.23e-11
ERKs are inactivated	13	4.26e-06	1.60e-05	0.8210	-3.33e-01	-0.751000	3.74e-02	2.76e-06
Receptor Mediated Mitophagy	11	2.63e-05	8.10e-05	0.8190	-7.76e-01	-0.263000	8.30e-06	1.31e-01
S33 mutants of beta-catenin aren’t phosphorylated	15	7.71e-07	3.45e-06	0.8110	-2.60e-01	-0.768000	8.08e-02	2.62e-07
S37 mutants of beta-catenin aren’t phosphorylated	15	7.71e-07	3.45e-06	0.8110	-2.60e-01	-0.768000	8.08e-02	2.62e-07
S45 mutants of beta-catenin aren’t phosphorylated	15	7.71e-07	3.45e-06	0.8110	-2.60e-01	-0.768000	8.08e-02	2.62e-07
Signaling by CTNNB1 phospho-site mutants	15	7.71e-07	3.45e-06	0.8110	-2.60e-01	-0.768000	8.08e-02	2.62e-07
Signaling by GSK3beta mutants	15	7.71e-07	3.45e-06	0.8110	-2.60e-01	-0.768000	8.08e-02	2.62e-07
T41 mutants of beta-catenin aren’t phosphorylated	15	7.71e-07	3.45e-06	0.8110	-2.60e-01	-0.768000	8.08e-02	2.62e-07
Mucopolysaccharidoses	11	1.36e-05	4.58e-05	0.7990	7.56e-01	-0.258000	1.41e-05	1.38e-01
Defective EXT1 causes exostoses 1, TRPS2 and CHDS	13	1.43e-06	5.93e-06	0.7990	3.58e-01	-0.714000	2.55e-02	8.23e-06
Defective EXT2 causes exostoses 2	13	1.43e-06	5.93e-06	0.7990	3.58e-01	-0.714000	2.55e-02	8.23e-06
Establishment of Sister Chromatid Cohesion	11	5.26e-05	1.53e-04	0.7950	-2.98e-01	-0.737000	8.65e-02	2.30e-05
Eukaryotic Translation Termination	91	2.19e-41	1.89e-39	0.7940	-4.02e-01	0.684000	3.27e-11	1.32e-29
Eukaryotic Translation Elongation	92	1.82e-41	1.67e-39	0.7900	-4.12e-01	0.674000	8.16e-12	4.97e-29
Formation of a pool of free 40S subunits	99	1.26e-44	1.68e-42	0.7890	-4.44e-01	0.652000	2.03e-14	3.21e-29
Signaling by Hippo	20	1.90e-08	1.19e-07	0.7810	-1.62e-01	-0.764000	2.09e-01	3.23e-09
Synthesis of PIPs at the early endosome membrane	16	1.36e-06	5.69e-06	0.7730	-2.98e-01	-0.713000	3.91e-02	7.87e-07
Synthesis of PIPs at the late endosome membrane	11	1.09e-04	2.94e-04	0.7710	-3.83e-01	-0.670000	2.78e-02	1.20e-04
HDMs demethylate histones	22	1.14e-08	7.46e-08	0.7710	-3.58e-01	-0.683000	3.61e-03	2.94e-08
Unwinding of DNA	12	5.50e-05	1.60e-04	0.7700	6.03e-01	0.479000	2.99e-04	4.02e-03
Activation of RAC1	13	2.04e-05	6.47e-05	0.7700	-3.40e-01	-0.690000	3.36e-02	1.63e-05
Selenocysteine synthesis	91	1.38e-38	8.77e-37	0.7680	-3.55e-01	0.681000	4.60e-09	2.66e-29
Cell-extracellular matrix interactions	16	2.20e-06	8.89e-06	0.7660	-4.18e-01	-0.642000	3.77e-03	8.63e-06
MET activates PTK2 signaling	18	6.80e-08	3.72e-07	0.7650	1.55e-01	-0.749000	2.56e-01	3.71e-08
Signaling by PDGFRA extracellular domain mutants	12	4.81e-05	1.41e-04	0.7630	-2.63e-01	-0.716000	1.14e-01	1.74e-05
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants	12	4.81e-05	1.41e-04	0.7630	-2.63e-01	-0.716000	1.14e-01	1.74e-05
Beta-catenin phosphorylation cascade	17	8.19e-07	3.66e-06	0.7620	-2.73e-01	-0.711000	5.12e-02	3.79e-07
tRNA processing in the mitochondrion	20	6.21e-08	3.42e-07	0.7550	1.60e-01	0.738000	2.16e-01	1.09e-08
Response of EIF2AK4 (GCN2) to amino acid deficiency	99	6.60e-41	5.37e-39	0.7550	-4.23e-01	0.625000	3.36e-13	5.07e-27
ERK/MAPK targets	22	2.93e-08	1.77e-07	0.7510	-3.52e-01	-0.663000	4.27e-03	7.08e-08
Non-integrin membrane-ECM interactions	41	1.27e-16	2.25e-15	0.7510	2.00e-01	-0.724000	2.68e-02	1.00e-15
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)	93	6.86e-38	4.02e-36	0.7490	-4.24e-01	0.617000	1.55e-12	6.83e-25
Complex I biogenesis	57	8.21e-22	2.23e-20	0.7400	-1.23e-01	0.729000	1.09e-01	1.49e-21
Defective B4GALT7 causes EDS, progeroid type	18	1.10e-07	5.83e-07	0.7390	3.71e-01	-0.639000	6.44e-03	2.71e-06
Formation of the ternary complex, and subsequently, the 43S complex	50	7.28e-20	1.67e-18	0.7310	-5.01e-01	0.532000	8.83e-10	7.23e-11
Signaling by PDGFR in disease	19	5.53e-07	2.59e-06	0.7260	-1.98e-01	-0.698000	1.35e-01	1.36e-07
MET promotes cell motility	29	1.04e-10	1.03e-09	0.7250	-1.10e-02	-0.725000	9.19e-01	1.37e-11
Regulation of gene expression by Hypoxia-inducible Factor	10	4.08e-04	9.76e-04	0.7210	-2.91e-02	-0.720000	8.74e-01	7.95e-05
Deadenylation of mRNA	22	1.59e-07	8.27e-07	0.7200	-4.91e-01	-0.526000	6.62e-05	1.96e-05
Interleukin-6 signaling	11	3.64e-04	8.89e-04	0.7160	-3.18e-01	-0.642000	6.81e-02	2.26e-04
Regulation of PTEN mRNA translation	12	2.08e-04	5.35e-04	0.7160	-4.54e-01	-0.554000	6.49e-03	8.83e-04
Platelet sensitization by LDL	15	2.23e-05	7.00e-05	0.7110	-2.78e-01	-0.654000	6.24e-02	1.14e-05
L13a-mediated translational silencing of Ceruloplasmin expression	109	3.24e-39	2.26e-37	0.7020	-4.66e-01	0.525000	3.94e-17	2.32e-21
FOXO-mediated transcription of cell cycle genes	15	1.84e-05	5.97e-05	0.6970	-3.90e-02	-0.696000	7.94e-01	3.06e-06
Caspase activation via Dependence Receptors in the absence of ligand	10	1.11e-03	2.41e-03	0.6950	-2.83e-01	-0.635000	1.22e-01	5.07e-04
DCC mediated attractive signaling	14	4.56e-05	1.34e-04	0.6940	-7.57e-02	-0.690000	6.24e-01	7.81e-06
CTLA4 inhibitory signaling	17	1.05e-05	3.60e-05	0.6930	-3.05e-01	-0.623000	2.93e-02	8.78e-06
Gastrin-CREB signalling pathway via PKC and MAPK	17	1.16e-05	3.97e-05	0.6920	-3.40e-01	-0.603000	1.52e-02	1.66e-05
Competing endogenous RNAs (ceRNAs) regulate PTEN translation	11	7.22e-04	1.64e-03	0.6910	-4.38e-01	-0.534000	1.18e-02	2.15e-03
GTP hydrolysis and joining of the 60S ribosomal subunit	110	3.32e-38	2.03e-36	0.6900	-4.42e-01	0.530000	1.11e-15	6.60e-22
Other semaphorin interactions	15	8.68e-06	3.06e-05	0.6890	3.59e-01	-0.588000	1.59e-02	7.98e-05
Defective B3GAT3 causes JDSSDHD	18	9.01e-07	3.96e-06	0.6870	3.76e-01	-0.575000	5.69e-03	2.43e-05
Downstream signal transduction	29	5.13e-09	3.61e-08	0.6860	-3.18e-01	-0.608000	3.03e-03	1.44e-08
Signaling by FGFR3 fusions in cancer	10	1.28e-03	2.75e-03	0.6780	-1.64e-01	-0.658000	3.69e-01	3.13e-04
Defective B3GALT6 causes EDSP2 and SEMDJL1	18	1.31e-06	5.63e-06	0.6770	3.75e-01	-0.564000	5.92e-03	3.38e-05
Signaling by Activin	15	7.85e-05	2.18e-04	0.6760	-5.34e-01	-0.414000	3.40e-04	5.44e-03
rRNA processing in the mitochondrion	24	8.25e-08	4.43e-07	0.6740	4.17e-02	0.673000	7.24e-01	1.14e-08
Adenylate cyclase inhibitory pathway	12	3.49e-04	8.58e-04	0.6700	-8.82e-02	-0.664000	5.97e-01	6.71e-05
Synthesis of PIPs at the Golgi membrane	15	7.24e-05	2.04e-04	0.6700	-2.52e-01	-0.621000	9.07e-02	3.14e-05
RORA activates gene expression	18	9.75e-06	3.38e-05	0.6670	-1.79e-01	-0.643000	1.89e-01	2.34e-06
RHO GTPases activate KTN1	11	1.20e-03	2.60e-03	0.6650	-3.84e-01	-0.543000	2.75e-02	1.81e-03
SRP-dependent cotranslational protein targeting to membrane	110	3.90e-35	1.97e-33	0.6620	-3.93e-01	0.533000	9.93e-13	4.19e-22
Cap-dependent Translation Initiation	117	2.43e-37	1.32e-35	0.6620	-4.23e-01	0.509000	2.56e-15	1.77e-21
Eukaryotic Translation Initiation	117	2.43e-37	1.32e-35	0.6620	-4.23e-01	0.509000	2.56e-15	1.77e-21
STAT5 activation downstream of FLT3 ITD mutants	10	2.20e-03	4.43e-03	0.6610	-3.03e-01	-0.588000	9.75e-02	1.28e-03
Signaling by KIT in disease	19	7.69e-06	2.73e-05	0.6590	-2.17e-01	-0.623000	1.02e-01	2.62e-06
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	19	7.69e-06	2.73e-05	0.6590	-2.17e-01	-0.623000	1.02e-01	2.62e-06
Signaling by FLT3 fusion proteins	19	4.96e-06	1.85e-05	0.6570	-5.33e-02	-0.655000	6.88e-01	7.73e-07
Reduction of cytosolic Ca++ levels	12	1.99e-04	5.13e-04	0.6560	4.23e-01	-0.502000	1.12e-02	2.59e-03
Regulation of signaling by CBL	18	1.73e-05	5.69e-05	0.6560	-2.42e-01	-0.609000	7.58e-02	7.56e-06
Signal transduction by L1	21	3.76e-06	1.44e-05	0.6500	-2.66e-01	-0.593000	3.49e-02	2.54e-06
ALK mutants bind TKIs	12	5.44e-04	1.27e-03	0.6470	-4.16e-02	-0.646000	8.03e-01	1.06e-04
PKA activation	16	2.75e-05	8.39e-05	0.6460	1.45e-01	-0.630000	3.17e-01	1.29e-05
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S	58	5.49e-18	1.13e-16	0.6460	-5.21e-01	0.382000	6.74e-12	4.78e-07
Erythropoietin activates Phosphoinositide-3-kinase (PI3K)	11	1.15e-03	2.50e-03	0.6450	-8.01e-02	-0.640000	6.45e-01	2.36e-04
YAP1- and WWTR1 (TAZ)-stimulated gene expression	12	7.09e-04	1.62e-03	0.6420	-1.11e-01	-0.633000	5.04e-01	1.48e-04
PKA-mediated phosphorylation of CREB	18	1.23e-05	4.18e-05	0.6380	6.90e-02	-0.634000	6.12e-01	3.14e-06
Nephrin family interactions	20	9.91e-06	3.42e-05	0.6370	-2.26e-01	-0.596000	8.06e-02	3.99e-06
Mitochondrial iron-sulfur cluster biogenesis	13	1.73e-04	4.50e-04	0.6350	-4.37e-01	0.462000	6.39e-03	3.96e-03
Membrane binding and targetting of GAG proteins	14	2.14e-04	5.50e-04	0.6350	-6.34e-01	-0.032300	4.00e-05	8.34e-01
Synthesis And Processing Of GAG, GAGPOL Polyproteins	14	2.14e-04	5.50e-04	0.6350	-6.34e-01	-0.032300	4.00e-05	8.34e-01
Translation initiation complex formation	57	4.76e-17	8.61e-16	0.6340	-5.12e-01	0.373000	2.15e-11	1.12e-06
CREB1 phosphorylation through the activation of Adenylate Cyclase	10	1.71e-03	3.56e-03	0.6320	1.95e-01	-0.602000	2.86e-01	9.85e-04
GRB2:SOS provides linkage to MAPK signaling for Integrins	12	1.31e-03	2.80e-03	0.6320	-3.49e-01	-0.527000	3.66e-02	1.57e-03
Biotin transport and metabolism	11	8.11e-04	1.83e-03	0.6310	5.61e-01	-0.290000	1.28e-03	9.61e-02
Formation of ATP by chemiosmotic coupling	18	1.94e-05	6.18e-05	0.6270	-4.48e-02	0.626000	7.42e-01	4.27e-06
MAPK targets/ Nuclear events mediated by MAP kinases	31	4.32e-08	2.46e-07	0.6270	-3.15e-01	-0.542000	2.42e-03	1.73e-07
Signal regulatory protein family interactions	11	2.40e-03	4.78e-03	0.6260	-2.94e-01	-0.553000	9.18e-02	1.48e-03
Role of LAT2/NTAL/LAB on calcium mobilization	13	5.82e-04	1.35e-03	0.6250	-1.01e-01	-0.616000	5.27e-01	1.18e-04
RHOV GTPase cycle	37	8.07e-10	6.87e-09	0.6240	-1.36e-01	-0.609000	1.51e-01	1.41e-10
Prolonged ERK activation events	14	3.85e-04	9.29e-04	0.6230	-1.54e-01	-0.604000	3.17e-01	9.13e-05
Ephrin signaling	19	3.10e-05	9.42e-05	0.6230	-2.58e-01	-0.567000	5.18e-02	1.86e-05
Selenoamino acid metabolism	115	5.95e-32	2.64e-30	0.6180	-3.36e-01	0.519000	4.63e-10	6.31e-22
p130Cas linkage to MAPK signaling for integrins	12	1.86e-03	3.83e-03	0.6160	-3.77e-01	-0.488000	2.39e-02	3.42e-03
The activation of arylsulfatases	10	1.91e-03	3.91e-03	0.6160	4.17e-01	-0.454000	2.25e-02	1.29e-02
Signaling by FLT3 ITD and TKD mutants	16	1.83e-04	4.76e-04	0.6150	-2.16e-01	-0.576000	1.35e-01	6.60e-05
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.	125	8.79e-33	4.03e-31	0.6150	-1.21e-01	0.603000	1.91e-02	2.15e-31
Ribosomal scanning and start codon recognition	57	4.22e-16	7.19e-15	0.6150	-4.88e-01	0.374000	1.87e-10	1.03e-06
HS-GAG degradation	19	7.84e-06	2.77e-05	0.6120	4.24e-01	-0.441000	1.36e-03	8.62e-04
Respiratory electron transport	103	4.70e-27	1.64e-25	0.6100	-1.60e-01	0.589000	4.90e-03	4.56e-25
VEGFR2 mediated cell proliferation	19	2.74e-05	8.38e-05	0.6090	-4.60e-02	-0.607000	7.28e-01	4.58e-06
Mitotic Telophase/Cytokinesis	13	1.14e-03	2.48e-03	0.6090	-2.51e-01	-0.554000	1.17e-01	5.37e-04
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs	11	1.38e-03	2.94e-03	0.6070	-5.43e-01	0.273000	1.83e-03	1.18e-01
Major pathway of rRNA processing in the nucleolus and cytosol	180	4.39e-48	7.14e-46	0.6070	-4.42e-01	0.415000	1.15e-24	6.33e-22
rRNA processing in the nucleus and cytosol	190	1.23e-50	2.57e-48	0.6060	-4.52e-01	0.404000	4.72e-27	6.94e-22
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)	113	2.07e-30	8.41e-29	0.6060	-3.92e-01	0.462000	5.64e-13	1.93e-17
Nonsense-Mediated Decay (NMD)	113	2.07e-30	8.41e-29	0.6060	-3.92e-01	0.462000	5.64e-13	1.93e-17
RHO GTPases Activate WASPs and WAVEs	36	8.07e-09	5.40e-08	0.6060	-2.40e-01	-0.556000	1.28e-02	7.57e-09
Interleukin-15 signaling	14	3.64e-04	8.89e-04	0.6060	6.72e-02	-0.602000	6.64e-01	9.64e-05
Miscellaneous transport and binding events	23	3.63e-06	1.39e-05	0.6050	-5.55e-02	-0.603000	6.45e-01	5.57e-07
Regulation of RUNX1 Expression and Activity	18	1.01e-04	2.75e-04	0.6030	-2.52e-01	-0.547000	6.39e-02	5.81e-05
Assembly Of The HIV Virion	16	1.68e-04	4.39e-04	0.6020	-6.01e-01	-0.028600	3.10e-05	8.43e-01
Heme signaling	42	5.08e-10	4.45e-09	0.6010	-2.39e-01	-0.552000	7.42e-03	6.08e-10
Spry regulation of FGF signaling	16	3.46e-04	8.50e-04	0.6010	-4.80e-01	-0.361000	8.77e-04	1.24e-02
Frs2-mediated activation	12	2.00e-03	4.07e-03	0.6010	-1.74e-01	-0.575000	2.96e-01	5.63e-04
EGR2 and SOX10-mediated initiation of Schwann cell myelination	25	2.63e-06	1.04e-05	0.6000	-1.93e-01	-0.568000	9.51e-02	8.71e-07
RHOU GTPase cycle	40	4.02e-10	3.66e-09	0.5990	-1.03e-02	-0.599000	9.10e-01	5.39e-11
Signaling by BMP	23	1.21e-05	4.13e-05	0.5970	-3.55e-01	-0.480000	3.17e-03	6.74e-05
RHOF GTPase cycle	41	1.50e-10	1.46e-09	0.5970	8.37e-02	-0.591000	3.54e-01	5.78e-11
Estrogen-dependent nuclear events downstream of ESR-membrane signaling	22	1.97e-05	6.25e-05	0.5960	-3.27e-01	-0.498000	7.83e-03	5.18e-05
Signaling by WNT in cancer	33	7.54e-08	4.09e-07	0.5950	-2.51e-01	-0.539000	1.27e-02	8.22e-08
Golgi Cisternae Pericentriolar Stack Reorganization	14	1.17e-03	2.55e-03	0.5920	-4.24e-01	-0.413000	5.97e-03	7.43e-03
CD209 (DC-SIGN) signaling	19	8.89e-05	2.43e-04	0.5910	-2.55e-01	-0.534000	5.46e-02	5.65e-05
Erythropoietin activates RAS	13	1.70e-03	3.55e-03	0.5910	-2.54e-01	-0.534000	1.13e-01	8.63e-04
Synthesis of active ubiquitin: roles of E1 and E2 enzymes	30	3.20e-07	1.56e-06	0.5900	-5.63e-01	-0.175000	9.25e-08	9.71e-02
rRNA processing	214	9.35e-54	2.74e-51	0.5890	-3.97e-01	0.435000	1.09e-23	4.38e-28
FCGR3A-mediated phagocytosis	56	1.53e-12	1.94e-11	0.5890	-2.61e-01	-0.528000	7.44e-04	7.96e-12
Leishmania phagocytosis	56	1.53e-12	1.94e-11	0.5890	-2.61e-01	-0.528000	7.44e-04	7.96e-12
Parasite infection	56	1.53e-12	1.94e-11	0.5890	-2.61e-01	-0.528000	7.44e-04	7.96e-12
SLBP independent Processing of Histone Pre-mRNAs	10	3.65e-03	6.97e-03	0.5860	-5.02e-01	0.303000	6.02e-03	9.69e-02
DNA strand elongation	32	2.68e-07	1.32e-06	0.5860	4.59e-01	0.365000	7.01e-06	3.58e-04
RAF-independent MAPK1/3 activation	22	1.85e-05	5.97e-05	0.5850	-1.43e-01	-0.567000	2.44e-01	4.05e-06
Zinc transporters	14	1.14e-03	2.48e-03	0.5850	-2.24e-01	-0.540000	1.46e-01	4.62e-04
ATF4 activates genes in response to endoplasmic reticulum stress	26	4.79e-07	2.26e-06	0.5830	-4.53e-01	0.367000	6.33e-05	1.20e-03
Nucleotide biosynthesis	12	3.67e-03	7.00e-03	0.5810	-4.82e-01	-0.324000	3.83e-03	5.17e-02
Regulation of localization of FOXO transcription factors	12	1.54e-03	3.24e-03	0.5800	2.06e-01	-0.542000	2.16e-01	1.15e-03
HS-GAG biosynthesis	27	6.29e-07	2.89e-06	0.5800	1.32e-01	-0.565000	2.37e-01	3.75e-07
Signaling by Leptin	10	7.15e-03	1.31e-02	0.5790	-8.57e-02	-0.573000	6.39e-01	1.70e-03
MET receptor recycling	10	9.22e-03	1.66e-02	0.5790	-2.63e-01	-0.515000	1.50e-01	4.77e-03
RHOJ GTPase cycle	54	6.18e-13	8.46e-12	0.5780	9.79e-02	-0.570000	2.13e-01	4.18e-13
GAB1 signalosome	15	8.90e-04	1.99e-03	0.5760	-2.23e-01	-0.531000	1.35e-01	3.72e-04
Mitochondrial translation elongation	90	3.60e-21	9.26e-20	0.5750	-1.63e-01	0.551000	7.65e-03	1.50e-19
N-Glycan antennae elongation	14	1.75e-03	3.62e-03	0.5740	-3.79e-01	-0.432000	1.41e-02	5.18e-03
Lysosphingolipid and LPA receptors	11	6.23e-03	1.15e-02	0.5740	-5.11e-01	-0.261000	3.31e-03	1.34e-01
Mitochondrial translation initiation	90	5.71e-21	1.42e-19	0.5720	-1.61e-01	0.549000	8.28e-03	2.15e-19
Aflatoxin activation and detoxification	14	1.43e-03	3.02e-03	0.5720	1.75e-01	0.544000	2.57e-01	4.21e-04
MECP2 regulates neuronal receptors and channels	17	2.74e-04	6.95e-04	0.5710	-6.83e-02	-0.567000	6.26e-01	5.16e-05
Regulation of expression of SLITs and ROBOs	166	3.50e-39	2.33e-37	0.5700	-3.56e-01	0.445000	2.19e-15	4.05e-23
Activation of gene expression by SREBF (SREBP)	42	7.43e-09	5.04e-08	0.5680	-3.37e-01	-0.458000	1.54e-04	2.86e-07
Downregulation of SMAD2/3:SMAD4 transcriptional activity	28	4.01e-06	1.52e-05	0.5680	-3.74e-01	-0.428000	6.15e-04	8.87e-05
A tetrasaccharide linker sequence is required for GAG synthesis	24	3.10e-06	1.21e-05	0.5670	3.25e-01	-0.465000	5.89e-03	7.89e-05
RHOH GTPase cycle	35	5.00e-08	2.80e-07	0.5660	-2.49e-02	-0.565000	7.99e-01	6.96e-09
BMAL1:CLOCK,NPAS2 activates circadian gene expression	26	8.42e-06	2.97e-05	0.5660	-2.41e-01	-0.511000	3.31e-02	6.32e-06
Circadian Clock	67	1.05e-13	1.52e-12	0.5650	-2.65e-01	-0.499000	1.72e-04	1.54e-12
Regulation of FOXO transcriptional activity by acetylation	10	1.20e-02	2.11e-02	0.5640	-2.95e-01	-0.481000	1.06e-01	8.47e-03
Insulin processing	25	6.46e-06	2.34e-05	0.5620	2.24e-03	-0.562000	9.85e-01	1.14e-06
Apoptotic cleavage of cellular proteins	34	3.51e-08	2.05e-07	0.5620	1.90e-01	-0.529000	5.47e-02	9.48e-08
Netrin-1 signaling	45	1.13e-09	9.38e-09	0.5610	-1.21e-01	-0.548000	1.59e-01	1.96e-10
CS/DS degradation	13	1.34e-03	2.84e-03	0.5610	5.11e-01	-0.233000	1.43e-03	1.46e-01
Signaling by ALK fusions and activated point mutants	55	3.22e-11	3.49e-10	0.5590	-2.34e-01	-0.508000	2.65e-03	7.26e-11
Signaling by ALK in cancer	55	3.22e-11	3.49e-10	0.5590	-2.34e-01	-0.508000	2.65e-03	7.26e-11
Mitochondrial translation termination	90	5.11e-20	1.21e-18	0.5590	-1.51e-01	0.538000	1.33e-02	1.05e-18
Citric acid cycle (TCA cycle)	22	8.12e-05	2.24e-04	0.5570	-4.51e-01	-0.326000	2.48e-04	8.06e-03
Uptake and function of anthrax toxins	11	7.80e-03	1.42e-02	0.5570	-1.91e-01	-0.523000	2.73e-01	2.66e-03
Influenza Viral RNA Transcription and Replication	134	3.21e-30	1.27e-28	0.5550	-3.86e-01	0.398000	1.09e-14	1.59e-15
RAC2 GTPase cycle	85	1.86e-17	3.51e-16	0.5540	-6.36e-02	-0.550000	3.10e-01	1.71e-18
RAC3 GTPase cycle	89	4.30e-18	9.00e-17	0.5540	-8.72e-02	-0.547000	1.55e-01	4.58e-19
Signaling by Erythropoietin	24	2.94e-05	8.95e-05	0.5530	-1.99e-01	-0.517000	9.19e-02	1.18e-05
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	45	6.16e-09	4.28e-08	0.5530	-4.00e-01	-0.382000	3.36e-06	9.34e-06
Chondroitin sulfate biosynthesis	19	7.00e-05	1.98e-04	0.5530	3.50e-01	-0.428000	8.18e-03	1.25e-03
Antigen Presentation: Folding, assembly and peptide loading of class I MHC	25	2.47e-05	7.69e-05	0.5520	-2.82e-01	-0.475000	1.47e-02	3.91e-05
RHOQ GTPase cycle	58	1.84e-12	2.27e-11	0.5520	4.17e-02	-0.550000	5.83e-01	4.18e-13
RUNX3 regulates NOTCH signaling	14	2.15e-03	4.34e-03	0.5510	-1.40e-01	-0.533000	3.64e-01	5.51e-04
Diseases associated with glycosaminoglycan metabolism	35	2.97e-08	1.79e-07	0.5510	2.73e-01	-0.479000	5.21e-03	9.35e-07
Signaling by FGFR4 in disease	11	9.34e-03	1.68e-02	0.5500	-2.40e-01	-0.495000	1.68e-01	4.47e-03
Regulation of cholesterol biosynthesis by SREBP (SREBF)	55	7.08e-11	7.20e-10	0.5490	-2.15e-01	-0.505000	5.84e-03	9.09e-11
Response of EIF2AK1 (HRI) to heme deficiency	15	7.54e-04	1.70e-03	0.5480	-5.20e-01	0.174000	4.89e-04	2.43e-01
Growth hormone receptor signaling	20	1.39e-04	3.70e-04	0.5460	-4.84e-02	-0.544000	7.08e-01	2.51e-05
STAT3 nuclear events downstream of ALK signaling	10	9.72e-03	1.73e-02	0.5430	1.14e-01	-0.531000	5.32e-01	3.61e-03
Translocation of SLC2A4 (GLUT4) to the plasma membrane	50	4.90e-10	4.35e-09	0.5410	-9.61e-02	-0.533000	2.39e-01	6.95e-11
Regulation of commissural axon pathfinding by SLIT and ROBO	10	1.14e-02	2.01e-02	0.5400	4.05e-02	-0.539000	8.25e-01	3.18e-03
FOXO-mediated transcription of cell death genes	15	2.32e-03	4.63e-03	0.5390	-4.65e-01	-0.272000	1.80e-03	6.80e-02
Mitochondrial translation	96	6.75e-20	1.57e-18	0.5390	-1.48e-01	0.518000	1.21e-02	1.55e-18
RHOC GTPase cycle	72	2.08e-14	3.27e-13	0.5390	-5.20e-03	-0.539000	9.39e-01	2.54e-15
Recycling pathway of L1	27	8.83e-06	3.10e-05	0.5380	-4.56e-02	-0.536000	6.81e-01	1.41e-06
Signaling by NODAL	19	5.24e-04	1.23e-03	0.5380	-3.62e-01	-0.398000	6.34e-03	2.66e-03
Mitophagy	28	6.80e-06	2.42e-05	0.5350	-5.32e-01	-0.047600	1.07e-06	6.63e-01
Vif-mediated degradation of APOBEC3G	52	2.64e-11	2.95e-10	0.5340	-4.31e-01	0.315000	7.39e-08	8.41e-05
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A	50	6.88e-11	7.09e-10	0.5340	-4.25e-01	0.323000	2.00e-07	7.81e-05
p53-Independent DNA Damage Response	50	6.88e-11	7.09e-10	0.5340	-4.25e-01	0.323000	2.00e-07	7.81e-05
p53-Independent G1/S DNA damage checkpoint	50	6.88e-11	7.09e-10	0.5340	-4.25e-01	0.323000	2.00e-07	7.81e-05
ROS sensing by NFE2L2	55	1.02e-11	1.18e-10	0.5340	-4.83e-01	0.226000	5.60e-10	3.69e-03
KSRP (KHSRP) binds and destabilizes mRNA	17	3.75e-04	9.07e-04	0.5320	-4.47e-01	0.289000	1.42e-03	3.89e-02
Regulation of KIT signaling	15	2.63e-03	5.20e-03	0.5320	-2.44e-01	-0.473000	1.02e-01	1.52e-03
Disassembly of the destruction complex and recruitment of AXIN to the membrane	30	5.16e-06	1.91e-05	0.5320	-1.54e-01	-0.509000	1.45e-01	1.38e-06
rRNA modification in the nucleus and cytosol	60	2.08e-12	2.52e-11	0.5310	-5.05e-01	0.163000	1.24e-11	2.94e-02
Insertion of tail-anchored proteins into the endoplasmic reticulum membrane	22	1.35e-04	3.60e-04	0.5290	-5.13e-01	-0.129000	3.08e-05	2.95e-01
Tie2 Signaling	17	1.29e-03	2.76e-03	0.5280	-2.28e-01	-0.476000	1.04e-01	6.72e-04
TICAM1,TRAF6-dependent induction of TAK1 complex	11	1.29e-02	2.25e-02	0.5280	-4.93e-01	-0.189000	4.66e-03	2.77e-01
RAF activation	33	2.44e-06	9.72e-06	0.5270	-2.18e-01	-0.480000	3.02e-02	1.78e-06
COPI-mediated anterograde transport	79	5.32e-14	8.12e-13	0.5270	-2.53e-01	-0.462000	1.02e-04	1.17e-12
APC/C:Cdc20 mediated degradation of Cyclin B	24	2.14e-05	6.76e-05	0.5270	-2.16e-01	0.480000	6.68e-02	4.62e-05
Regulation of activated PAK-2p34 by proteasome mediated degradation	48	3.40e-10	3.15e-09	0.5270	-4.38e-01	0.293000	1.54e-07	4.48e-04
Autodegradation of the E3 ubiquitin ligase COP1	49	2.15e-10	2.06e-09	0.5260	-4.25e-01	0.309000	2.54e-07	1.79e-04
Downregulation of TGF-beta receptor signaling	26	5.37e-05	1.56e-04	0.5250	-3.95e-01	-0.346000	4.95e-04	2.29e-03
Transport of the SLBP Dependant Mature mRNA	36	1.24e-06	5.35e-06	0.5240	-4.04e-01	-0.334000	2.73e-05	5.26e-04
Protein methylation	15	2.89e-03	5.67e-03	0.5230	-4.93e-01	-0.175000	9.48e-04	2.40e-01
Interleukin-27 signaling	10	2.01e-02	3.31e-02	0.5230	-1.65e-01	-0.496000	3.66e-01	6.59e-03
RND1 GTPase cycle	42	1.49e-08	9.52e-08	0.5220	1.22e-01	-0.508000	1.72e-01	1.22e-08
Signaling by TGF-beta Receptor Complex	74	9.30e-13	1.23e-11	0.5220	-3.43e-01	-0.394000	3.29e-07	4.71e-09
Signaling by cytosolic FGFR1 fusion mutants	18	7.09e-04	1.62e-03	0.5210	-5.62e-02	-0.518000	6.80e-01	1.40e-04
PERK regulates gene expression	31	1.33e-06	5.64e-06	0.5210	-4.78e-01	0.205000	3.99e-06	4.82e-02
Processive synthesis on the lagging strand	15	3.65e-03	6.97e-03	0.5200	4.33e-01	0.287000	3.66e-03	5.42e-02
MAPK3 (ERK1) activation	10	2.24e-02	3.67e-02	0.5190	-2.09e-01	-0.475000	2.52e-01	9.29e-03
G-protein mediated events	48	5.57e-09	3.89e-08	0.5180	-6.95e-02	-0.514000	4.05e-01	7.30e-10
Postmitotic nuclear pore complex (NPC) reformation	27	4.27e-05	1.26e-04	0.5180	-4.42e-01	-0.270000	6.92e-05	1.53e-02
Cellular response to starvation	150	2.14e-29	8.05e-28	0.5180	-3.22e-01	0.406000	9.62e-12	9.26e-18
Transport of the SLBP independent Mature mRNA	35	2.53e-06	1.00e-05	0.5180	-3.88e-01	-0.342000	7.04e-05	4.54e-04
Synthesis of PIPs at the plasma membrane	50	3.81e-09	2.82e-08	0.5170	-1.14e-01	-0.504000	1.63e-01	6.82e-10
RHOG GTPase cycle	74	1.84e-13	2.59e-12	0.5160	-3.51e-02	-0.514000	6.02e-01	1.91e-14
Stabilization of p53	53	9.56e-11	9.52e-10	0.5150	-4.25e-01	0.291000	8.54e-08	2.43e-04
Signaling by VEGF	99	1.95e-17	3.61e-16	0.5150	-8.45e-02	-0.508000	1.46e-01	2.18e-18
Integrin signaling	24	1.21e-04	3.25e-04	0.5150	-1.94e-01	-0.477000	9.98e-02	5.16e-05
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	28	1.04e-05	3.59e-05	0.5150	6.77e-02	-0.510000	5.35e-01	2.96e-06
VEGFA-VEGFR2 Pathway	91	4.15e-16	7.15e-15	0.5140	-7.20e-02	-0.509000	2.35e-01	4.25e-17
Leading Strand Synthesis	14	6.05e-03	1.12e-02	0.5130	4.26e-01	0.287000	5.81e-03	6.29e-02
Polymerase switching	14	6.05e-03	1.12e-02	0.5130	4.26e-01	0.287000	5.81e-03	6.29e-02
FCGR3A-mediated IL10 synthesis	32	4.09e-06	1.54e-05	0.5130	-7.50e-02	-0.508000	4.63e-01	6.58e-07
SUMOylation of SUMOylation proteins	35	3.03e-06	1.18e-05	0.5130	-4.10e-01	-0.308000	2.63e-05	1.61e-03
RHOBTB1 GTPase cycle	23	2.21e-04	5.67e-04	0.5130	-4.41e-01	-0.261000	2.47e-04	3.00e-02
Vpr-mediated nuclear import of PICs	34	4.88e-06	1.82e-05	0.5120	-3.83e-01	-0.339000	1.09e-04	6.25e-04
Platelet calcium homeostasis	24	3.77e-05	1.12e-04	0.5110	2.30e-01	-0.457000	5.10e-02	1.07e-04
Fcgamma receptor (FCGR) dependent phagocytosis	82	9.39e-14	1.38e-12	0.5110	-2.19e-01	-0.461000	6.15e-04	4.84e-13
COPI-independent Golgi-to-ER retrograde traffic	33	5.40e-06	1.97e-05	0.5110	-2.05e-01	-0.468000	4.15e-02	3.30e-06
FCERI mediated Ca+2 mobilization	28	2.54e-05	7.84e-05	0.5100	-1.16e-01	-0.497000	2.88e-01	5.26e-06
Signaling by SCF-KIT	41	2.32e-07	1.18e-06	0.5100	-1.54e-01	-0.486000	8.79e-02	7.00e-08
PKA activation in glucagon signalling	15	2.33e-03	4.65e-03	0.5090	8.80e-02	-0.501000	5.55e-01	7.70e-04
DAG and IP3 signaling	37	6.07e-07	2.81e-06	0.5070	-1.19e-02	-0.507000	9.00e-01	9.38e-08
PLC beta mediated events	44	5.86e-08	3.27e-07	0.5060	-6.47e-02	-0.502000	4.57e-01	8.07e-09
Ca-dependent events	33	3.31e-06	1.29e-05	0.5060	-3.51e-02	-0.505000	7.27e-01	5.11e-07
Activated NTRK2 signals through FRS2 and FRS3	11	1.73e-02	2.90e-02	0.5060	-1.33e-01	-0.488000	4.45e-01	5.06e-03
APC/C:Cdc20 mediated degradation of Securin	66	8.36e-13	1.12e-11	0.5060	-3.68e-01	0.347000	2.36e-07	1.06e-06
MAP kinase activation	62	3.43e-10	3.16e-09	0.5040	-2.83e-01	-0.418000	1.18e-04	1.27e-08
Regulation of actin dynamics for phagocytic cup formation	58	9.15e-10	7.66e-09	0.5040	-1.96e-01	-0.464000	9.64e-03	9.31e-10
PI Metabolism	77	8.85e-13	1.18e-11	0.5030	-1.70e-01	-0.474000	1.01e-02	6.17e-13
MET activates RAS signaling	11	1.73e-02	2.91e-02	0.5030	-1.03e-01	-0.492000	5.55e-01	4.67e-03
Hyaluronan uptake and degradation	10	2.27e-02	3.70e-02	0.5020	5.02e-01	0.022200	5.98e-03	9.03e-01
RUNX2 regulates osteoblast differentiation	22	3.20e-04	7.96e-04	0.5010	-1.02e-01	-0.491000	4.09e-01	6.74e-05
Transcriptional activation of mitochondrial biogenesis	53	1.16e-08	7.56e-08	0.5010	-3.33e-01	-0.374000	2.66e-05	2.45e-06
Constitutive Signaling by Overexpressed ERBB2	11	1.41e-02	2.42e-02	0.5010	5.76e-02	-0.498000	7.41e-01	4.25e-03
HIV elongation arrest and recovery	32	5.19e-06	1.91e-05	0.5000	-5.00e-01	0.016000	9.78e-07	8.75e-01
Pausing and recovery of HIV elongation	32	5.19e-06	1.91e-05	0.5000	-5.00e-01	0.016000	9.78e-07	8.75e-01
RHOB GTPase cycle	69	2.01e-12	2.46e-11	0.5000	9.99e-02	-0.490000	1.51e-01	1.98e-12
PECAM1 interactions	11	1.71e-02	2.88e-02	0.4970	-2.91e-02	-0.496000	8.67e-01	4.35e-03
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	31	2.48e-05	7.69e-05	0.4950	-4.33e-01	-0.241000	3.02e-05	2.02e-02
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors	11	1.31e-02	2.27e-02	0.4940	2.06e-01	-0.449000	2.37e-01	9.90e-03
RND3 GTPase cycle	41	1.42e-07	7.41e-07	0.4930	1.27e-01	-0.477000	1.59e-01	1.26e-07
Extra-nuclear estrogen signaling	66	1.59e-10	1.53e-09	0.4930	-1.99e-01	-0.451000	5.14e-03	2.35e-10
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1	17	3.12e-03	6.08e-03	0.4930	-2.28e-01	-0.437000	1.03e-01	1.82e-03
Signaling by TGFB family members	98	6.70e-15	1.07e-13	0.4930	-3.24e-01	-0.371000	2.90e-08	2.12e-10
Regulation of RUNX3 expression and activity	54	7.29e-10	6.32e-09	0.4930	-4.58e-01	0.183000	5.93e-09	2.02e-02
TBC/RABGAPs	43	6.20e-07	2.86e-06	0.4920	-3.46e-01	-0.350000	8.54e-05	7.21e-05
SCF-beta-TrCP mediated degradation of Emi1	53	7.99e-10	6.84e-09	0.4920	-4.19e-01	0.257000	1.27e-07	1.20e-03
Vpu mediated degradation of CD4	50	2.77e-09	2.12e-08	0.4900	-4.07e-01	0.274000	6.34e-07	8.11e-04
Autodegradation of Cdh1 by Cdh1:APC/C	64	9.85e-12	1.15e-10	0.4900	-3.54e-01	0.339000	9.46e-07	2.72e-06
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1	72	4.45e-13	6.18e-12	0.4900	-3.66e-01	0.326000	8.04e-08	1.71e-06
RHOD GTPase cycle	52	4.60e-09	3.32e-08	0.4890	5.43e-02	-0.486000	4.98e-01	1.27e-09
Transport of Ribonucleoproteins into the Host Nucleus	32	2.67e-05	8.19e-05	0.4890	-3.19e-01	-0.371000	1.80e-03	2.79e-04
Pausing and recovery of Tat-mediated HIV elongation	30	1.76e-05	5.73e-05	0.4890	-4.88e-01	0.027600	3.67e-06	7.93e-01
Tat-mediated HIV elongation arrest and recovery	30	1.76e-05	5.73e-05	0.4890	-4.88e-01	0.027600	3.67e-06	7.93e-01
VLDLR internalisation and degradation	11	1.39e-02	2.39e-02	0.4880	2.40e-01	-0.425000	1.68e-01	1.46e-02
Cargo concentration in the ER	31	1.74e-05	5.71e-05	0.4880	-5.14e-02	-0.486000	6.20e-01	2.85e-06
Hyaluronan metabolism	14	5.33e-03	9.99e-03	0.4870	4.73e-01	-0.117000	2.18e-03	4.50e-01
Regulation of Apoptosis	51	2.62e-09	2.02e-08	0.4870	-4.15e-01	0.255000	2.98e-07	1.60e-03
Regulated proteolysis of p75NTR	11	1.82e-02	3.03e-02	0.4870	4.49e-02	-0.484000	7.96e-01	5.39e-03
Signaling by MET	66	7.37e-11	7.44e-10	0.4860	-2.43e-02	-0.485000	7.32e-01	8.78e-12
Heparan sulfate/heparin (HS-GAG) metabolism	48	8.73e-09	5.79e-08	0.4850	2.78e-01	-0.398000	8.49e-04	1.84e-06
mRNA decay by 3’ to 5’ exoribonuclease	16	2.01e-03	4.07e-03	0.4850	-3.11e-01	0.372000	3.11e-02	9.91e-03
Caspase-mediated cleavage of cytoskeletal proteins	12	1.13e-02	2.00e-02	0.4850	1.35e-01	-0.466000	4.20e-01	5.17e-03
Molecules associated with elastic fibres	25	1.02e-04	2.75e-04	0.4850	9.30e-02	-0.476000	4.21e-01	3.77e-05
Degradation of DVL	55	7.35e-10	6.33e-09	0.4850	-4.25e-01	0.234000	5.01e-08	2.70e-03
Interactions of Vpr with host cellular proteins	37	6.60e-06	2.37e-05	0.4850	-3.44e-01	-0.341000	2.87e-04	3.33e-04
CD28 co-stimulation	29	6.81e-05	1.93e-04	0.4840	-1.88e-01	-0.446000	8.03e-02	3.20e-05
Josephin domain DUBs	10	2.90e-02	4.61e-02	0.4830	-4.83e-01	0.011300	8.21e-03	9.50e-01
Negative regulation of NOTCH4 signaling	54	1.04e-09	8.69e-09	0.4830	-3.83e-01	0.293000	1.09e-06	1.91e-04
EPHB-mediated forward signaling	34	1.78e-05	5.79e-05	0.4820	-2.69e-01	-0.400000	6.58e-03	5.38e-05
Removal of the Flap Intermediate	14	1.09e-02	1.93e-02	0.4820	4.16e-01	0.242000	6.98e-03	1.17e-01
TGF-beta receptor signaling activates SMADs	32	3.78e-05	1.13e-04	0.4810	-3.65e-01	-0.314000	3.52e-04	2.14e-03
Influenza Infection	153	7.01e-26	2.28e-24	0.4800	-3.57e-01	0.320000	2.24e-14	7.58e-12
CaM pathway	31	1.91e-05	6.12e-05	0.4800	2.04e-02	-0.479000	8.44e-01	3.83e-06
Calmodulin induced events	31	1.91e-05	6.12e-05	0.4800	2.04e-02	-0.479000	8.44e-01	3.83e-06
Signaling by NTRK3 (TRKC)	16	5.33e-03	9.99e-03	0.4800	-1.67e-01	-0.450000	2.48e-01	1.84e-03
The role of GTSE1 in G2/M progression after G2 checkpoint	58	3.30e-10	3.08e-09	0.4790	-3.92e-01	0.275000	2.38e-07	2.85e-04
Nuclear events stimulated by ALK signaling in cancer	19	2.25e-03	4.51e-03	0.4790	-4.26e-01	-0.219000	1.31e-03	9.79e-02
Sema3A PAK dependent Axon repulsion	16	4.75e-03	8.95e-03	0.4780	-8.09e-02	-0.471000	5.76e-01	1.11e-03
Signaling by PDGF	51	3.43e-08	2.01e-07	0.4770	-4.95e-02	-0.474000	5.40e-01	4.55e-09
Transport of Mature mRNAs Derived from Intronless Transcripts	43	1.36e-06	5.69e-06	0.4770	-3.94e-01	-0.268000	7.65e-06	2.36e-03
L1CAM interactions	92	3.02e-14	4.65e-13	0.4760	-2.88e-02	-0.475000	6.33e-01	3.10e-15
Elastic fibre formation	35	4.03e-06	1.52e-05	0.4760	9.77e-02	-0.466000	3.17e-01	1.83e-06
Regulation of IFNA signaling	12	2.37e-02	3.85e-02	0.4750	-2.82e-01	-0.382000	9.03e-02	2.18e-02
p75NTR signals via NF-kB	16	5.94e-03	1.11e-02	0.4750	-4.43e-01	-0.171000	2.14e-03	2.36e-01
Lagging Strand Synthesis	20	2.01e-03	4.07e-03	0.4750	3.72e-01	0.295000	3.97e-03	2.23e-02
Formation of HIV elongation complex in the absence of HIV Tat	44	2.67e-07	1.32e-06	0.4750	-4.74e-01	0.025900	5.22e-08	7.66e-01
NEP/NS2 Interacts with the Cellular Export Machinery	32	5.08e-05	1.48e-04	0.4740	-3.31e-01	-0.340000	1.18e-03	8.84e-04
VEGFR2 mediated vascular permeability	27	8.57e-05	2.36e-04	0.4740	5.46e-02	-0.471000	6.23e-01	2.27e-05
Cristae formation	31	2.43e-05	7.57e-05	0.4720	-4.86e-02	0.469000	6.39e-01	6.06e-06
APC/C:Cdc20 mediated degradation of mitotic proteins	74	1.65e-12	2.07e-11	0.4720	-3.51e-01	0.315000	1.72e-07	2.76e-06
Hh mutants are degraded by ERAD	54	3.17e-09	2.38e-08	0.4710	-4.04e-01	0.243000	2.79e-07	2.03e-03
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins	75	1.46e-12	1.89e-11	0.4700	-3.59e-01	0.303000	7.46e-08	5.60e-06
Metal ion SLC transporters	22	8.27e-04	1.86e-03	0.4700	-8.64e-02	-0.462000	4.83e-01	1.77e-04
Interleukin-3, Interleukin-5 and GM-CSF signaling	38	5.07e-06	1.88e-05	0.4700	-9.98e-02	-0.459000	2.87e-01	9.64e-07
Transport of Mature mRNA Derived from an Intronless Transcript	42	2.92e-06	1.14e-05	0.4690	-3.81e-01	-0.273000	1.93e-05	2.16e-03
Activation of the TFAP2 (AP-2) family of transcription factors	11	3.54e-02	5.51e-02	0.4680	-3.91e-01	-0.258000	2.47e-02	1.39e-01
CDT1 association with the CDC6:ORC:origin complex	57	1.21e-09	9.92e-09	0.4680	-3.38e-01	0.323000	1.01e-05	2.43e-05
Abortive elongation of HIV-1 transcript in the absence of Tat	23	4.02e-04	9.66e-04	0.4670	-4.61e-01	0.077700	1.30e-04	5.19e-01
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand	37	9.31e-06	3.24e-05	0.4670	-1.32e-01	-0.448000	1.66e-01	2.39e-06
PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases	14	1.18e-02	2.08e-02	0.4660	-8.72e-02	-0.458000	5.72e-01	3.03e-03
Formation of HIV-1 elongation complex containing HIV-1 Tat	42	8.74e-07	3.86e-06	0.4660	-4.64e-01	0.034700	1.89e-07	6.97e-01
HIV Transcription Elongation	42	8.74e-07	3.86e-06	0.4660	-4.64e-01	0.034700	1.89e-07	6.97e-01
Tat-mediated elongation of the HIV-1 transcript	42	8.74e-07	3.86e-06	0.4660	-4.64e-01	0.034700	1.89e-07	6.97e-01
mRNA decay by 5’ to 3’ exoribonuclease	15	8.97e-03	1.62e-02	0.4650	-4.54e-01	-0.101000	2.33e-03	4.99e-01
RAC1 GTPase cycle	176	5.03e-26	1.67e-24	0.4650	4.44e-02	-0.463000	3.09e-01	2.75e-26
AUF1 (hnRNP D0) binds and destabilizes mRNA	53	7.57e-09	5.11e-08	0.4640	-3.83e-01	0.261000	1.37e-06	9.89e-04
VxPx cargo-targeting to cilium	19	2.71e-03	5.33e-03	0.4640	-1.13e-01	-0.450000	3.95e-01	6.85e-04
Oncogenic MAPK signaling	75	5.44e-11	5.73e-10	0.4630	-7.07e-02	-0.458000	2.90e-01	6.81e-12
Chondroitin sulfate/dermatan sulfate metabolism	48	4.57e-08	2.58e-07	0.4630	2.95e-01	-0.356000	4.08e-04	1.93e-05
Keratan sulfate biosynthesis	24	5.37e-04	1.25e-03	0.4620	-7.45e-02	-0.456000	5.27e-01	1.09e-04
IRE1alpha activates chaperones	50	3.90e-07	1.87e-06	0.4620	-2.62e-01	-0.381000	1.34e-03	3.19e-06
Regulation of ornithine decarboxylase (ODC)	49	4.03e-08	2.32e-07	0.4620	-4.01e-01	0.230000	1.22e-06	5.39e-03
Folding of actin by CCT/TriC	10	4.03e-02	6.18e-02	0.4620	-4.62e-01	-0.009750	1.15e-02	9.57e-01
Cholesterol biosynthesis	24	7.17e-04	1.63e-03	0.4610	-4.31e-01	-0.164000	2.57e-04	1.65e-01
Rev-mediated nuclear export of HIV RNA	35	3.50e-05	1.05e-04	0.4610	-3.74e-01	-0.269000	1.27e-04	5.86e-03
CDC42 GTPase cycle	153	1.05e-22	3.02e-21	0.4590	1.07e-01	-0.447000	2.26e-02	1.32e-21
Interleukin-35 Signalling	12	2.94e-02	4.67e-02	0.4590	-2.21e-01	-0.402000	1.86e-01	1.58e-02
Ovarian tumor domain proteases	37	2.37e-05	7.40e-05	0.4580	-3.15e-01	-0.333000	9.25e-04	4.61e-04
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis	53	1.24e-08	8.05e-08	0.4580	-3.78e-01	0.259000	1.94e-06	1.12e-03
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC)	32	1.00e-04	2.72e-04	0.4580	-3.25e-01	-0.323000	1.48e-03	1.57e-03
Regulation of Glucokinase by Glucokinase Regulatory Protein	32	1.00e-04	2.72e-04	0.4580	-3.25e-01	-0.323000	1.48e-03	1.57e-03
ER to Golgi Anterograde Transport	131	1.75e-17	3.37e-16	0.4570	-1.73e-01	-0.423000	6.41e-04	5.72e-17
SUMOylation of ubiquitinylation proteins	39	1.39e-05	4.64e-05	0.4570	-3.42e-01	-0.303000	2.20e-04	1.05e-03
Signal amplification	28	3.29e-04	8.11e-04	0.4550	-2.64e-01	-0.371000	1.55e-02	6.77e-04
Ubiquitin-dependent degradation of Cyclin D	50	4.03e-08	2.32e-07	0.4550	-3.66e-01	0.271000	7.51e-06	9.15e-04
Cross-presentation of soluble exogenous antigens (endosomes)	45	2.31e-07	1.18e-06	0.4550	-3.78e-01	0.253000	1.12e-05	3.28e-03
RHO GTPases activate IQGAPs	11	3.52e-02	5.49e-02	0.4540	-5.48e-02	-0.450000	7.53e-01	9.70e-03
NIK–>noncanonical NF-kB signaling	57	5.45e-09	3.82e-08	0.4530	-4.02e-01	0.211000	1.55e-07	5.94e-03
Transport to the Golgi and subsequent modification	161	5.55e-21	1.40e-19	0.4530	-1.71e-01	-0.420000	1.78e-04	3.44e-20
Interleukin receptor SHC signaling	21	1.42e-03	3.00e-03	0.4530	1.52e-02	-0.453000	9.04e-01	3.26e-04
N-glycan antennae elongation in the medial/trans-Golgi	25	8.58e-04	1.93e-03	0.4530	-2.91e-01	-0.347000	1.17e-02	2.65e-03
Activation of BAD and translocation to mitochondria	15	1.24e-02	2.17e-02	0.4530	-1.50e-01	-0.428000	3.14e-01	4.14e-03
RET signaling	37	1.90e-05	6.12e-05	0.4520	-1.29e-01	-0.434000	1.74e-01	4.99e-06
NOTCH4 Activation and Transmission of Signal to the Nucleus	11	2.45e-02	3.97e-02	0.4520	3.47e-01	-0.290000	4.64e-02	9.53e-02
RUNX2 regulates bone development	29	1.61e-04	4.24e-04	0.4520	-6.12e-02	-0.448000	5.69e-01	2.98e-05
Signalling to ERKs	33	7.38e-05	2.07e-04	0.4520	-1.75e-01	-0.417000	8.18e-02	3.44e-05
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint	72	3.21e-11	3.49e-10	0.4520	-3.41e-01	0.296000	5.74e-07	1.36e-05
Nuclear import of Rev protein	34	7.17e-05	2.02e-04	0.4510	-3.58e-01	-0.275000	3.02e-04	5.53e-03
Intra-Golgi and retrograde Golgi-to-ER traffic	179	4.87e-23	1.43e-21	0.4510	-1.67e-01	-0.419000	1.14e-04	3.49e-22
Constitutive Signaling by AKT1 E17K in Cancer	26	6.76e-04	1.55e-03	0.4490	-2.31e-01	-0.385000	4.11e-02	6.70e-04
Signaling by EGFR	48	9.16e-07	4.02e-06	0.4490	-1.29e-01	-0.430000	1.21e-01	2.46e-07
Dectin-1 mediated noncanonical NF-kB signaling	59	4.29e-09	3.13e-08	0.4490	-4.05e-01	0.194000	7.27e-08	9.81e-03
Degradation of AXIN	53	2.88e-08	1.75e-07	0.4490	-3.98e-01	0.209000	5.45e-07	8.50e-03
Processing and activation of SUMO	10	6.27e-02	9.11e-02	0.4490	-3.22e-01	-0.313000	7.78e-02	8.68e-02
Defective CFTR causes cystic fibrosis	58	7.11e-09	4.89e-08	0.4490	-4.16e-01	0.169000	4.27e-08	2.61e-02
mRNA Splicing - Minor Pathway	52	3.23e-08	1.91e-07	0.4490	-3.11e-01	0.323000	1.03e-04	5.51e-05
Alpha-protein kinase 1 signaling pathway	11	3.94e-02	6.06e-02	0.4490	-4.41e-01	-0.084500	1.14e-02	6.28e-01
Sodium/Calcium exchangers	10	3.76e-02	5.79e-02	0.4480	2.24e-01	-0.388000	2.20e-01	3.34e-02
Dermatan sulfate biosynthesis	10	4.00e-02	6.14e-02	0.4480	1.55e-01	-0.420000	3.95e-01	2.13e-02
Signaling by ALK	26	4.49e-04	1.07e-03	0.4480	-5.61e-02	-0.444000	6.20e-01	8.71e-05
Interleukin-7 signaling	23	7.17e-04	1.63e-03	0.4480	9.62e-02	-0.437000	4.24e-01	2.81e-04
Deadenylation-dependent mRNA decay	53	2.51e-07	1.25e-06	0.4480	-4.27e-01	-0.135000	7.48e-08	9.02e-02
Cell-Cell communication	105	2.33e-14	3.63e-13	0.4480	-2.52e-02	-0.447000	6.55e-01	2.40e-15
NOTCH2 intracellular domain regulates transcription	11	3.76e-02	5.79e-02	0.4470	-2.84e-02	-0.446000	8.70e-01	1.05e-02
Cdc20:Phospho-APC/C mediated degradation of Cyclin A	71	7.49e-11	7.52e-10	0.4470	-3.37e-01	0.293000	8.99e-07	1.93e-05
EPHA-mediated growth cone collapse	15	1.56e-02	2.66e-02	0.4470	-2.29e-01	-0.383000	1.25e-01	1.01e-02
STING mediated induction of host immune responses	15	1.53e-02	2.62e-02	0.4460	-3.97e-01	-0.203000	7.74e-03	1.73e-01
Interactions of Rev with host cellular proteins	37	3.83e-05	1.14e-04	0.4460	-3.67e-01	-0.253000	1.11e-04	7.64e-03
Export of Viral Ribonucleoproteins from Nucleus	33	1.23e-04	3.27e-04	0.4460	-2.96e-01	-0.333000	3.22e-03	9.30e-04
Synthesis of bile acids and bile salts via 27-hydroxycholesterol	11	4.54e-02	6.87e-02	0.4450	-4.14e-01	-0.163000	1.74e-02	3.48e-01
XBP1(S) activates chaperone genes	48	2.04e-06	8.29e-06	0.4440	-2.47e-01	-0.369000	3.04e-03	9.55e-06
RHOA GTPase cycle	146	3.70e-20	8.89e-19	0.4440	8.18e-02	-0.436000	8.77e-02	8.35e-20
Formation of the Early Elongation Complex	33	3.73e-05	1.12e-04	0.4430	-4.30e-01	0.106000	1.91e-05	2.90e-01
Formation of the HIV-1 Early Elongation Complex	33	3.73e-05	1.12e-04	0.4430	-4.30e-01	0.106000	1.91e-05	2.90e-01
Nuclear Events (kinase and transcription factor activation)	60	9.77e-08	5.23e-07	0.4430	-3.20e-01	-0.306000	1.83e-05	4.02e-05
Negative regulators of DDX58/IFIH1 signaling	35	7.18e-05	2.02e-04	0.4430	-3.83e-01	-0.222000	8.85e-05	2.28e-02
Regulation of TP53 Activity through Acetylation	29	4.05e-04	9.71e-04	0.4430	-3.36e-01	-0.288000	1.72e-03	7.27e-03
Interleukin-17 signaling	67	1.55e-08	9.85e-08	0.4410	-2.48e-01	-0.364000	4.44e-04	2.46e-07
FLT3 Signaling	35	7.57e-05	2.12e-04	0.4400	-1.92e-01	-0.396000	4.94e-02	5.10e-05
Glycosaminoglycan metabolism	109	1.72e-15	2.86e-14	0.4390	1.92e-01	-0.395000	5.45e-04	9.56e-13
Glutathione conjugation	29	3.04e-04	7.61e-04	0.4380	9.20e-02	0.428000	3.91e-01	6.50e-05
NS1 Mediated Effects on Host Pathways	40	2.66e-05	8.16e-05	0.4380	-3.27e-01	-0.292000	3.49e-04	1.41e-03
PINK1-PRKN Mediated Mitophagy	21	2.10e-03	4.26e-03	0.4370	-4.36e-01	0.036100	5.43e-04	7.75e-01
NOTCH3 Intracellular Domain Regulates Transcription	22	2.01e-03	4.07e-03	0.4360	-3.76e-02	-0.434000	7.60e-01	4.25e-04
Translation	293	3.38e-40	2.60e-38	0.4350	-2.89e-01	0.326000	1.51e-17	7.64e-22
Keratan sulfate/keratin metabolism	29	2.02e-04	5.20e-04	0.4350	5.93e-02	-0.431000	5.80e-01	5.81e-05
GPVI-mediated activation cascade	29	3.42e-04	8.41e-04	0.4350	-9.36e-02	-0.425000	3.83e-01	7.42e-05
p53-Dependent G1 DNA Damage Response	62	4.70e-09	3.36e-08	0.4350	-3.68e-01	0.232000	5.27e-07	1.60e-03
p53-Dependent G1/S DNA damage checkpoint	62	4.70e-09	3.36e-08	0.4350	-3.68e-01	0.232000	5.27e-07	1.60e-03
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known	36	7.69e-05	2.15e-04	0.4350	-2.18e-01	-0.376000	2.34e-02	9.33e-05
CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling	26	9.27e-04	2.06e-03	0.4350	-1.52e-01	-0.407000	1.78e-01	3.25e-04
Myogenesis	25	6.74e-04	1.55e-03	0.4350	5.42e-02	-0.431000	6.39e-01	1.88e-04
Adherens junctions interactions	29	1.22e-04	3.25e-04	0.4340	2.81e-01	-0.331000	8.81e-03	2.02e-03
Gap junction trafficking and regulation	20	2.45e-03	4.87e-03	0.4340	1.37e-01	-0.412000	2.89e-01	1.42e-03
Lewis blood group biosynthesis	14	2.65e-02	4.26e-02	0.4330	-2.36e-01	-0.362000	1.26e-01	1.89e-02
Metabolism of polyamines	57	3.42e-08	2.01e-07	0.4320	-3.92e-01	0.182000	3.00e-07	1.78e-02
Regulation of HMOX1 expression and activity	63	7.66e-09	5.15e-08	0.4320	-4.10e-01	0.136000	1.83e-08	6.23e-02
GRB2 events in EGFR signaling	11	5.95e-02	8.71e-02	0.4310	-2.60e-01	-0.344000	1.35e-01	4.82e-02
Constitutive Signaling by EGFRvIII	15	1.70e-02	2.87e-02	0.4310	-7.65e-02	-0.424000	6.08e-01	4.47e-03
Signaling by EGFRvIII in Cancer	15	1.70e-02	2.87e-02	0.4310	-7.65e-02	-0.424000	6.08e-01	4.47e-03
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion	14	2.83e-02	4.52e-02	0.4300	-2.74e-01	-0.332000	7.61e-02	3.16e-02
Cellular response to heat stress	94	4.47e-11	4.74e-10	0.4300	-3.14e-01	-0.294000	1.39e-07	8.51e-07
Antiviral mechanism by IFN-stimulated genes	80	1.52e-09	1.23e-08	0.4300	-3.31e-01	-0.275000	3.17e-07	2.12e-05
Golgi-to-ER retrograde transport	111	4.47e-13	6.18e-12	0.4300	-2.19e-01	-0.370000	6.79e-05	1.60e-11
Toll Like Receptor 3 (TLR3) Cascade	89	1.59e-10	1.53e-09	0.4300	-2.77e-01	-0.328000	6.05e-06	8.53e-08
Post NMDA receptor activation events	56	2.51e-07	1.25e-06	0.4300	-6.31e-02	-0.425000	4.14e-01	3.70e-08
Neurotoxicity of clostridium toxins	10	7.51e-02	1.07e-01	0.4300	3.85e-01	0.190000	3.49e-02	2.97e-01
Regulation of IFNG signaling	13	3.46e-02	5.42e-02	0.4290	-3.87e-01	-0.185000	1.56e-02	2.49e-01
CDK-mediated phosphorylation and removal of Cdc6	71	4.49e-10	4.04e-09	0.4290	-3.11e-01	0.295000	5.75e-06	1.67e-05
MyD88 cascade initiated on plasma membrane	80	1.67e-09	1.31e-08	0.4290	-2.68e-01	-0.334000	3.29e-05	2.31e-07
Toll Like Receptor 10 (TLR10) Cascade	80	1.67e-09	1.31e-08	0.4290	-2.68e-01	-0.334000	3.29e-05	2.31e-07
Toll Like Receptor 5 (TLR5) Cascade	80	1.67e-09	1.31e-08	0.4290	-2.68e-01	-0.334000	3.29e-05	2.31e-07
IRAK2 mediated activation of TAK1 complex	10	7.67e-02	1.09e-01	0.4280	-3.80e-01	-0.198000	3.74e-02	2.79e-01
Translocation of ZAP-70 to Immunological synapse	13	3.65e-02	5.66e-02	0.4280	2.26e-01	0.364000	1.57e-01	2.32e-02
Retrograde transport at the Trans-Golgi-Network	49	1.50e-06	6.22e-06	0.4280	-2.25e-02	-0.427000	7.86e-01	2.29e-07
Notch-HLH transcription pathway	28	4.82e-04	1.14e-03	0.4270	-2.10e-02	-0.426000	8.48e-01	9.43e-05
Receptor-type tyrosine-protein phosphatases	18	1.03e-02	1.82e-02	0.4270	-2.00e-01	-0.377000	1.42e-01	5.62e-03
DARPP-32 events	23	1.52e-03	3.19e-03	0.4260	6.90e-02	-0.420000	5.67e-01	4.83e-04
Signaling by BRAF and RAF1 fusions	58	2.73e-07	1.34e-06	0.4260	-1.15e-01	-0.410000	1.31e-01	6.59e-08
ECM proteoglycans	43	4.73e-06	1.77e-05	0.4250	1.06e-01	-0.412000	2.28e-01	2.97e-06
ISG15 antiviral mechanism	72	1.81e-08	1.14e-07	0.4250	-3.18e-01	-0.282000	3.08e-06	3.53e-05
RHOBTB GTPase Cycle	35	1.72e-04	4.49e-04	0.4250	-2.79e-01	-0.320000	4.28e-03	1.05e-03
Signaling by NTRKs	131	5.79e-15	9.33e-14	0.4240	-2.03e-01	-0.372000	5.92e-05	1.75e-13
FGFR2 alternative splicing	25	7.43e-04	1.68e-03	0.4240	-3.94e-01	0.155000	6.46e-04	1.78e-01
Signaling by ERBB2 ECD mutants	16	1.28e-02	2.24e-02	0.4240	8.55e-03	-0.423000	9.53e-01	3.36e-03
Glycolysis	67	4.30e-08	2.46e-07	0.4240	-1.63e-01	-0.391000	2.10e-02	3.09e-08
Signaling by NTRK1 (TRKA)	113	6.78e-13	9.20e-12	0.4220	-2.05e-01	-0.369000	1.72e-04	1.13e-11
TICAM1, RIP1-mediated IKK complex recruitment	18	1.02e-02	1.82e-02	0.4220	-4.02e-01	-0.128000	3.17e-03	3.46e-01
G1/S DNA Damage Checkpoints	64	8.32e-09	5.54e-08	0.4220	-3.55e-01	0.228000	9.19e-07	1.59e-03
SUMOylation of immune response proteins	11	5.38e-02	7.95e-02	0.4210	-4.21e-01	-0.022400	1.57e-02	8.98e-01
TNFR1-induced proapoptotic signaling	13	4.20e-02	6.42e-02	0.4210	-3.13e-01	-0.282000	5.07e-02	7.85e-02
DAP12 interactions	33	2.83e-04	7.15e-04	0.4210	-1.97e-01	-0.372000	5.04e-02	2.15e-04
Intra-Golgi traffic	43	1.54e-05	5.13e-05	0.4200	-7.85e-02	-0.413000	3.73e-01	2.81e-06
Degradation of GLI1 by the proteasome	57	7.94e-08	4.28e-07	0.4200	-3.68e-01	0.203000	1.55e-06	8.13e-03
Hh mutants abrogate ligand secretion	57	7.78e-08	4.20e-07	0.4200	-3.60e-01	0.215000	2.54e-06	4.93e-03
RNA Polymerase I Promoter Opening	24	9.80e-04	2.16e-03	0.4190	-2.44e-01	0.341000	3.87e-02	3.81e-03
Membrane Trafficking	577	6.20e-62	4.54e-59	0.4190	-1.53e-01	-0.390000	3.46e-10	4.07e-58
FCERI mediated MAPK activation	29	8.16e-04	1.84e-03	0.4180	-1.85e-01	-0.375000	8.42e-02	4.72e-04
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	89	1.44e-10	1.42e-09	0.4180	-7.35e-02	-0.411000	2.31e-01	2.00e-11
The citric acid (TCA) cycle and respiratory electron transport	173	1.18e-21	3.14e-20	0.4180	-1.52e-01	0.389000	5.42e-04	1.04e-18
SHC1 events in EGFR signaling	12	5.21e-02	7.72e-02	0.4170	-1.57e-01	-0.386000	3.45e-01	2.05e-02
RND2 GTPase cycle	41	1.41e-05	4.71e-05	0.4170	8.75e-02	-0.408000	3.32e-01	6.24e-06
Opioid Signalling	78	2.80e-09	2.13e-08	0.4170	-8.55e-02	-0.408000	1.92e-01	4.59e-10
Negative regulation of the PI3K/AKT network	96	3.32e-11	3.58e-10	0.4150	-7.23e-02	-0.408000	2.21e-01	4.49e-12
Golgi Associated Vesicle Biogenesis	55	1.01e-06	4.41e-06	0.4140	-6.73e-02	-0.408000	3.88e-01	1.61e-07
APC-Cdc20 mediated degradation of Nek2A	26	6.87e-04	1.57e-03	0.4140	-2.25e-01	0.347000	4.73e-02	2.17e-03
Activation of NMDA receptors and postsynaptic events	69	3.22e-08	1.91e-07	0.4140	-7.28e-02	-0.407000	2.96e-01	4.87e-09
Signaling by NTRK2 (TRKB)	24	3.09e-03	6.03e-03	0.4130	-1.67e-01	-0.378000	1.58e-01	1.33e-03
activated TAK1 mediates p38 MAPK activation	18	1.38e-02	2.38e-02	0.4130	-2.01e-01	-0.361000	1.39e-01	8.05e-03
Protein ubiquitination	73	3.11e-08	1.86e-07	0.4130	-3.55e-01	-0.211000	1.56e-07	1.79e-03
Elevation of cytosolic Ca2+ levels	12	4.33e-02	6.60e-02	0.4130	3.73e-02	-0.411000	8.23e-01	1.37e-02
RHO GTPase cycle	433	1.74e-48	3.19e-46	0.4130	-5.48e-05	-0.413000	9.98e-01	2.34e-49
Gap junction degradation	10	8.36e-02	1.17e-01	0.4110	-7.02e-02	-0.405000	7.01e-01	2.64e-02
Phosphorylation of the APC/C	20	4.28e-03	8.12e-03	0.4100	-1.84e-01	0.367000	1.55e-01	4.52e-03
mRNA Capping	29	5.04e-04	1.19e-03	0.4100	-4.03e-01	0.075500	1.75e-04	4.82e-01
Platelet Aggregation (Plug Formation)	29	1.06e-03	2.32e-03	0.4100	-1.67e-01	-0.374000	1.19e-01	4.91e-04
Ca2+ pathway	56	1.02e-06	4.45e-06	0.4090	-5.54e-02	-0.405000	4.73e-01	1.55e-07
Regulation of RUNX2 expression and activity	70	7.42e-09	5.04e-08	0.4090	-3.82e-01	0.145000	3.16e-08	3.60e-02
Regulation of MECP2 expression and activity	29	8.64e-04	1.94e-03	0.4080	-7.05e-02	-0.401000	5.11e-01	1.82e-04
Toll Like Receptor 9 (TLR9) Cascade	90	1.36e-09	1.10e-08	0.4060	-2.50e-01	-0.320000	4.21e-05	1.47e-07
Integrin cell surface interactions	57	2.12e-07	1.09e-06	0.4060	2.19e-01	-0.342000	4.17e-03	8.06e-06
Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA	17	1.28e-02	2.24e-02	0.4050	-3.99e-01	0.072800	4.42e-03	6.03e-01
SHC1 events in ERBB2 signaling	20	7.50e-03	1.37e-02	0.4050	-2.98e-02	-0.404000	8.18e-01	1.76e-03
Role of phospholipids in phagocytosis	22	5.81e-03	1.08e-02	0.4050	-1.30e-01	-0.384000	2.92e-01	1.84e-03
Signaling by FGFR1 in disease	36	2.45e-04	6.25e-04	0.4050	-1.58e-01	-0.372000	1.01e-01	1.10e-04
Cell junction organization	75	4.87e-09	3.46e-08	0.4040	7.64e-02	-0.397000	2.53e-01	2.67e-09
FLT3 signaling in disease	28	1.32e-03	2.82e-03	0.4040	-9.71e-02	-0.393000	3.74e-01	3.22e-04
RNA Pol II CTD phosphorylation and interaction with CE	27	9.01e-04	2.01e-03	0.4040	-3.85e-01	0.122000	5.28e-04	2.74e-01
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection	27	9.01e-04	2.01e-03	0.4040	-3.85e-01	0.122000	5.28e-04	2.74e-01
WNT5A-dependent internalization of FZD2, FZD5 and ROR2	13	3.71e-02	5.74e-02	0.4040	6.61e-02	-0.398000	6.80e-01	1.29e-02
ADP signalling through P2Y purinoceptor 1	21	9.19e-03	1.65e-02	0.4030	-2.68e-01	-0.301000	3.36e-02	1.68e-02
The NLRP3 inflammasome	15	3.48e-02	5.44e-02	0.4030	-3.19e-01	-0.246000	3.24e-02	9.85e-02
Sphingolipid de novo biosynthesis	42	6.52e-05	1.86e-04	0.4020	-1.40e-01	-0.377000	1.17e-01	2.36e-05
Regulation of APC/C activators between G1/S and early anaphase	79	8.70e-10	7.36e-09	0.4010	-3.28e-01	0.232000	4.73e-07	3.63e-04
Nuclear Pore Complex (NPC) Disassembly	36	3.56e-04	8.72e-04	0.4010	-2.89e-01	-0.277000	2.64e-03	3.99e-03
MyD88-independent TLR4 cascade	93	1.24e-09	1.01e-08	0.4010	-2.54e-01	-0.310000	2.23e-05	2.40e-07
TRIF(TICAM1)-mediated TLR4 signaling	93	1.24e-09	1.01e-08	0.4010	-2.54e-01	-0.310000	2.23e-05	2.40e-07
Asymmetric localization of PCP proteins	62	1.30e-07	6.85e-07	0.4010	-3.79e-01	0.129000	2.34e-07	8.00e-02
Initial triggering of complement	13	3.71e-02	5.74e-02	0.4000	-1.09e-01	0.385000	4.94e-01	1.64e-02
Regulation of HSF1-mediated heat shock response	78	3.68e-08	2.14e-07	0.4000	-3.08e-01	-0.255000	2.54e-06	9.92e-05
Prolactin receptor signaling	11	8.33e-02	1.17e-01	0.3990	-1.42e-01	-0.373000	4.15e-01	3.23e-02
Gap junction trafficking	18	9.94e-03	1.77e-02	0.3990	1.57e-01	-0.367000	2.50e-01	7.07e-03
Rab regulation of trafficking	120	4.21e-12	5.02e-11	0.3990	-2.45e-01	-0.315000	3.62e-06	2.54e-09
Pentose phosphate pathway	13	5.33e-02	7.89e-02	0.3980	-3.73e-01	-0.139000	1.98e-02	3.86e-01
Synaptic adhesion-like molecules	21	1.01e-02	1.79e-02	0.3980	-2.26e-01	-0.327000	7.28e-02	9.37e-03
COPII-mediated vesicle transport	66	2.86e-07	1.40e-06	0.3970	-9.43e-02	-0.386000	1.85e-01	5.78e-08
HDACs deacetylate histones	52	3.95e-06	1.50e-05	0.3970	-3.97e-01	0.009860	7.25e-07	9.02e-01
APC/C-mediated degradation of cell cycle proteins	86	2.19e-10	2.07e-09	0.3970	-3.16e-01	0.240000	4.01e-07	1.17e-04
Regulation of mitotic cell cycle	86	2.19e-10	2.07e-09	0.3970	-3.16e-01	0.240000	4.01e-07	1.17e-04
COPI-dependent Golgi-to-ER retrograde traffic	78	4.33e-08	2.46e-07	0.3970	-2.24e-01	-0.328000	6.22e-04	5.63e-07
G alpha (z) signalling events	39	8.99e-05	2.46e-04	0.3970	1.24e-02	-0.396000	8.93e-01	1.83e-05
EGFR downregulation	29	1.90e-03	3.91e-03	0.3960	-2.46e-01	-0.311000	2.20e-02	3.77e-03
Formation of RNA Pol II elongation complex	57	2.17e-06	8.78e-06	0.3950	-3.90e-01	-0.068100	3.60e-07	3.74e-01
RNA Polymerase II Transcription Elongation	57	2.17e-06	8.78e-06	0.3950	-3.90e-01	-0.068100	3.60e-07	3.74e-01
Vesicle-mediated transport	606	5.44e-58	1.99e-55	0.3950	-1.36e-01	-0.371000	1.01e-08	3.43e-55
Late Phase of HIV Life Cycle	135	1.15e-13	1.65e-12	0.3940	-3.72e-01	-0.131000	8.16e-14	8.59e-03
Pre-NOTCH Processing in Golgi	18	2.08e-02	3.41e-02	0.3940	-2.14e-01	-0.331000	1.17e-01	1.50e-02
FGFR1 mutant receptor activation	29	1.54e-03	3.23e-03	0.3940	-1.05e-01	-0.380000	3.27e-01	4.03e-04
RAB GEFs exchange GTP for GDP on RABs	88	6.36e-09	4.40e-08	0.3930	-2.06e-01	-0.335000	8.27e-04	5.42e-08
ER Quality Control Compartment (ERQC)	21	1.15e-02	2.02e-02	0.3930	-2.99e-01	-0.255000	1.75e-02	4.30e-02
Activation of NF-kappaB in B cells	65	1.21e-07	6.41e-07	0.3930	-3.76e-01	0.114000	1.56e-07	1.11e-01
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells	14	3.29e-02	5.18e-02	0.3920	1.08e-01	-0.377000	4.83e-01	1.46e-02
Apoptotic execution phase	47	1.06e-05	3.62e-05	0.3910	1.20e-01	-0.373000	1.53e-01	9.87e-06
Viral Messenger RNA Synthesis	44	7.31e-05	2.05e-04	0.3910	-3.62e-01	-0.147000	3.18e-05	9.05e-02
Regulation of pyruvate dehydrogenase (PDH) complex	15	4.28e-02	6.52e-02	0.3910	-2.92e-01	-0.260000	5.03e-02	8.11e-02
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)	14	4.00e-02	6.14e-02	0.3900	3.90e-01	0.001030	1.15e-02	9.95e-01
Negative regulation of MAPK pathway	42	1.15e-04	3.09e-04	0.3900	-1.36e-01	-0.366000	1.29e-01	4.12e-05
CRMPs in Sema3A signaling	16	2.47e-02	3.99e-02	0.3900	1.89e-02	-0.389000	8.96e-01	7.04e-03
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation	85	2.08e-08	1.29e-07	0.3890	-2.38e-01	-0.307000	1.43e-04	9.56e-07
Glutamate and glutamine metabolism	13	4.86e-02	7.28e-02	0.3890	3.68e-02	-0.387000	8.19e-01	1.56e-02
PKMTs methylate histone lysines	45	8.74e-05	2.40e-04	0.3890	-2.84e-01	-0.266000	9.74e-04	2.04e-03
Thrombin signalling through proteinase activated receptors (PARs)	27	3.65e-03	6.97e-03	0.3890	-2.44e-01	-0.302000	2.82e-02	6.51e-03
NOTCH1 Intracellular Domain Regulates Transcription	47	4.53e-05	1.33e-04	0.3880	-1.40e-01	-0.361000	9.64e-02	1.82e-05
RNA polymerase II transcribes snRNA genes	71	1.96e-07	1.01e-06	0.3870	-3.79e-01	-0.077900	3.36e-08	2.56e-01
MyD88 dependent cascade initiated on endosome	86	2.39e-08	1.47e-07	0.3860	-2.46e-01	-0.296000	7.74e-05	1.99e-06
Toll Like Receptor 7/8 (TLR7/8) Cascade	86	2.39e-08	1.47e-07	0.3860	-2.46e-01	-0.296000	7.74e-05	1.99e-06
Trafficking of GluR2-containing AMPA receptors	16	2.01e-02	3.32e-02	0.3850	3.06e-01	-0.234000	3.39e-02	1.06e-01
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation	34	3.81e-04	9.21e-04	0.3850	-3.79e-01	0.070700	1.32e-04	4.75e-01
G1/S-Specific Transcription	29	2.57e-03	5.10e-03	0.3850	3.25e-01	0.207000	2.45e-03	5.39e-02
SUMOylation of DNA replication proteins	46	8.22e-05	2.26e-04	0.3840	-3.21e-01	-0.212000	1.68e-04	1.28e-02
RNA Polymerase II Transcription Termination	65	1.41e-07	7.37e-07	0.3840	-2.99e-01	0.241000	3.01e-05	7.73e-04
Degradation of GLI2 by the proteasome	57	1.10e-06	4.75e-06	0.3840	-3.25e-01	0.205000	2.23e-05	7.47e-03
DAP12 signaling	26	4.58e-03	8.65e-03	0.3830	-1.47e-01	-0.354000	1.96e-01	1.80e-03
Mitochondrial protein import	64	2.31e-07	1.18e-06	0.3820	-2.03e-01	0.324000	4.91e-03	7.42e-06
SUMOylation of intracellular receptors	27	1.92e-03	3.94e-03	0.3820	1.08e-01	-0.367000	3.33e-01	9.71e-04
FCERI mediated NF-kB activation	75	4.56e-08	2.58e-07	0.3820	-3.79e-01	0.050100	1.40e-08	4.53e-01
Negative regulation of FGFR1 signaling	29	2.96e-03	5.79e-03	0.3820	-2.98e-01	-0.239000	5.55e-03	2.56e-02
Regulation of glycolysis by fructose 2,6-bisphosphate metabolism	11	8.06e-02	1.14e-01	0.3820	8.32e-02	-0.373000	6.33e-01	3.23e-02
Formation of TC-NER Pre-Incision Complex	53	5.23e-06	1.91e-05	0.3810	-3.69e-01	0.096700	3.36e-06	2.23e-01
Metabolism of Angiotensinogen to Angiotensins	11	7.75e-02	1.10e-01	0.3810	3.59e-01	-0.128000	3.91e-02	4.62e-01
Dissolution of Fibrin Clot	12	6.30e-02	9.14e-02	0.3810	1.08e-01	-0.365000	5.16e-01	2.84e-02
HIV Life Cycle	147	6.78e-14	1.01e-12	0.3810	-3.61e-01	-0.123000	4.29e-14	9.88e-03
CLEC7A (Dectin-1) signaling	97	9.10e-10	7.66e-09	0.3810	-3.79e-01	-0.039800	1.10e-10	4.98e-01
Retrograde neurotrophin signalling	14	3.66e-02	5.67e-02	0.3810	1.90e-01	-0.330000	2.18e-01	3.26e-02
LDL clearance	16	2.30e-02	3.74e-02	0.3810	1.86e-01	-0.332000	1.99e-01	2.14e-02
Transcription of the HIV genome	69	3.36e-07	1.63e-06	0.3800	-3.80e-01	-0.021800	4.85e-08	7.54e-01
Budding and maturation of HIV virion	28	3.35e-03	6.48e-03	0.3800	-3.47e-01	-0.156000	1.48e-03	1.54e-01
Disorders of Developmental Biology	13	4.86e-02	7.28e-02	0.3800	1.48e-01	-0.350000	3.54e-01	2.90e-02
Disorders of Nervous System Development	13	4.86e-02	7.28e-02	0.3800	1.48e-01	-0.350000	3.54e-01	2.90e-02
Loss of function of MECP2 in Rett syndrome	13	4.86e-02	7.28e-02	0.3800	1.48e-01	-0.350000	3.54e-01	2.90e-02
Pervasive developmental disorders	13	4.86e-02	7.28e-02	0.3800	1.48e-01	-0.350000	3.54e-01	2.90e-02
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism	12	5.73e-02	8.41e-02	0.3800	2.69e-01	-0.268000	1.07e-01	1.07e-01
alpha-linolenic acid (ALA) metabolism	12	5.73e-02	8.41e-02	0.3800	2.69e-01	-0.268000	1.07e-01	1.07e-01
Interleukin-2 family signaling	34	5.64e-04	1.31e-03	0.3800	2.00e-02	-0.379000	8.40e-01	1.29e-04
Defective GALNT12 causes CRCS1	10	1.36e-01	1.80e-01	0.3800	2.18e-01	0.311000	2.33e-01	8.86e-02
Signaling by NOTCH1	72	2.46e-07	1.23e-06	0.3800	-5.90e-02	-0.375000	3.86e-01	3.69e-08
PI3K/AKT Signaling in Cancer	89	1.12e-08	7.41e-08	0.3790	-1.06e-01	-0.364000	8.44e-02	2.98e-09
AKT phosphorylates targets in the cytosol	14	5.40e-02	7.98e-02	0.3780	-7.82e-02	-0.370000	6.13e-01	1.65e-02
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha	64	3.92e-07	1.88e-06	0.3780	-3.44e-01	0.156000	1.91e-06	3.05e-02
ATF6 (ATF6-alpha) activates chaperone genes	10	1.13e-01	1.54e-01	0.3770	-3.77e-01	0.025200	3.92e-02	8.90e-01
RNA Polymerase III Transcription Termination	23	6.86e-03	1.26e-02	0.3770	-3.77e-01	0.017100	1.76e-03	8.87e-01
CD28 dependent PI3K/Akt signaling	18	2.57e-02	4.14e-02	0.3770	-1.14e-01	-0.359000	4.02e-01	8.34e-03
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA	17	2.26e-02	3.69e-02	0.3760	-3.63e-01	0.096500	9.54e-03	4.91e-01
Glycosphingolipid metabolism	42	6.19e-05	1.77e-04	0.3760	3.18e-01	-0.201000	3.67e-04	2.45e-02
Signaling by FGFR2 IIIa TM	19	1.36e-02	2.35e-02	0.3750	-3.50e-01	0.137000	8.35e-03	3.01e-01
PPARA activates gene expression	108	4.30e-10	3.89e-09	0.3750	-1.30e-01	-0.352000	1.91e-02	2.56e-10
Activation of the pre-replicative complex	33	1.74e-03	3.61e-03	0.3740	2.29e-01	0.295000	2.27e-02	3.31e-03
Regulation of TP53 Degradation	35	1.20e-03	2.60e-03	0.3730	-3.00e-01	-0.222000	2.11e-03	2.32e-02
Cell-cell junction organization	50	1.13e-05	3.85e-05	0.3730	2.15e-01	-0.305000	8.64e-03	1.92e-04
Endosomal/Vacuolar pathway	12	9.77e-02	1.34e-01	0.3720	-1.66e-01	-0.333000	3.18e-01	4.60e-02
Nuclear Envelope Breakdown	53	4.21e-05	1.24e-04	0.3720	-2.37e-01	-0.287000	2.86e-03	3.03e-04
Asparagine N-linked glycosylation	278	3.87e-24	1.16e-22	0.3720	-1.41e-01	-0.344000	4.89e-05	4.83e-23
Signaling by RAF1 mutants	35	8.89e-04	1.99e-03	0.3720	-7.94e-02	-0.363000	4.16e-01	2.01e-04
Potential therapeutics for SARS	81	2.35e-07	1.19e-06	0.3710	-2.55e-01	-0.269000	7.11e-05	2.84e-05
TRAF3-dependent IRF activation pathway	14	6.66e-02	9.60e-02	0.3700	-1.48e-01	-0.340000	3.39e-01	2.78e-02
DNA methylation	26	3.21e-03	6.24e-03	0.3700	-1.54e-01	0.336000	1.73e-01	3.02e-03
Interleukin-20 family signaling	19	2.74e-02	4.37e-02	0.3700	-2.00e-01	-0.311000	1.32e-01	1.89e-02
Regulation of lipid metabolism by PPARalpha	110	5.92e-10	5.16e-09	0.3690	-1.28e-01	-0.346000	2.06e-02	3.40e-10
HuR (ELAVL1) binds and stabilizes mRNA	10	1.15e-01	1.55e-01	0.3690	1.07e-01	-0.353000	5.57e-01	5.32e-02
Assembly of the pre-replicative complex	90	1.93e-09	1.50e-08	0.3690	-2.19e-01	0.297000	3.38e-04	1.10e-06
Diseases of signal transduction by growth factor receptors and second messengers	404	1.35e-33	6.38e-32	0.3680	-1.69e-01	-0.327000	5.80e-09	1.06e-29
GLI3 is processed to GLI3R by the proteasome	57	3.47e-06	1.34e-05	0.3680	-3.21e-01	0.180000	2.76e-05	1.85e-02
Inflammasomes	19	2.84e-02	4.53e-02	0.3680	-3.06e-01	-0.205000	2.11e-02	1.22e-01
Translation of Replicase and Assembly of the Replication Transcription Complex	13	6.88e-02	9.85e-02	0.3680	1.33e-02	-0.368000	9.34e-01	2.17e-02
Carnitine metabolism	11	1.04e-01	1.43e-01	0.3680	9.71e-03	-0.368000	9.56e-01	3.47e-02
Clathrin-mediated endocytosis	135	9.09e-12	1.06e-10	0.3680	-1.69e-01	-0.326000	6.80e-04	5.67e-11
Cytosolic iron-sulfur cluster assembly	13	8.09e-02	1.14e-01	0.3680	1.13e-01	0.350000	4.82e-01	2.89e-02
HATs acetylate histones	99	3.21e-09	2.40e-08	0.3680	-3.62e-01	-0.060900	4.50e-10	2.95e-01
PI3K events in ERBB2 signaling	14	6.84e-02	9.81e-02	0.3670	-1.24e-01	-0.345000	4.20e-01	2.53e-02
RNA Polymerase III Abortive And Retractive Initiation	41	2.69e-04	6.85e-04	0.3660	-3.66e-01	-0.022300	5.06e-05	8.05e-01
RNA Polymerase III Transcription	41	2.69e-04	6.85e-04	0.3660	-3.66e-01	-0.022300	5.06e-05	8.05e-01
RHO GTPases activate CIT	19	3.06e-02	4.85e-02	0.3650	-2.56e-01	-0.261000	5.38e-02	4.87e-02
UCH proteinases	90	4.12e-09	3.02e-08	0.3650	-3.31e-01	0.153000	5.58e-08	1.22e-02
Attenuation phase	23	1.37e-02	2.37e-02	0.3650	-1.58e-01	-0.329000	1.90e-01	6.36e-03
Signaling by ROBO receptors	210	1.76e-20	4.30e-19	0.3640	-2.91e-01	0.219000	3.63e-13	4.27e-08
Insulin receptor signalling cascade	48	8.22e-05	2.26e-04	0.3640	-4.07e-02	-0.362000	6.25e-01	1.45e-05
mRNA Splicing - Major Pathway	179	1.87e-17	3.51e-16	0.3640	-3.13e-01	0.187000	5.22e-13	1.66e-05
NF-kB is activated and signals survival	13	8.12e-02	1.14e-01	0.3640	-3.57e-01	-0.069700	2.58e-02	6.64e-01
Signaling by FGFR3	38	9.76e-04	2.15e-03	0.3640	-2.16e-01	-0.293000	2.13e-02	1.79e-03
Assembly of active LPL and LIPC lipase complexes	12	8.78e-02	1.23e-01	0.3630	3.66e-02	-0.361000	8.26e-01	3.03e-02
EPH-ephrin mediated repulsion of cells	48	5.92e-05	1.70e-04	0.3620	4.72e-02	-0.359000	5.72e-01	1.66e-05
WNT5A-dependent internalization of FZD4	15	4.44e-02	6.75e-02	0.3620	9.55e-02	-0.349000	5.22e-01	1.91e-02
EPH-Ephrin signaling	91	2.93e-08	1.77e-07	0.3620	-7.37e-02	-0.355000	2.24e-01	4.91e-09
ESR-mediated signaling	170	5.47e-14	8.26e-13	0.3620	-2.19e-01	-0.288000	8.17e-07	8.87e-11
Chromatin modifying enzymes	222	3.74e-18	7.95e-17	0.3610	-3.16e-01	-0.175000	4.33e-16	7.24e-06
Chromatin organization	222	3.74e-18	7.95e-17	0.3610	-3.16e-01	-0.175000	4.33e-16	7.24e-06
Association of TriC/CCT with target proteins during biosynthesis	37	1.32e-03	2.82e-03	0.3610	-2.45e-01	-0.265000	9.89e-03	5.21e-03
NOTCH4 Intracellular Domain Regulates Transcription	19	1.93e-02	3.19e-02	0.3600	1.25e-01	-0.338000	3.47e-01	1.07e-02
Cobalamin (Cbl, vitamin B12) transport and metabolism	18	3.20e-02	5.05e-02	0.3600	-3.57e-01	-0.050500	8.80e-03	7.11e-01
Metabolism of RNA	677	2.53e-61	1.24e-58	0.3600	-3.20e-01	0.166000	5.42e-46	1.74e-13
Regulation of TP53 Expression and Degradation	36	1.67e-03	3.49e-03	0.3600	-2.66e-01	-0.242000	5.67e-03	1.21e-02
mRNA Splicing	187	1.09e-17	2.18e-16	0.3580	-2.99e-01	0.196000	1.57e-12	3.60e-06
Amine ligand-binding receptors	22	9.60e-03	1.72e-02	0.3580	2.36e-01	-0.269000	5.54e-02	2.88e-02
HCMV Early Events	80	7.37e-07	3.36e-06	0.3570	-3.03e-01	-0.189000	2.84e-06	3.39e-03
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation	10	1.39e-01	1.84e-01	0.3570	3.53e-01	-0.048500	5.30e-02	7.91e-01
RUNX1 regulates transcription of genes involved in differentiation of HSCs	87	1.47e-08	9.48e-08	0.3560	-2.95e-01	0.199000	1.96e-06	1.31e-03
Sialic acid metabolism	31	4.34e-03	8.23e-03	0.3560	-1.90e-01	-0.301000	6.68e-02	3.76e-03
Processing of Capped Intron-Containing Pre-mRNA	238	1.80e-21	4.70e-20	0.3550	-3.32e-01	0.125000	9.00e-19	8.86e-04
Transport of Mature Transcript to Cytoplasm	81	1.61e-07	8.33e-07	0.3550	-3.53e-01	0.036400	4.02e-08	5.72e-01
Fatty acyl-CoA biosynthesis	35	1.26e-03	2.70e-03	0.3540	1.93e-02	-0.353000	8.44e-01	2.99e-04
Regulation of mRNA stability by proteins that bind AU-rich elements	87	3.13e-08	1.86e-07	0.3540	-3.36e-01	0.109000	5.79e-08	7.86e-02
AKT phosphorylates targets in the nucleus	10	1.45e-01	1.90e-01	0.3530	4.70e-02	-0.350000	7.97e-01	5.53e-02
SHC1 events in ERBB4 signaling	12	1.19e-01	1.60e-01	0.3520	-1.10e-01	-0.334000	5.08e-01	4.49e-02
p75NTR recruits signalling complexes	13	9.50e-02	1.31e-01	0.3520	-3.46e-01	-0.063800	3.08e-02	6.90e-01
Effects of PIP2 hydrolysis	24	1.16e-02	2.05e-02	0.3520	-1.21e-02	-0.351000	9.18e-01	2.89e-03
Extracellular matrix organization	249	5.50e-22	1.52e-20	0.3510	1.28e-01	-0.327000	4.90e-04	5.56e-19
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase	20	1.77e-02	2.95e-02	0.3510	-1.83e-01	0.300000	1.57e-01	2.02e-02
HIV Infection	222	6.65e-18	1.35e-16	0.3510	-3.43e-01	-0.074100	1.09e-18	5.68e-02
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters	17	4.55e-02	6.88e-02	0.3510	-4.70e-02	-0.348000	7.37e-01	1.30e-02
NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux	35	2.24e-03	4.49e-03	0.3510	-1.29e-01	-0.326000	1.87e-01	8.33e-04
SUMOylation of chromatin organization proteins	57	6.72e-05	1.91e-04	0.3510	-2.43e-01	-0.252000	1.49e-03	9.77e-04
Switching of origins to a post-replicative state	89	1.60e-08	1.01e-07	0.3510	-2.17e-01	0.276000	4.11e-04	6.93e-06
Blood group systems biosynthesis	18	4.57e-02	6.89e-02	0.3500	-1.65e-01	-0.309000	2.25e-01	2.32e-02
Constitutive Signaling by Aberrant PI3K in Cancer	62	1.38e-05	4.64e-05	0.3500	-4.45e-02	-0.347000	5.45e-01	2.27e-06
Semaphorin interactions	60	1.52e-05	5.07e-05	0.3500	1.82e-03	-0.350000	9.81e-01	2.75e-06
PCNA-Dependent Long Patch Base Excision Repair	21	2.89e-02	4.60e-02	0.3500	2.03e-01	0.285000	1.07e-01	2.40e-02
Resolution of D-Loop Structures	33	3.94e-03	7.48e-03	0.3500	2.41e-01	0.253000	1.66e-02	1.18e-02
WNT ligand biogenesis and trafficking	24	1.31e-02	2.27e-02	0.3490	-3.67e-02	-0.347000	7.55e-01	3.23e-03
SUMOylation of transcription cofactors	44	6.32e-04	1.46e-03	0.3490	-2.22e-01	-0.269000	1.08e-02	2.00e-03
Orc1 removal from chromatin	69	9.86e-07	4.31e-06	0.3490	-2.36e-01	0.257000	7.00e-04	2.21e-04
GRB2 events in ERBB2 signaling	14	9.41e-02	1.30e-01	0.3480	-1.69e-01	-0.304000	2.72e-01	4.90e-02
Cargo recognition for clathrin-mediated endocytosis	97	6.57e-08	3.60e-07	0.3480	-1.36e-01	-0.320000	2.06e-02	4.93e-08
SCF(Skp2)-mediated degradation of p27/p21	60	6.61e-06	2.37e-05	0.3480	-2.73e-01	0.215000	2.51e-04	3.92e-03
Synthesis of very long-chain fatty acyl-CoAs	22	1.39e-02	2.39e-02	0.3480	1.33e-01	-0.321000	2.81e-01	9.08e-03
Negative regulation of TCF-dependent signaling by WNT ligand antagonists	11	1.53e-01	2.00e-01	0.3470	-1.34e-01	-0.320000	4.41e-01	6.59e-02
Cytosolic tRNA aminoacylation	24	1.72e-02	2.89e-02	0.3470	-3.15e-01	-0.145000	7.49e-03	2.19e-01
trans-Golgi Network Vesicle Budding	71	2.73e-06	1.07e-05	0.3470	-1.03e-02	-0.347000	8.81e-01	4.36e-07
NRAGE signals death through JNK	59	1.79e-05	5.80e-05	0.3460	4.38e-02	-0.344000	5.60e-01	4.94e-06
Reactions specific to the complex N-glycan synthesis pathway	10	1.90e-01	2.43e-01	0.3460	-2.88e-01	-0.192000	1.14e-01	2.94e-01
Deactivation of the beta-catenin transactivating complex	41	3.69e-04	8.98e-04	0.3460	1.37e-01	-0.318000	1.30e-01	4.28e-04
RNA Polymerase II Pre-transcription Events	80	8.69e-07	3.86e-06	0.3450	-3.40e-01	-0.059400	1.40e-07	3.58e-01
SUMOylation of RNA binding proteins	47	4.50e-04	1.07e-03	0.3450	-2.78e-01	-0.204000	9.64e-04	1.56e-02
DSCAM interactions	10	1.93e-01	2.47e-01	0.3450	-1.95e-01	-0.284000	2.85e-01	1.20e-01
Host Interactions of HIV factors	124	3.03e-10	2.84e-09	0.3450	-3.44e-01	-0.024300	3.60e-11	6.41e-01
HSF1 activation	26	1.46e-02	2.51e-02	0.3440	-2.32e-01	-0.254000	4.08e-02	2.48e-02
SARS-CoV-2 Infection	70	6.78e-06	2.42e-05	0.3440	-9.37e-02	-0.331000	1.75e-01	1.66e-06
Assembly and cell surface presentation of NMDA receptors	23	2.31e-02	3.77e-02	0.3440	-1.92e-01	-0.286000	1.11e-01	1.78e-02
Condensation of Prophase Chromosomes	34	1.32e-03	2.82e-03	0.3440	-2.51e-01	0.235000	1.14e-02	1.75e-02
Transport of bile salts and organic acids, metal ions and amine compounds	58	2.16e-05	6.79e-05	0.3440	7.21e-02	-0.336000	3.42e-01	9.37e-06
Metabolism of non-coding RNA	53	1.47e-04	3.89e-04	0.3430	-3.19e-01	-0.127000	5.99e-05	1.09e-01
snRNP Assembly	53	1.47e-04	3.89e-04	0.3430	-3.19e-01	-0.127000	5.99e-05	1.09e-01
RAB geranylgeranylation	62	3.75e-05	1.12e-04	0.3430	-1.54e-01	-0.306000	3.58e-02	3.03e-05
SARS-CoV Infections	150	2.75e-11	3.05e-10	0.3420	-1.75e-01	-0.294000	2.07e-04	5.04e-10
Transport of Mature mRNA derived from an Intron-Containing Transcript	72	2.55e-06	1.01e-05	0.3400	-3.37e-01	0.044700	7.35e-07	5.12e-01
TNFR1-induced NFkappaB signaling pathway	26	1.58e-02	2.68e-02	0.3400	-2.73e-01	-0.204000	1.61e-02	7.23e-02
Signaling by ERBB2 in Cancer	24	1.75e-02	2.93e-02	0.3400	-6.50e-02	-0.334000	5.82e-01	4.66e-03
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression	37	9.88e-04	2.17e-03	0.3400	-3.03e-01	0.153000	1.42e-03	1.06e-01
HSF1-dependent transactivation	31	6.44e-03	1.19e-02	0.3390	-1.29e-01	-0.314000	2.13e-01	2.49e-03
Fc epsilon receptor (FCERI) signaling	126	1.67e-09	1.31e-08	0.3390	-3.04e-01	-0.150000	3.80e-09	3.58e-03
Regulation of RAS by GAPs	64	9.56e-06	3.32e-05	0.3390	-3.29e-01	0.082000	5.40e-06	2.56e-01
Defective B3GALTL causes PpS	36	1.22e-03	2.63e-03	0.3390	3.00e-01	-0.158000	1.86e-03	1.01e-01
Unfolded Protein Response (UPR)	89	6.86e-07	3.14e-06	0.3380	-2.97e-01	-0.163000	1.28e-06	7.96e-03
Processing of Capped Intronless Pre-mRNA	28	6.59e-03	1.22e-02	0.3380	-3.31e-01	0.068900	2.40e-03	5.28e-01
Hedgehog ‘on’ state	84	2.42e-07	1.22e-06	0.3370	-3.19e-01	0.109000	4.14e-07	8.40e-02
RHOBTB2 GTPase cycle	23	2.74e-02	4.37e-02	0.3370	-2.64e-01	-0.210000	2.84e-02	8.18e-02
Glucagon signaling in metabolic regulation	26	1.48e-02	2.53e-02	0.3370	-1.06e-01	-0.320000	3.49e-01	4.76e-03
IGF1R signaling cascade	47	2.97e-04	7.47e-04	0.3370	1.76e-02	-0.336000	8.34e-01	6.65e-05
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	47	2.97e-04	7.47e-04	0.3370	1.76e-02	-0.336000	8.34e-01	6.65e-05
Signaling by Receptor Tyrosine Kinases	468	1.35e-34	6.60e-33	0.3370	-2.07e-02	-0.336000	4.42e-01	9.18e-36
ABC transporters in lipid homeostasis	15	8.39e-02	1.17e-01	0.3360	3.31e-01	0.054300	2.64e-02	7.16e-01
Interferon alpha/beta signaling	56	5.90e-05	1.70e-04	0.3350	-3.30e-01	0.054900	1.93e-05	4.77e-01
mRNA 3’-end processing	56	3.39e-05	1.02e-04	0.3340	-2.63e-01	0.206000	6.60e-04	7.51e-03
Regulation of PTEN stability and activity	67	9.25e-06	3.23e-05	0.3330	-3.26e-01	0.066400	3.90e-06	3.47e-01
O-linked glycosylation of mucins	48	1.94e-04	5.03e-04	0.3310	1.51e-01	-0.295000	7.06e-02	4.04e-04
E3 ubiquitin ligases ubiquitinate target proteins	53	3.03e-04	7.59e-04	0.3310	-2.90e-01	-0.160000	2.56e-04	4.44e-02
Inhibition of DNA recombination at telomere	39	9.43e-04	2.09e-03	0.3310	-2.88e-01	0.164000	1.87e-03	7.67e-02
G alpha (12/13) signalling events	75	2.45e-06	9.72e-06	0.3310	7.84e-02	-0.322000	2.40e-01	1.45e-06
Packaging Of Telomere Ends	24	1.53e-02	2.61e-02	0.3300	-3.13e-01	0.107000	8.03e-03	3.63e-01
Selective autophagy	58	1.67e-04	4.38e-04	0.3300	-2.59e-01	-0.205000	6.48e-04	6.92e-03
PI-3K cascade:FGFR1	18	6.31e-02	9.15e-02	0.3300	-1.35e-01	-0.301000	3.21e-01	2.69e-02
Thromboxane signalling through TP receptor	20	5.00e-02	7.48e-02	0.3300	-2.22e-01	-0.244000	8.54e-02	5.86e-02
Transcriptional regulation by RUNX3	94	6.02e-07	2.80e-06	0.3300	-2.96e-01	-0.146000	7.02e-07	1.42e-02
Activation of the AP-1 family of transcription factors	10	2.24e-01	2.82e-01	0.3300	-2.20e-01	-0.246000	2.29e-01	1.78e-01
NGF-stimulated transcription	38	2.67e-03	5.26e-03	0.3290	-3.17e-01	-0.090300	7.27e-04	3.35e-01
Cellular response to hypoxia	72	5.56e-06	2.03e-05	0.3290	-3.25e-01	0.051400	1.83e-06	4.51e-01
DNA Replication Pre-Initiation	107	7.36e-09	5.04e-08	0.3290	-1.45e-01	0.295000	9.36e-03	1.29e-07
Interleukin-12 signaling	43	9.30e-04	2.06e-03	0.3290	-3.29e-01	-0.012800	1.90e-04	8.85e-01
Downstream signaling events of B Cell Receptor (BCR)	79	1.94e-06	7.93e-06	0.3290	-3.27e-01	0.036500	5.01e-07	5.75e-01
CDC6 association with the ORC:origin complex	11	1.88e-01	2.41e-01	0.3290	1.34e-01	0.300000	4.41e-01	8.50e-02
ER-Phagosome pathway	86	3.29e-07	1.60e-06	0.3290	-3.02e-01	0.130000	1.32e-06	3.66e-02
Signaling by FGFR1	46	9.84e-04	2.16e-03	0.3270	-1.40e-01	-0.296000	1.00e-01	5.11e-04
Degradation of beta-catenin by the destruction complex	83	2.03e-06	8.29e-06	0.3270	-3.25e-01	-0.040200	3.10e-07	5.27e-01
NR1H2 and NR1H3-mediated signaling	43	1.61e-03	3.37e-03	0.3270	-1.45e-01	-0.293000	1.00e-01	8.86e-04
Negative regulation of FGFR3 signaling	27	1.92e-02	3.18e-02	0.3270	-2.33e-01	-0.228000	3.58e-02	4.00e-02
Translesion synthesis by POLI	17	6.27e-02	9.11e-02	0.3260	-2.19e-02	0.326000	8.76e-01	2.01e-02
Fanconi Anemia Pathway	36	3.63e-03	6.96e-03	0.3260	5.24e-02	0.322000	5.87e-01	8.28e-04
Caspase activation via extrinsic apoptotic signalling pathway	25	2.09e-02	3.43e-02	0.3250	-5.92e-02	-0.320000	6.08e-01	5.61e-03
IRS-related events triggered by IGF1R	46	6.60e-04	1.52e-03	0.3250	-3.13e-03	-0.325000	9.71e-01	1.37e-04
Signaling by Rho GTPases	625	3.81e-42	3.72e-40	0.3250	-4.17e-02	-0.322000	7.44e-02	2.52e-43
Intracellular signaling by second messengers	287	9.43e-19	2.09e-17	0.3250	-1.83e-01	-0.269000	9.73e-08	4.49e-15
DDX58/IFIH1-mediated induction of interferon-alpha/beta	66	6.43e-05	1.83e-04	0.3250	-2.79e-01	-0.167000	9.04e-05	1.92e-02
Platelet activation, signaling and aggregation	224	1.18e-15	1.99e-14	0.3240	-5.07e-02	-0.320000	1.91e-01	1.31e-16
Signaling by high-kinase activity BRAF mutants	31	8.07e-03	1.46e-02	0.3240	-3.76e-02	-0.322000	7.17e-01	1.91e-03
Inactivation of APC/C via direct inhibition of the APC/C complex	21	2.72e-02	4.36e-02	0.3240	-1.71e-01	0.275000	1.74e-01	2.92e-02
Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components	21	2.72e-02	4.36e-02	0.3240	-1.71e-01	0.275000	1.74e-01	2.92e-02
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	641	1.00e-42	1.05e-40	0.3240	-4.79e-02	-0.320000	3.82e-02	7.99e-44
Transcriptional regulation of white adipocyte differentiation	81	6.52e-06	2.35e-05	0.3240	-1.28e-01	-0.297000	4.71e-02	3.70e-06
Synthesis of IP2, IP, and Ins in the cytosol	14	1.33e-01	1.77e-01	0.3230	-2.08e-01	-0.247000	1.77e-01	1.09e-01
Signaling by FGFR4	37	4.87e-03	9.16e-03	0.3230	-1.95e-01	-0.258000	4.05e-02	6.61e-03
Metabolism of amine-derived hormones	12	1.79e-01	2.31e-01	0.3220	2.58e-01	0.194000	1.22e-01	2.45e-01
Transcriptional Regulation by MECP2	55	1.44e-04	3.81e-04	0.3220	4.85e-02	-0.318000	5.34e-01	4.39e-05
TRAF6 mediated IRF7 activation	16	1.00e-01	1.38e-01	0.3220	-1.67e-01	-0.275000	2.46e-01	5.70e-02
SUMOylation of DNA damage response and repair proteins	76	2.12e-05	6.69e-05	0.3210	-2.17e-01	-0.237000	1.06e-03	3.53e-04
Resolution of D-loop Structures through Holliday Junction Intermediates	32	1.07e-02	1.90e-02	0.3210	2.21e-01	0.233000	3.05e-02	2.23e-02
Digestion and absorption	10	1.89e-01	2.42e-01	0.3210	-1.39e-01	0.289000	4.46e-01	1.13e-01
The role of Nef in HIV-1 replication and disease pathogenesis	23	3.44e-02	5.38e-02	0.3200	-1.02e-01	-0.304000	3.95e-01	1.17e-02
Regulation of beta-cell development	29	7.66e-03	1.40e-02	0.3200	1.74e-01	-0.269000	1.05e-01	1.22e-02
Diseases of carbohydrate metabolism	30	8.99e-03	1.62e-02	0.3200	3.19e-01	-0.026300	2.49e-03	8.03e-01
G beta:gamma signalling through CDC42	16	1.06e-01	1.44e-01	0.3200	-2.26e-01	-0.226000	1.18e-01	1.17e-01
Phospholipid metabolism	186	3.53e-12	4.24e-11	0.3190	-1.47e-01	-0.283000	5.25e-04	2.57e-11
Paradoxical activation of RAF signaling by kinase inactive BRAF	39	3.33e-03	6.44e-03	0.3190	-8.88e-02	-0.306000	3.37e-01	9.24e-04
Signaling by RAS mutants	39	3.33e-03	6.44e-03	0.3190	-8.88e-02	-0.306000	3.37e-01	9.24e-04
Signaling by moderate kinase activity BRAF mutants	39	3.33e-03	6.44e-03	0.3190	-8.88e-02	-0.306000	3.37e-01	9.24e-04
Signaling downstream of RAS mutants	39	3.33e-03	6.44e-03	0.3190	-8.88e-02	-0.306000	3.37e-01	9.24e-04
RNA Polymerase I Promoter Escape	52	1.64e-04	4.31e-04	0.3190	-2.23e-01	0.228000	5.39e-03	4.45e-03
Class I peroxisomal membrane protein import	19	4.28e-02	6.52e-02	0.3190	1.65e-01	-0.272000	2.12e-01	3.99e-02
Interleukin-1 signaling	95	4.85e-07	2.29e-06	0.3190	-3.19e-01	0.000406	7.91e-08	9.95e-01
HIV Transcription Initiation	47	5.12e-04	1.20e-03	0.3180	-3.01e-01	0.103000	3.57e-04	2.23e-01
RNA Polymerase II HIV Promoter Escape	47	5.12e-04	1.20e-03	0.3180	-3.01e-01	0.103000	3.57e-04	2.23e-01
RNA Polymerase II Promoter Escape	47	5.12e-04	1.20e-03	0.3180	-3.01e-01	0.103000	3.57e-04	2.23e-01
RNA Polymerase II Transcription Initiation	47	5.12e-04	1.20e-03	0.3180	-3.01e-01	0.103000	3.57e-04	2.23e-01
RNA Polymerase II Transcription Initiation And Promoter Clearance	47	5.12e-04	1.20e-03	0.3180	-3.01e-01	0.103000	3.57e-04	2.23e-01
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening	47	5.12e-04	1.20e-03	0.3180	-3.01e-01	0.103000	3.57e-04	2.23e-01
PRC2 methylates histones and DNA	34	3.48e-03	6.69e-03	0.3180	-2.11e-01	0.237000	3.28e-02	1.66e-02
Glycogen breakdown (glycogenolysis)	15	9.56e-02	1.32e-01	0.3170	4.87e-02	-0.314000	7.44e-01	3.54e-02
Hedgehog ligand biogenesis	63	3.20e-05	9.70e-05	0.3170	-2.70e-01	0.166000	2.05e-04	2.27e-02
HCMV Infection	104	5.76e-07	2.69e-06	0.3170	-2.52e-01	-0.192000	8.92e-06	6.93e-04
Platelet homeostasis	72	1.53e-05	5.10e-05	0.3170	2.66e-02	-0.316000	6.96e-01	3.53e-06
N-glycan trimming in the ER and Calnexin/Calreticulin cycle	35	7.45e-03	1.36e-02	0.3170	-1.55e-01	-0.277000	1.13e-01	4.62e-03
O-glycosylation of TSR domain-containing proteins	37	2.31e-03	4.62e-03	0.3170	2.69e-01	-0.167000	4.57e-03	7.91e-02
MyD88:MAL(TIRAP) cascade initiated on plasma membrane	94	2.40e-06	9.59e-06	0.3170	-2.08e-01	-0.239000	4.84e-04	6.22e-05
Toll Like Receptor 2 (TLR2) Cascade	94	2.40e-06	9.59e-06	0.3170	-2.08e-01	-0.239000	4.84e-04	6.22e-05
Toll Like Receptor TLR1:TLR2 Cascade	94	2.40e-06	9.59e-06	0.3170	-2.08e-01	-0.239000	4.84e-04	6.22e-05
Toll Like Receptor TLR6:TLR2 Cascade	94	2.40e-06	9.59e-06	0.3170	-2.08e-01	-0.239000	4.84e-04	6.22e-05
Costimulation by the CD28 family	57	2.82e-04	7.13e-04	0.3170	-9.74e-02	-0.301000	2.03e-01	8.23e-05
Activation of ATR in response to replication stress	37	6.12e-03	1.13e-02	0.3170	2.27e-01	0.221000	1.71e-02	1.97e-02
Toll Like Receptor 4 (TLR4) Cascade	121	5.94e-08	3.30e-07	0.3170	-1.98e-01	-0.247000	1.69e-04	2.63e-06
Autophagy	124	4.03e-08	2.32e-07	0.3160	-1.92e-01	-0.251000	2.18e-04	1.35e-06
TNFR2 non-canonical NF-kB pathway	89	5.23e-07	2.46e-06	0.3160	-2.73e-01	0.159000	8.36e-06	9.54e-03
Mitochondrial Fatty Acid Beta-Oxidation	34	9.47e-03	1.70e-02	0.3150	1.94e-01	0.249000	5.07e-02	1.19e-02
FGFRL1 modulation of FGFR1 signaling	11	1.66e-01	2.16e-01	0.3150	1.85e-01	-0.255000	2.87e-01	1.43e-01
Deubiquitination	246	2.48e-15	4.04e-14	0.3150	-2.66e-01	-0.169000	5.99e-13	5.06e-06
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding	34	8.73e-03	1.58e-02	0.3150	-2.88e-01	-0.126000	3.64e-03	2.02e-01
PIP3 activates AKT signaling	251	2.31e-15	3.80e-14	0.3140	-2.09e-01	-0.234000	1.22e-08	1.52e-10
IRF3-mediated induction of type I IFN	12	1.91e-01	2.44e-01	0.3130	-2.85e-01	-0.130000	8.74e-02	4.37e-01
Negative regulation of MET activity	21	5.46e-02	8.05e-02	0.3130	-1.18e-01	-0.290000	3.51e-01	2.15e-02
Listeria monocytogenes entry into host cells	20	6.40e-02	9.24e-02	0.3130	-1.33e-01	-0.283000	3.04e-01	2.84e-02
p75 NTR receptor-mediated signalling	94	1.25e-06	5.37e-06	0.3130	-3.24e-02	-0.311000	5.87e-01	1.85e-07
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants	57	3.22e-04	7.96e-04	0.3120	-7.07e-02	-0.304000	3.56e-01	7.17e-05
Constitutive Signaling by NOTCH1 PEST Domain Mutants	57	3.22e-04	7.96e-04	0.3120	-7.07e-02	-0.304000	3.56e-01	7.17e-05
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer	57	3.22e-04	7.96e-04	0.3120	-7.07e-02	-0.304000	3.56e-01	7.17e-05
Signaling by NOTCH1 PEST Domain Mutants in Cancer	57	3.22e-04	7.96e-04	0.3120	-7.07e-02	-0.304000	3.56e-01	7.17e-05
Signaling by NOTCH1 in Cancer	57	3.22e-04	7.96e-04	0.3120	-7.07e-02	-0.304000	3.56e-01	7.17e-05
DNA Damage Recognition in GG-NER	38	2.66e-03	5.26e-03	0.3110	-2.86e-01	0.123000	2.30e-03	1.88e-01
Formation of the cornified envelope	21	5.33e-02	7.89e-02	0.3110	-7.98e-02	-0.301000	5.27e-01	1.71e-02
Regulation of TLR by endogenous ligand	14	1.51e-01	1.97e-01	0.3110	1.48e-01	0.274000	3.38e-01	7.63e-02
Ub-specific processing proteases	175	4.13e-11	4.42e-10	0.3110	-2.91e-01	-0.110000	2.99e-11	1.23e-02
Signaling by ERBB2 KD Mutants	23	3.72e-02	5.75e-02	0.3100	-2.82e-02	-0.309000	8.15e-01	1.03e-02
Mismatch Repair	15	1.06e-01	1.44e-01	0.3100	3.06e-01	-0.052400	4.03e-02	7.25e-01
IRS-mediated signalling	43	2.19e-03	4.41e-03	0.3100	-3.32e-02	-0.308000	7.07e-01	4.66e-04
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)	14	1.29e-01	1.72e-01	0.3100	3.10e-01	-0.009920	4.47e-02	9.49e-01
Rap1 signalling	15	1.12e-01	1.52e-01	0.3100	7.79e-03	-0.310000	9.58e-01	3.77e-02
RNA Polymerase I Promoter Clearance	71	1.56e-05	5.17e-05	0.3100	-2.71e-01	0.150000	7.83e-05	2.90e-02
RNA Polymerase I Transcription	71	1.56e-05	5.17e-05	0.3100	-2.71e-01	0.150000	7.83e-05	2.90e-02
HCMV Late Events	76	3.86e-05	1.14e-04	0.3090	-2.76e-01	-0.141000	3.25e-05	3.39e-02
Deposition of new CENPA-containing nucleosomes at the centromere	44	1.23e-03	2.64e-03	0.3090	-9.58e-02	0.294000	2.71e-01	7.33e-04
Nucleosome assembly	44	1.23e-03	2.64e-03	0.3090	-9.58e-02	0.294000	2.71e-01	7.33e-04
O-linked glycosylation	95	3.52e-07	1.70e-06	0.3090	1.82e-01	-0.250000	2.16e-03	2.59e-05
NoRC negatively regulates rRNA expression	67	2.83e-05	8.62e-05	0.3090	-2.45e-01	0.188000	5.24e-04	7.90e-03
Synthesis of DNA	118	2.44e-08	1.50e-07	0.3090	-6.24e-02	0.302000	2.42e-01	1.40e-08
RNA Polymerase III Transcription Initiation	36	5.80e-03	1.08e-02	0.3080	-3.08e-01	-0.007560	1.36e-03	9.37e-01
Nonhomologous End-Joining (NHEJ)	43	3.41e-03	6.57e-03	0.3080	-2.67e-01	-0.154000	2.45e-03	8.02e-02
Antigen processing: Ubiquitination & Proteasome degradation	292	3.99e-17	7.32e-16	0.3080	-2.35e-01	-0.200000	4.88e-12	4.23e-09
RNA Polymerase III Transcription Initiation From Type 2 Promoter	27	2.38e-02	3.86e-02	0.3080	-3.03e-01	-0.057100	6.51e-03	6.08e-01
Sensory processing of sound by outer hair cells of the cochlea	43	1.46e-03	3.08e-03	0.3080	1.12e-01	-0.287000	2.06e-01	1.13e-03
Negative epigenetic regulation of rRNA expression	70	1.97e-05	6.25e-05	0.3080	-2.59e-01	0.166000	1.79e-04	1.60e-02
C-type lectin receptors (CLRs)	123	4.96e-08	2.79e-07	0.3070	-3.00e-01	-0.066700	8.92e-09	2.01e-01
Synthesis of PA	32	1.63e-02	2.77e-02	0.3060	-2.24e-01	-0.208000	2.80e-02	4.16e-02
Integration of energy metabolism	93	3.60e-06	1.38e-05	0.3060	-7.54e-02	-0.296000	2.09e-01	7.77e-07
Cytosolic sensors of pathogen-associated DNA	61	3.20e-04	7.96e-04	0.3060	-2.83e-01	-0.117000	1.34e-04	1.15e-01
RNA Polymerase I Transcription Initiation	47	1.03e-03	2.25e-03	0.3050	-2.98e-01	0.067400	4.08e-04	4.24e-01
Translesion synthesis by REV1	16	1.05e-01	1.44e-01	0.3050	1.83e-03	0.305000	9.90e-01	3.46e-02
Toll-like Receptor Cascades	139	2.05e-08	1.28e-07	0.3040	-1.78e-01	-0.247000	2.86e-04	4.97e-07
Glutamate binding, activation of AMPA receptors and synaptic plasticity	27	1.76e-02	2.94e-02	0.3040	1.29e-01	-0.275000	2.44e-01	1.33e-02
Trafficking of AMPA receptors	27	1.76e-02	2.94e-02	0.3040	1.29e-01	-0.275000	2.44e-01	1.33e-02
Cell surface interactions at the vascular wall	97	1.19e-06	5.16e-06	0.3040	1.38e-02	-0.304000	8.14e-01	2.29e-07
Prefoldin mediated transfer of substrate to CCT/TriC	27	1.79e-02	2.98e-02	0.3040	-2.78e-01	0.123000	1.24e-02	2.68e-01
Physiological factors	10	2.75e-01	3.35e-01	0.3040	-1.40e-01	-0.269000	4.43e-01	1.40e-01
DNA Replication	150	4.83e-10	4.31e-09	0.3030	-5.70e-02	0.298000	2.28e-01	2.95e-10
Acyl chain remodelling of PI	10	2.26e-01	2.84e-01	0.3030	2.72e-01	-0.134000	1.36e-01	4.64e-01
Sphingolipid metabolism	84	5.03e-06	1.87e-05	0.3030	8.92e-02	-0.289000	1.58e-01	4.55e-06
Downstream TCR signaling	88	3.70e-06	1.41e-05	0.3020	-2.97e-01	0.056200	1.48e-06	3.62e-01
ABC transporter disorders	73	2.16e-05	6.79e-05	0.3020	-2.72e-01	0.132000	6.00e-05	5.19e-02
PTEN Regulation	140	1.48e-08	9.52e-08	0.3020	-2.83e-01	-0.105000	7.59e-09	3.12e-02
Metabolism of carbohydrates	262	7.77e-17	1.39e-15	0.3020	6.63e-02	-0.294000	6.44e-02	2.26e-16
ADP signalling through P2Y purinoceptor 12	17	1.20e-01	1.61e-01	0.3010	-2.02e-01	-0.224000	1.50e-01	1.10e-01
Nuclear Receptor transcription pathway	46	2.21e-03	4.44e-03	0.3010	-4.40e-02	-0.297000	6.06e-01	4.80e-04
Negative regulation of FGFR4 signaling	27	3.52e-02	5.49e-02	0.3000	-2.28e-01	-0.196000	4.05e-02	7.84e-02
Interaction between L1 and Ankyrins	25	2.47e-02	3.99e-02	0.3000	2.22e-01	-0.201000	5.45e-02	8.16e-02
Death Receptor Signalling	137	2.74e-08	1.67e-07	0.3000	-1.03e-01	-0.281000	3.72e-02	1.29e-08
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways	49	2.40e-03	4.78e-03	0.2990	-2.01e-01	-0.222000	1.48e-02	7.25e-03
Defective pyroptosis	34	7.65e-03	1.40e-02	0.2990	-1.02e-01	0.282000	3.05e-01	4.48e-03
FOXO-mediated transcription	58	5.71e-04	1.33e-03	0.2990	-8.04e-02	-0.288000	2.89e-01	1.46e-04
PI3K Cascade	39	5.46e-03	1.02e-02	0.2990	-1.85e-02	-0.299000	8.41e-01	1.25e-03
Inositol phosphate metabolism	45	3.42e-03	6.59e-03	0.2990	-1.17e-01	-0.275000	1.75e-01	1.39e-03
Signaling by ERBB2	48	2.31e-03	4.62e-03	0.2990	-1.05e-01	-0.280000	2.09e-01	8.02e-04
Cytoprotection by HMOX1	118	6.08e-08	3.36e-07	0.2980	-2.85e-01	0.086500	8.34e-08	1.04e-01
Pyruvate metabolism and Citric Acid (TCA) cycle	52	1.75e-03	3.62e-03	0.2980	-2.35e-01	-0.183000	3.34e-03	2.25e-02
Glutathione synthesis and recycling	12	2.28e-01	2.86e-01	0.2980	1.55e-01	0.255000	3.53e-01	1.27e-01
Mitotic Prophase	103	3.55e-06	1.37e-05	0.2970	-2.45e-01	-0.168000	1.71e-05	3.16e-03
Aberrant regulation of mitotic exit in cancer due to RB1 defects	20	5.80e-02	8.49e-02	0.2970	-1.18e-01	0.273000	3.62e-01	3.46e-02
SIRT1 negatively regulates rRNA expression	29	1.49e-02	2.56e-02	0.2970	-1.88e-01	0.229000	7.91e-02	3.25e-02
Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)	10	2.43e-01	3.02e-01	0.2970	-2.75e-01	0.112000	1.33e-01	5.39e-01
Repression of WNT target genes	14	1.63e-01	2.13e-01	0.2960	-4.28e-02	-0.293000	7.82e-01	5.74e-02
Ion homeostasis	45	1.63e-03	3.42e-03	0.2960	1.42e-01	-0.260000	9.93e-02	2.55e-03
Antimicrobial peptides	23	6.33e-02	9.17e-02	0.2950	1.88e-01	0.228000	1.19e-01	5.85e-02
Leishmania infection	187	6.95e-11	7.12e-10	0.2940	-6.54e-02	-0.287000	1.23e-01	1.23e-11
Transcriptional regulation by small RNAs	68	1.64e-04	4.31e-04	0.2930	-2.93e-01	-0.021000	2.99e-05	7.64e-01
Calnexin/calreticulin cycle	26	4.58e-02	6.91e-02	0.2930	-1.68e-01	-0.240000	1.39e-01	3.39e-02
Cytochrome c-mediated apoptotic response	13	2.16e-01	2.73e-01	0.2930	-2.16e-01	-0.198000	1.78e-01	2.17e-01
Uptake and actions of bacterial toxins	28	2.69e-02	4.32e-02	0.2920	1.80e-04	-0.292000	9.99e-01	7.41e-03
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	33	2.07e-02	3.41e-02	0.2920	-2.34e-01	-0.175000	2.02e-02	8.17e-02
Vasopressin regulates renal water homeostasis via Aquaporins	35	1.02e-02	1.82e-02	0.2920	2.79e-02	-0.291000	7.75e-01	2.92e-03
Signaling by Non-Receptor Tyrosine Kinases	52	1.97e-03	4.02e-03	0.2920	-1.17e-01	-0.267000	1.44e-01	8.56e-04
Signaling by PTK6	52	1.97e-03	4.02e-03	0.2920	-1.17e-01	-0.267000	1.44e-01	8.56e-04
Cargo trafficking to the periciliary membrane	47	3.56e-03	6.84e-03	0.2920	-1.14e-01	-0.268000	1.77e-01	1.45e-03
Diseases of glycosylation	129	1.55e-08	9.85e-08	0.2910	1.99e-01	-0.213000	9.74e-05	2.89e-05
Protein-protein interactions at synapses	78	8.10e-05	2.24e-04	0.2910	-8.76e-02	-0.277000	1.81e-01	2.29e-05
Gap-filling DNA repair synthesis and ligation in GG-NER	25	5.12e-02	7.61e-02	0.2900	1.16e-01	0.266000	3.13e-01	2.13e-02
Downstream signaling of activated FGFR1	28	3.44e-02	5.38e-02	0.2900	-9.10e-02	-0.276000	4.04e-01	1.16e-02
Hemostasis	485	3.73e-27	1.33e-25	0.2900	4.08e-03	-0.290000	8.77e-01	5.28e-28
PI-3K cascade:FGFR3	16	1.32e-01	1.75e-01	0.2900	-6.86e-03	-0.290000	9.62e-01	4.45e-02
Signaling by Nuclear Receptors	236	1.69e-12	2.10e-11	0.2900	-1.78e-01	-0.229000	2.47e-06	1.33e-09
Ion transport by P-type ATPases	47	1.65e-03	3.45e-03	0.2900	1.39e-01	-0.254000	9.90e-02	2.59e-03
Interferon Signaling	172	2.09e-09	1.62e-08	0.2890	-2.60e-01	-0.126000	4.12e-09	4.36e-03
ERBB2 Regulates Cell Motility	13	2.12e-01	2.69e-01	0.2880	-8.51e-02	-0.275000	5.95e-01	8.54e-02
Diseases associated with glycosylation precursor biosynthesis	18	1.17e-01	1.57e-01	0.2870	-7.23e-02	-0.278000	5.95e-01	4.10e-02
RNA Polymerase I Transcription Termination	30	1.80e-02	2.99e-02	0.2870	-2.48e-01	0.144000	1.86e-02	1.74e-01
Endosomal Sorting Complex Required For Transport (ESCRT)	31	2.96e-02	4.69e-02	0.2870	-2.36e-01	-0.163000	2.31e-02	1.16e-01
Negative regulation of NMDA receptor-mediated neuronal transmission	19	1.04e-01	1.42e-01	0.2860	-5.64e-02	-0.280000	6.70e-01	3.44e-02
p38MAPK events	13	2.32e-01	2.90e-01	0.2860	-2.24e-01	-0.177000	1.61e-01	2.69e-01
Diseases associated with O-glycosylation of proteins	60	3.97e-04	9.56e-04	0.2860	2.68e-01	-0.099200	3.30e-04	1.84e-01
TICAM1-dependent activation of IRF3/IRF7	12	1.99e-01	2.54e-01	0.2860	-2.25e-01	0.176000	1.78e-01	2.90e-01
Class I MHC mediated antigen processing & presentation	352	1.25e-17	2.44e-16	0.2850	-1.99e-01	-0.204000	1.23e-10	4.32e-11
RNA Polymerase III Transcription Initiation From Type 3 Promoter	28	3.25e-02	5.11e-02	0.2850	-2.85e-01	-0.001950	9.08e-03	9.86e-01
Glucose metabolism	84	5.55e-05	1.61e-04	0.2840	-6.68e-02	-0.276000	2.90e-01	1.20e-05
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion	34	1.49e-02	2.56e-02	0.2840	2.12e-02	-0.283000	8.30e-01	4.24e-03
Cell death signalling via NRAGE, NRIF and NADE	76	7.93e-05	2.20e-04	0.2840	3.34e-02	-0.282000	6.15e-01	2.12e-05
Regulation of PTEN gene transcription	61	1.20e-03	2.59e-03	0.2840	-1.95e-01	-0.206000	8.31e-03	5.48e-03
Negative regulation of FLT3	13	2.30e-01	2.88e-01	0.2830	-2.60e-01	-0.112000	1.04e-01	4.85e-01
RHO GTPases Activate ROCKs	19	1.22e-01	1.63e-01	0.2830	-1.53e-01	-0.237000	2.47e-01	7.33e-02
Ras activation upon Ca2+ influx through NMDA receptor	18	1.17e-01	1.57e-01	0.2820	-1.17e-02	-0.282000	9.32e-01	3.84e-02
Downstream signaling of activated FGFR3	23	6.75e-02	9.71e-02	0.2820	-3.63e-02	-0.279000	7.63e-01	2.03e-02
Interleukin-12 family signaling	51	2.90e-03	5.68e-03	0.2810	-2.74e-01	-0.065900	7.23e-04	4.16e-01
G-protein beta:gamma signalling	27	5.06e-02	7.55e-02	0.2810	-1.31e-01	-0.249000	2.38e-01	2.52e-02
Macroautophagy	111	5.73e-06	2.08e-05	0.2800	-1.47e-01	-0.239000	7.51e-03	1.37e-05
Signaling by WNT	276	1.42e-13	2.01e-12	0.2800	-1.70e-01	-0.223000	1.15e-06	1.82e-10
FRS-mediated FGFR1 signaling	20	1.14e-01	1.54e-01	0.2800	-1.53e-01	-0.235000	2.36e-01	6.93e-02
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)	26	6.02e-02	8.80e-02	0.2800	2.31e-01	0.158000	4.17e-02	1.63e-01
Signal Transduction	2157	1.77e-97	2.59e-94	0.2780	-6.13e-02	-0.271000	2.50e-06	3.81e-97
Interleukin-6 family signaling	23	6.39e-02	9.23e-02	0.2780	3.79e-02	-0.275000	7.53e-01	2.23e-02
Assembly of the ORC complex at the origin of replication	30	2.23e-02	3.65e-02	0.2770	-2.05e-01	0.187000	5.19e-02	7.66e-02
Condensation of Prometaphase Chromosomes	11	2.69e-01	3.28e-01	0.2770	-4.55e-02	0.273000	7.94e-01	1.17e-01
Metabolism of cofactors	19	1.36e-01	1.80e-01	0.2760	1.94e-01	0.197000	1.44e-01	1.37e-01
Depolymerisation of the Nuclear Lamina	15	1.90e-01	2.43e-01	0.2760	-5.82e-02	-0.270000	6.97e-01	7.04e-02
Signaling by CSF3 (G-CSF)	30	4.37e-02	6.66e-02	0.2760	-1.82e-01	-0.207000	8.44e-02	4.98e-02
MAPK6/MAPK4 signaling	87	6.31e-05	1.80e-04	0.2750	-2.72e-01	-0.042600	1.14e-05	4.92e-01
Synthesis of PE	12	2.53e-01	3.12e-01	0.2750	-2.75e-01	0.001940	9.89e-02	9.91e-01
Aquaporin-mediated transport	37	1.33e-02	2.31e-02	0.2750	3.27e-02	-0.273000	7.31e-01	4.04e-03
Methylation	14	1.75e-01	2.26e-01	0.2750	-1.84e-01	0.204000	2.33e-01	1.85e-01
Acetylcholine binding and downstream events	10	3.54e-01	4.15e-01	0.2750	1.78e-01	0.210000	3.31e-01	2.51e-01
Postsynaptic nicotinic acetylcholine receptors	10	3.54e-01	4.15e-01	0.2750	1.78e-01	0.210000	3.31e-01	2.51e-01
Metabolism of amino acids and derivatives	337	1.43e-18	3.12e-17	0.2750	-1.45e-01	0.234000	5.01e-06	1.59e-13
Late endosomal microautophagy	29	4.41e-02	6.71e-02	0.2740	-2.61e-01	-0.084900	1.50e-02	4.29e-01
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain	20	1.27e-01	1.68e-01	0.2740	-1.91e-01	-0.197000	1.39e-01	1.27e-01
Estrogen-dependent gene expression	107	1.62e-05	5.34e-05	0.2740	-2.07e-01	-0.180000	2.20e-04	1.26e-03
RHO GTPases activate PAKs	21	9.96e-02	1.37e-01	0.2740	-4.79e-02	-0.270000	7.04e-01	3.24e-02
TNF signaling	44	9.71e-03	1.73e-02	0.2740	-2.49e-01	-0.113000	4.21e-03	1.96e-01
Cyclin A:Cdk2-associated events at S phase entry	85	3.45e-05	1.04e-04	0.2730	-2.46e-01	0.119000	8.74e-05	5.71e-02
Positive epigenetic regulation of rRNA expression	67	3.97e-04	9.56e-04	0.2730	-2.66e-01	0.060500	1.64e-04	3.92e-01
Synthesis of substrates in N-glycan biosythesis	61	1.86e-03	3.83e-03	0.2730	-1.47e-01	-0.230000	4.69e-02	1.90e-03
SLC transporter disorders	80	2.77e-04	7.01e-04	0.2730	-1.60e-01	-0.221000	1.36e-02	6.27e-04
Long-term potentiation	20	1.14e-01	1.54e-01	0.2720	-5.01e-02	-0.268000	6.98e-01	3.81e-02
Defects in vitamin and cofactor metabolism	21	8.34e-02	1.17e-01	0.2720	8.71e-02	-0.258000	4.90e-01	4.06e-02
MAPK family signaling cascades	292	9.16e-14	1.36e-12	0.2710	-1.09e-01	-0.248000	1.32e-03	2.59e-13
RNA Polymerase III Chain Elongation	18	1.25e-01	1.66e-01	0.2710	-2.65e-01	0.057600	5.14e-02	6.72e-01
Retinoid metabolism and transport	32	2.19e-02	3.60e-02	0.2710	1.22e-01	-0.242000	2.32e-01	1.77e-02
Defects in cobalamin (B12) metabolism	13	2.41e-01	3.00e-01	0.2710	-2.70e-01	-0.023900	9.16e-02	8.81e-01
Activated NOTCH1 Transmits Signal to the Nucleus	30	3.63e-02	5.64e-02	0.2700	7.09e-03	-0.270000	9.46e-01	1.05e-02
Negative regulation of FGFR2 signaling	30	5.01e-02	7.48e-02	0.2700	-1.86e-01	-0.195000	7.76e-02	6.44e-02
Metabolism of fat-soluble vitamins	36	1.64e-02	2.77e-02	0.2690	6.53e-02	-0.261000	4.98e-01	6.67e-03
RNA Polymerase III Transcription Initiation From Type 1 Promoter	28	4.86e-02	7.28e-02	0.2690	-2.68e-01	-0.020700	1.39e-02	8.50e-01
Cyclin E associated events during G1/S transition	83	5.97e-05	1.71e-04	0.2690	-2.34e-01	0.131000	2.24e-04	3.87e-02
HDR through Homologous Recombination (HRR)	66	1.50e-03	3.17e-03	0.2680	1.77e-01	0.202000	1.31e-02	4.63e-03
Signalling to RAS	20	1.34e-01	1.78e-01	0.2680	-1.21e-01	-0.239000	3.49e-01	6.42e-02
MicroRNA (miRNA) biogenesis	24	7.37e-02	1.05e-01	0.2670	-2.66e-01	0.017200	2.40e-02	8.84e-01
Processing of Intronless Pre-mRNAs	19	1.51e-01	1.97e-01	0.2660	-2.41e-01	-0.114000	6.94e-02	3.89e-01
Post-translational protein modification	1261	1.50e-52	3.66e-50	0.2660	-1.18e-01	-0.238000	1.51e-12	1.84e-46
Pyrimidine salvage	10	3.78e-01	4.39e-01	0.2660	1.70e-01	0.205000	3.52e-01	2.62e-01
Heme biosynthesis	13	2.59e-01	3.17e-01	0.2660	2.63e-01	0.037200	1.01e-01	8.17e-01
G-protein activation	18	1.78e-01	2.30e-01	0.2640	-1.95e-01	-0.179000	1.52e-01	1.90e-01
Cellular response to chemical stress	147	7.05e-08	3.84e-07	0.2640	-2.43e-01	0.105000	3.74e-07	2.85e-02
Cellular hexose transport	17	1.85e-01	2.39e-01	0.2640	2.49e-01	0.085600	7.52e-02	5.41e-01
Oncogene Induced Senescence	31	5.13e-02	7.61e-02	0.2630	-2.18e-01	-0.147000	3.53e-02	1.56e-01
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3	26	5.20e-02	7.71e-02	0.2630	-2.12e-01	0.156000	6.16e-02	1.68e-01
PCP/CE pathway	90	1.06e-04	2.85e-04	0.2630	-2.61e-01	-0.033800	1.90e-05	5.79e-01
Neurexins and neuroligins	49	6.07e-03	1.13e-02	0.2630	-1.80e-03	-0.263000	9.83e-01	1.45e-03
IRAK1 recruits IKK complex	10	3.79e-01	4.39e-01	0.2630	-1.12e-01	-0.238000	5.41e-01	1.93e-01
IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation	10	3.79e-01	4.39e-01	0.2630	-1.12e-01	-0.238000	5.41e-01	1.93e-01
Formation of apoptosome	11	3.42e-01	4.04e-01	0.2630	-2.44e-01	-0.097800	1.62e-01	5.74e-01
Regulation of the apoptosome activity	11	3.42e-01	4.04e-01	0.2630	-2.44e-01	-0.097800	1.62e-01	5.74e-01
SUMOylation	170	1.09e-07	5.82e-07	0.2620	-1.42e-01	-0.219000	1.34e-03	7.86e-07
eNOS activation	11	3.01e-01	3.63e-01	0.2610	9.04e-02	-0.245000	6.04e-01	1.60e-01
Sulfur amino acid metabolism	25	7.23e-02	1.03e-01	0.2610	-3.56e-02	0.258000	7.58e-01	2.55e-02
Regulation of TP53 Activity through Methylation	19	1.22e-01	1.62e-01	0.2600	-2.14e-01	0.147000	1.06e-01	2.66e-01
Phosphorylation of CD3 and TCR zeta chains	15	2.49e-01	3.09e-01	0.2590	2.03e-01	0.162000	1.74e-01	2.78e-01
TCR signaling	108	1.86e-05	6.01e-05	0.2590	-2.59e-01	-0.003220	3.28e-06	9.54e-01
TP53 Regulates Transcription of DNA Repair Genes	61	1.91e-03	3.91e-03	0.2590	-2.58e-01	0.021100	4.89e-04	7.75e-01
Signaling by EGFR in Cancer	23	1.22e-01	1.62e-01	0.2580	-1.77e-01	-0.188000	1.42e-01	1.18e-01
Interleukin-1 family signaling	124	5.14e-06	1.90e-05	0.2570	-2.56e-01	-0.020900	8.01e-07	6.88e-01
Signaling by FGFR2	66	1.99e-03	4.06e-03	0.2570	-2.43e-01	-0.082800	6.23e-04	2.45e-01
MHC class II antigen presentation	97	5.64e-05	1.63e-04	0.2570	1.95e-02	-0.256000	7.40e-01	1.29e-05
Signaling by ERBB4	50	5.80e-03	1.08e-02	0.2570	5.09e-02	-0.252000	5.33e-01	2.08e-03
Factors involved in megakaryocyte development and platelet production	115	9.18e-06	3.21e-05	0.2560	2.62e-02	-0.255000	6.27e-01	2.28e-06
Resolution of AP sites via the multiple-nucleotide patch replacement pathway	25	1.06e-01	1.45e-01	0.2560	1.70e-01	0.191000	1.41e-01	9.89e-02
Unblocking of NMDA receptors, glutamate binding and activation	18	1.95e-01	2.49e-01	0.2550	-1.27e-01	-0.222000	3.52e-01	1.03e-01
Signaling by the B Cell Receptor (BCR)	106	5.99e-05	1.72e-04	0.2550	-2.34e-01	-0.102000	3.07e-05	6.99e-02
Signaling by FGFR in disease	59	5.20e-03	9.77e-03	0.2550	-1.64e-01	-0.195000	2.96e-02	9.51e-03
Beta-catenin independent WNT signaling	138	4.60e-06	1.73e-05	0.2550	-2.03e-01	-0.154000	3.91e-05	1.74e-03
Adaptive Immune System	639	3.12e-25	9.93e-24	0.2540	-1.21e-01	-0.224000	1.80e-07	3.43e-22
SUMO E3 ligases SUMOylate target proteins	164	4.62e-07	2.19e-06	0.2540	-1.46e-01	-0.208000	1.23e-03	4.15e-06
tRNA Aminoacylation	42	2.36e-02	3.84e-02	0.2540	-2.04e-01	-0.152000	2.19e-02	8.93e-02
Collagen degradation	34	3.72e-02	5.74e-02	0.2540	-9.40e-03	-0.254000	9.24e-01	1.04e-02
Regulation of innate immune responses to cytosolic DNA	14	2.46e-01	3.06e-01	0.2540	-2.50e-01	0.042200	1.05e-01	7.85e-01
Signaling by NOTCH2	32	3.64e-02	5.66e-02	0.2540	1.00e-01	-0.233000	3.27e-01	2.26e-02
NOTCH2 Activation and Transmission of Signal to the Nucleus	22	9.75e-02	1.34e-01	0.2530	1.96e-01	-0.161000	1.12e-01	1.91e-01
Defective C1GALT1C1 causes TNPS	11	3.79e-01	4.39e-01	0.2530	1.75e-01	0.183000	3.15e-01	2.92e-01
MAP2K and MAPK activation	35	3.43e-02	5.38e-02	0.2530	-3.95e-03	-0.253000	9.68e-01	9.62e-03
Regulation of insulin secretion	65	1.80e-03	3.72e-03	0.2530	1.50e-02	-0.252000	8.34e-01	4.39e-04
Neddylation	222	2.81e-09	2.13e-08	0.2520	-2.27e-01	-0.109000	5.04e-09	5.05e-03
Endogenous sterols	22	1.38e-01	1.81e-01	0.2520	-9.38e-02	-0.234000	4.46e-01	5.72e-02
Neurotransmitter receptors and postsynaptic signal transmission	152	3.97e-07	1.90e-06	0.2520	2.03e-02	-0.251000	6.66e-01	8.79e-08
Resolution of Abasic Sites (AP sites)	38	3.64e-02	5.66e-02	0.2520	1.65e-01	0.190000	7.85e-02	4.22e-02
Response to elevated platelet cytosolic Ca2+	114	1.37e-05	4.60e-05	0.2520	4.01e-02	-0.249000	4.59e-01	4.48e-06
RIP-mediated NFkB activation via ZBP1	16	2.48e-01	3.07e-01	0.2510	-2.03e-01	-0.148000	1.60e-01	3.04e-01
Activation of Matrix Metalloproteinases	25	1.15e-01	1.55e-01	0.2510	-1.82e-01	-0.173000	1.15e-01	1.34e-01
Lysosome Vesicle Biogenesis	34	3.96e-02	6.09e-02	0.2510	2.77e-04	-0.251000	9.98e-01	1.14e-02
FGFR4 ligand binding and activation	10	4.18e-01	4.78e-01	0.2510	2.12e-01	0.133000	2.46e-01	4.65e-01
Dual incision in TC-NER	65	1.26e-03	2.70e-03	0.2510	-2.07e-01	0.140000	3.81e-03	5.01e-02
Nuclear signaling by ERBB4	26	6.84e-02	9.81e-02	0.2510	1.49e-01	-0.201000	1.88e-01	7.57e-02
Formation of Incision Complex in GG-NER	43	1.71e-02	2.88e-02	0.2510	-2.51e-01	-0.003050	4.47e-03	9.72e-01
Triglyceride catabolism	17	1.77e-01	2.28e-01	0.2510	1.16e-01	-0.222000	4.06e-01	1.13e-01
Synthesis, secretion, and deacylation of Ghrelin	13	3.26e-01	3.90e-01	0.2500	1.97e-01	0.155000	2.20e-01	3.34e-01
SUMOylation of transcription factors	19	1.79e-01	2.30e-01	0.2500	-5.78e-02	-0.243000	6.63e-01	6.63e-02
Gene Silencing by RNA	95	1.97e-04	5.09e-04	0.2500	-2.41e-01	-0.066800	4.88e-05	2.60e-01
RHOBTB3 ATPase cycle	10	4.22e-01	4.81e-01	0.2500	-1.44e-01	-0.205000	4.31e-01	2.63e-01
Epigenetic regulation of gene expression	109	2.54e-05	7.84e-05	0.2500	-2.46e-01	0.043400	8.89e-06	4.34e-01
FGFR2 ligand binding and activation	14	2.96e-01	3.57e-01	0.2490	2.24e-01	0.110000	1.48e-01	4.78e-01
Regulation of gene expression in beta cells	13	2.71e-01	3.30e-01	0.2480	2.13e-01	-0.128000	1.84e-01	4.25e-01
NOD1/2 Signaling Pathway	31	6.97e-02	9.97e-02	0.2480	-1.16e-01	-0.219000	2.66e-01	3.45e-02
Translesion synthesis by POLK	17	2.13e-01	2.70e-01	0.2480	3.05e-02	0.246000	8.27e-01	7.90e-02
Interleukin-4 and Interleukin-13 signaling	95	1.69e-04	4.41e-04	0.2480	-1.48e-02	-0.247000	8.03e-01	3.10e-05
Transcription-Coupled Nucleotide Excision Repair (TC-NER)	78	4.30e-04	1.02e-03	0.2480	-2.19e-01	0.115000	8.21e-04	7.81e-02
Glycogen synthesis	15	2.35e-01	2.93e-01	0.2470	6.29e-02	-0.239000	6.73e-01	1.09e-01
Energy dependent regulation of mTOR by LKB1-AMPK	28	9.32e-02	1.29e-01	0.2470	-1.30e-01	-0.210000	2.34e-01	5.41e-02
MTOR signalling	40	3.41e-02	5.36e-02	0.2470	-1.31e-01	-0.209000	1.52e-01	2.20e-02
RAS processing	19	2.01e-01	2.55e-01	0.2460	-1.25e-01	-0.212000	3.45e-01	1.09e-01
Defective GALNT3 causes HFTC	10	4.28e-01	4.87e-01	0.2460	1.15e-01	0.218000	5.30e-01	2.33e-01
Platelet degranulation	109	3.81e-05	1.13e-04	0.2460	3.03e-02	-0.244000	5.85e-01	1.04e-05
Degradation of the extracellular matrix	90	2.72e-04	6.91e-04	0.2460	1.73e-05	-0.246000	1.00e+00	5.46e-05
Scavenging by Class A Receptors	16	2.65e-01	3.24e-01	0.2460	1.75e-01	0.173000	2.25e-01	2.32e-01
Dopamine Neurotransmitter Release Cycle	22	1.53e-01	1.99e-01	0.2460	-2.28e-01	-0.092300	6.44e-02	4.54e-01
Collagen formation	80	3.72e-04	9.02e-04	0.2450	1.90e-01	-0.155000	3.33e-03	1.64e-02
NCAM signaling for neurite out-growth	54	6.65e-03	1.23e-02	0.2450	3.27e-02	-0.243000	6.77e-01	2.02e-03
NCAM1 interactions	34	4.15e-02	6.34e-02	0.2440	2.36e-01	-0.061400	1.74e-02	5.35e-01
Cellular responses to stress	671	3.91e-26	1.33e-24	0.2440	-2.43e-01	-0.003840	4.01e-27	8.65e-01
ZBP1(DAI) mediated induction of type I IFNs	19	2.13e-01	2.70e-01	0.2430	-1.90e-01	-0.152000	1.52e-01	2.51e-01
Downstream signaling of activated FGFR4	23	1.35e-01	1.78e-01	0.2430	-2.97e-02	-0.241000	8.05e-01	4.53e-02
SARS-CoV-1 Infection	49	1.21e-02	2.11e-02	0.2430	1.81e-02	-0.242000	8.26e-01	3.37e-03
G beta:gamma signalling through PI3Kgamma	21	1.75e-01	2.26e-01	0.2420	-8.80e-02	-0.225000	4.85e-01	7.37e-02
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	19	2.18e-01	2.75e-01	0.2410	-1.47e-01	-0.191000	2.67e-01	1.49e-01
Signaling by Ligand-Responsive EGFR Variants in Cancer	19	2.18e-01	2.75e-01	0.2410	-1.47e-01	-0.191000	2.67e-01	1.49e-01
G2/M Checkpoints	140	1.66e-06	6.85e-06	0.2410	-1.54e-01	0.185000	1.59e-03	1.60e-04
TCF dependent signaling in response to WNT	186	3.89e-07	1.87e-06	0.2410	-1.93e-01	-0.144000	5.69e-06	7.02e-04
tRNA processing in the nucleus	59	6.94e-03	1.27e-02	0.2410	-2.36e-01	-0.048200	1.73e-03	5.22e-01
Peptide hormone metabolism	65	2.67e-03	5.26e-03	0.2400	6.60e-02	-0.231000	3.58e-01	1.28e-03
Pexophagy	11	4.19e-01	4.78e-01	0.2400	-1.49e-01	-0.188000	3.92e-01	2.81e-01
Polymerase switching on the C-strand of the telomere	26	1.14e-01	1.54e-01	0.2390	2.35e-01	0.046600	3.83e-02	6.81e-01
InlB-mediated entry of Listeria monocytogenes into host cell	15	3.07e-01	3.70e-01	0.2390	-1.40e-01	-0.193000	3.47e-01	1.95e-01
Mitochondrial biogenesis	91	6.45e-04	1.49e-03	0.2390	-2.23e-01	-0.084100	2.29e-04	1.65e-01
MAP3K8 (TPL2)-dependent MAPK1/3 activation	16	2.85e-01	3.45e-01	0.2390	-1.90e-01	-0.144000	1.88e-01	3.18e-01
IKK complex recruitment mediated by RIP1	22	1.68e-01	2.17e-01	0.2380	-2.27e-01	-0.072200	6.53e-02	5.58e-01
Degradation of cysteine and homocysteine	11	4.14e-01	4.73e-01	0.2380	9.12e-02	0.220000	6.00e-01	2.06e-01
Separation of Sister Chromatids	168	2.25e-07	1.15e-06	0.2380	-2.15e-01	0.102000	1.48e-06	2.29e-02
Plasma lipoprotein assembly	13	3.64e-01	4.24e-01	0.2380	1.81e-01	0.154000	2.59e-01	3.35e-01
RAF/MAP kinase cascade	247	4.97e-09	3.52e-08	0.2370	-1.14e-01	-0.207000	2.07e-03	1.91e-08
MAPK1/MAPK3 signaling	253	3.16e-09	2.38e-08	0.2360	-1.12e-01	-0.208000	2.18e-03	1.12e-08
Nuclear Envelope (NE) Reassembly	73	3.68e-03	7.01e-03	0.2360	-1.85e-01	-0.147000	6.33e-03	2.94e-02
Infectious disease	733	5.37e-25	1.67e-23	0.2360	-2.15e-01	-0.097200	2.82e-23	7.16e-06
Diseases of metabolism	213	3.97e-09	2.92e-08	0.2360	1.83e-01	-0.149000	4.06e-06	1.86e-04
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)	16	2.86e-01	3.47e-01	0.2350	-9.50e-02	-0.215000	5.10e-01	1.36e-01
Surfactant metabolism	19	2.32e-01	2.91e-01	0.2350	-2.00e-01	-0.123000	1.31e-01	3.51e-01
Downstream signaling of activated FGFR2	26	1.15e-01	1.55e-01	0.2350	-4.51e-03	-0.235000	9.68e-01	3.79e-02
PI-3K cascade:FGFR4	16	2.62e-01	3.21e-01	0.2350	2.64e-03	-0.235000	9.85e-01	1.04e-01
Signaling by FGFR3 in disease	20	2.00e-01	2.55e-01	0.2350	-4.73e-02	-0.230000	7.14e-01	7.49e-02
Signaling by FGFR3 point mutants in cancer	20	2.00e-01	2.55e-01	0.2350	-4.73e-02	-0.230000	7.14e-01	7.49e-02
Polo-like kinase mediated events	16	2.47e-01	3.06e-01	0.2350	-6.68e-02	0.225000	6.43e-01	1.19e-01
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding	30	6.83e-02	9.81e-02	0.2350	-2.09e-01	0.108000	4.80e-02	3.07e-01
Cellular responses to stimuli	680	9.62e-25	2.94e-23	0.2350	-2.35e-01	0.003420	1.35e-25	8.79e-01
Signaling by FGFR	78	2.76e-03	5.43e-03	0.2340	-1.85e-01	-0.145000	4.82e-03	2.73e-02
Cleavage of the damaged purine	28	8.05e-02	1.14e-01	0.2340	-1.87e-01	0.141000	8.65e-02	1.98e-01
Depurination	28	8.05e-02	1.14e-01	0.2340	-1.87e-01	0.141000	8.65e-02	1.98e-01
Recognition and association of DNA glycosylase with site containing an affected purine	28	8.05e-02	1.14e-01	0.2340	-1.87e-01	0.141000	8.65e-02	1.98e-01
Regulation of TP53 Activity	155	9.01e-06	3.16e-05	0.2340	-1.84e-01	-0.144000	7.67e-05	1.90e-03
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)	13	3.14e-01	3.76e-01	0.2340	-1.14e-01	0.204000	4.76e-01	2.03e-01
Activation of BH3-only proteins	29	8.86e-02	1.23e-01	0.2330	1.88e-02	-0.233000	8.61e-01	3.01e-02
Inactivation of CSF3 (G-CSF) signaling	25	1.44e-01	1.90e-01	0.2330	-2.19e-01	-0.079800	5.77e-02	4.90e-01
G beta:gamma signalling through PLC beta	15	3.10e-01	3.72e-01	0.2330	-2.23e-01	-0.067900	1.35e-01	6.49e-01
Presynaptic function of Kainate receptors	15	3.10e-01	3.72e-01	0.2330	-2.23e-01	-0.067900	1.35e-01	6.49e-01
Post-translational protein phosphorylation	85	5.22e-04	1.22e-03	0.2320	1.66e-01	-0.162000	7.97e-03	9.67e-03
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks	51	1.93e-02	3.19e-02	0.2320	-2.23e-01	-0.066100	5.91e-03	4.14e-01
FGFR2c ligand binding and activation	10	4.59e-01	5.15e-01	0.2320	2.24e-01	0.061100	2.20e-01	7.38e-01
Gap-filling DNA repair synthesis and ligation in TC-NER	64	3.46e-03	6.65e-03	0.2320	-1.84e-01	0.142000	1.10e-02	4.96e-02
Signaling by ERBB2 TMD/JMD mutants	20	2.00e-01	2.55e-01	0.2320	-1.63e-02	-0.232000	8.99e-01	7.29e-02
MyD88 deficiency (TLR2/4)	14	3.33e-01	3.95e-01	0.2320	4.57e-02	0.228000	7.67e-01	1.40e-01
Cyclin A/B1/B2 associated events during G2/M transition	25	1.20e-01	1.61e-01	0.2320	-2.25e-01	0.055600	5.11e-02	6.30e-01
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models	20	2.26e-01	2.85e-01	0.2320	-1.29e-01	-0.193000	3.18e-01	1.36e-01
Neurodegenerative Diseases	20	2.26e-01	2.85e-01	0.2320	-1.29e-01	-0.193000	3.18e-01	1.36e-01
G alpha (q) signalling events	152	1.07e-05	3.68e-05	0.2320	-9.22e-02	-0.212000	4.96e-02	6.10e-06
Phospholipase C-mediated cascade; FGFR4	11	4.42e-01	5.00e-01	0.2310	1.24e-01	0.195000	4.75e-01	2.63e-01
HDR through MMEJ (alt-NHEJ)	10	4.34e-01	4.92e-01	0.2310	2.26e-01	-0.047300	2.16e-01	7.96e-01
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest	18	2.36e-01	2.95e-01	0.2310	4.73e-03	0.231000	9.72e-01	9.02e-02
Transcriptional regulation by RUNX2	115	1.17e-04	3.14e-04	0.2300	-2.30e-01	-0.019500	2.10e-05	7.18e-01
Synthesis of glycosylphosphatidylinositol (GPI)	18	2.10e-01	2.66e-01	0.2300	1.95e-01	-0.122000	1.51e-01	3.70e-01
PI-3K cascade:FGFR2	19	2.10e-01	2.67e-01	0.2300	3.20e-02	-0.228000	8.09e-01	8.55e-02
Synthesis of IP3 and IP4 in the cytosol	24	1.49e-01	1.95e-01	0.2300	-6.57e-03	-0.230000	9.56e-01	5.15e-02
tRNA modification in the nucleus and cytosol	43	2.51e-02	4.05e-02	0.2290	-1.26e-01	0.191000	1.52e-01	3.04e-02
Glycogen metabolism	26	1.14e-01	1.54e-01	0.2290	7.88e-02	-0.215000	4.87e-01	5.83e-02
Purine catabolism	17	2.95e-01	3.57e-01	0.2280	1.50e-01	0.172000	2.83e-01	2.20e-01
Antigen processing-Cross presentation	96	3.24e-04	8.00e-04	0.2280	-2.11e-01	0.086600	3.43e-04	1.42e-01
Cytokine Signaling in Immune system	596	8.21e-19	1.85e-17	0.2280	-1.72e-01	-0.150000	6.83e-13	3.93e-10
Interferon gamma signaling	78	2.96e-03	5.79e-03	0.2280	-2.20e-01	-0.060100	7.89e-04	3.59e-01
Presynaptic depolarization and calcium channel opening	11	4.57e-01	5.13e-01	0.2280	1.69e-01	0.152000	3.32e-01	3.82e-01
Cleavage of the damaged pyrimidine	33	6.27e-02	9.11e-02	0.2270	-2.00e-01	0.108000	4.68e-02	2.83e-01
Depyrimidination	33	6.27e-02	9.11e-02	0.2270	-2.00e-01	0.108000	4.68e-02	2.83e-01
Recognition and association of DNA glycosylase with site containing an affected pyrimidine	33	6.27e-02	9.11e-02	0.2270	-2.00e-01	0.108000	4.68e-02	2.83e-01
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release	19	2.36e-01	2.95e-01	0.2260	-2.25e-01	-0.017900	8.94e-02	8.92e-01
Phase 2 - plateau phase	13	3.92e-01	4.50e-01	0.2260	2.10e-01	0.083400	1.91e-01	6.03e-01
Signaling by NOTCH3	46	2.91e-02	4.62e-02	0.2250	1.07e-02	-0.224000	9.00e-01	8.43e-03
Intraflagellar transport	39	6.35e-02	9.19e-02	0.2240	2.03e-01	0.095300	2.81e-02	3.03e-01
Senescence-Associated Secretory Phenotype (SASP)	71	3.18e-03	6.20e-03	0.2240	-2.02e-01	0.097300	3.30e-03	1.56e-01
Immune System	1611	9.34e-47	1.37e-44	0.2240	-1.02e-01	-0.199000	7.38e-12	5.32e-41
Homologous DNA Pairing and Strand Exchange	42	5.44e-02	8.02e-02	0.2240	1.89e-01	0.120000	3.45e-02	1.77e-01
IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation	15	3.55e-01	4.16e-01	0.2230	-1.91e-01	-0.116000	2.01e-01	4.38e-01
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	17	2.51e-01	3.11e-01	0.2230	1.87e-01	-0.120000	1.81e-01	3.90e-01
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	17	2.51e-01	3.11e-01	0.2230	1.87e-01	-0.120000	1.81e-01	3.90e-01
ATF6 (ATF6-alpha) activates chaperones	12	4.36e-01	4.94e-01	0.2230	-1.97e-01	-0.104000	2.38e-01	5.31e-01
Hedgehog ‘off’ state	95	6.08e-04	1.41e-03	0.2230	-2.15e-01	0.056300	2.86e-04	3.43e-01
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10	13	3.72e-01	4.33e-01	0.2220	2.09e-02	-0.221000	8.96e-01	1.67e-01
TAK1 activates NFkB by phosphorylation and activation of IKKs complex	25	1.82e-01	2.35e-01	0.2220	-1.76e-01	-0.136000	1.28e-01	2.38e-01
Gene expression (Transcription)	1368	1.52e-39	1.11e-37	0.2220	-1.95e-01	-0.107000	7.29e-34	2.22e-11
Activation of GABAB receptors	35	8.83e-02	1.23e-01	0.2220	-9.52e-02	-0.201000	3.30e-01	3.97e-02
GABA B receptor activation	35	8.83e-02	1.23e-01	0.2220	-9.52e-02	-0.201000	3.30e-01	3.97e-02
Synthesis of bile acids and bile salts via 24-hydroxycholesterol	12	3.80e-01	4.40e-01	0.2220	-1.88e-01	0.117000	2.58e-01	4.81e-01
Anti-inflammatory response favouring Leishmania parasite infection	106	3.70e-04	8.98e-04	0.2220	1.06e-02	-0.221000	8.51e-01	8.24e-05
Leishmania parasite growth and survival	106	3.70e-04	8.98e-04	0.2220	1.06e-02	-0.221000	8.51e-01	8.24e-05
FRS-mediated FGFR3 signaling	18	2.76e-01	3.36e-01	0.2210	-4.08e-02	-0.217000	7.65e-01	1.10e-01
Metabolism of steroids	136	7.84e-05	2.18e-04	0.2210	-6.75e-02	-0.210000	1.74e-01	2.26e-05
B-WICH complex positively regulates rRNA expression	52	1.67e-02	2.82e-02	0.2200	-1.95e-01	0.102000	1.50e-02	2.02e-01
Transport of vitamins, nucleosides, and related molecules	35	6.73e-02	9.69e-02	0.2200	6.69e-02	-0.210000	4.94e-01	3.17e-02
Disorders of transmembrane transporters	153	2.32e-05	7.26e-05	0.2200	-2.14e-01	-0.053000	5.02e-06	2.58e-01
Signaling by Interleukins	384	1.14e-11	1.30e-10	0.2200	-1.48e-01	-0.163000	6.13e-07	4.15e-08
Gluconeogenesis	29	1.02e-01	1.40e-01	0.2200	1.90e-01	-0.111000	7.70e-02	3.01e-01
G beta:gamma signalling through BTK	14	3.85e-01	4.44e-01	0.2200	-2.03e-01	-0.084800	1.89e-01	5.83e-01
Regulation of TNFR1 signaling	35	8.26e-02	1.16e-01	0.2200	-2.18e-01	-0.027300	2.56e-02	7.80e-01
Kinesins	39	5.59e-02	8.22e-02	0.2190	2.06e-02	-0.218000	8.23e-01	1.82e-02
RHO GTPases activate PKNs	52	3.07e-02	4.85e-02	0.2190	-1.98e-01	-0.093200	1.36e-02	2.45e-01
Heme degradation	11	4.23e-01	4.82e-01	0.2180	-1.57e-01	0.150000	3.66e-01	3.88e-01
PD-1 signaling	16	3.52e-01	4.14e-01	0.2180	1.34e-01	0.172000	3.54e-01	2.34e-01
Sensory processing of sound by inner hair cells of the cochlea	57	1.30e-02	2.26e-02	0.2180	8.48e-02	-0.200000	2.68e-01	8.83e-03
Signaling by Insulin receptor	71	6.92e-03	1.27e-02	0.2170	-1.72e-02	-0.216000	8.02e-01	1.61e-03
Phase 4 - resting membrane potential	16	3.44e-01	4.06e-01	0.2170	-7.60e-02	-0.203000	5.99e-01	1.60e-01
Telomere C-strand (Lagging Strand) Synthesis	34	1.10e-01	1.49e-01	0.2160	1.91e-01	0.100000	5.39e-02	3.11e-01
Nucleotide Excision Repair	110	2.62e-04	6.70e-04	0.2160	-1.94e-01	0.093000	4.24e-04	9.17e-02
Activated point mutants of FGFR2	13	4.21e-01	4.81e-01	0.2150	2.07e-01	0.059000	1.97e-01	7.13e-01
DNA Double Strand Break Response	52	3.13e-02	4.94e-02	0.2150	-2.09e-01	-0.049900	9.23e-03	5.33e-01
Assembly of collagen fibrils and other multimeric structures	50	2.30e-02	3.74e-02	0.2140	1.73e-01	-0.127000	3.48e-02	1.19e-01
Metalloprotease DUBs	24	1.94e-01	2.48e-01	0.2140	-2.13e-01	-0.018700	7.03e-02	8.74e-01
Cell recruitment (pro-inflammatory response)	23	2.33e-01	2.92e-01	0.2140	-1.26e-01	-0.173000	2.96e-01	1.50e-01
Purinergic signaling in leishmaniasis infection	23	2.33e-01	2.92e-01	0.2140	-1.26e-01	-0.173000	2.96e-01	1.50e-01
tRNA processing	124	9.58e-05	2.61e-04	0.2140	-1.25e-01	0.174000	1.66e-02	8.40e-04
Transcriptional regulation by RUNX1	184	6.54e-06	2.35e-05	0.2140	-2.03e-01	-0.065200	1.92e-06	1.27e-01
RHO GTPases Activate NADPH Oxidases	20	2.45e-01	3.05e-01	0.2130	2.83e-02	-0.211000	8.27e-01	1.02e-01
PIWI-interacting RNA (piRNA) biogenesis	24	1.66e-01	2.16e-01	0.2130	-1.59e-01	0.142000	1.78e-01	2.28e-01
RHO GTPase Effectors	254	1.36e-07	7.12e-07	0.2120	-1.07e-01	-0.184000	3.33e-03	4.56e-07
SHC-mediated cascade:FGFR3	16	3.09e-01	3.71e-01	0.2120	1.05e-01	-0.184000	4.67e-01	2.02e-01
Meiotic recombination	45	4.57e-02	6.89e-02	0.2120	-1.57e-02	0.211000	8.55e-01	1.43e-02
mitochondrial fatty acid beta-oxidation of saturated fatty acids	10	5.41e-01	6.00e-01	0.2110	1.46e-01	0.153000	4.24e-01	4.02e-01
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	95	9.66e-04	2.13e-03	0.2110	1.32e-01	-0.164000	2.59e-02	5.58e-03
Detoxification of Reactive Oxygen Species	30	1.18e-01	1.59e-01	0.2110	-7.20e-02	0.198000	4.95e-01	6.02e-02
SHC-mediated cascade:FGFR1	18	3.12e-01	3.74e-01	0.2100	-3.57e-02	-0.207000	7.93e-01	1.28e-01
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function	56	2.54e-02	4.09e-02	0.2100	-2.09e-01	-0.019100	6.72e-03	8.04e-01
Biosynthesis of DHA-derived SPMs	13	3.89e-01	4.48e-01	0.2100	-1.37e-01	0.159000	3.94e-01	3.20e-01
Diseases of DNA repair	34	1.18e-01	1.59e-01	0.2100	1.98e-01	0.069200	4.56e-02	4.85e-01
Chromosome Maintenance	109	6.48e-04	1.49e-03	0.2100	-1.99e-02	0.209000	7.20e-01	1.66e-04
Collagen biosynthesis and modifying enzymes	58	1.65e-02	2.79e-02	0.2100	1.92e-01	-0.085000	1.16e-02	2.63e-01
Nicotinate metabolism	29	1.46e-01	1.92e-01	0.2100	2.10e-01	0.001500	5.08e-02	9.89e-01
Innate Immune System	838	3.33e-22	9.38e-21	0.2090	-1.07e-01	-0.180000	1.39e-07	6.82e-19
Presynaptic phase of homologous DNA pairing and strand exchange	39	9.33e-02	1.29e-01	0.2090	1.82e-01	0.103000	4.93e-02	2.66e-01
Tight junction interactions	19	2.76e-01	3.36e-01	0.2090	3.15e-02	-0.206000	8.12e-01	1.19e-01
G1/S Transition	131	1.08e-04	2.91e-04	0.2090	-8.09e-02	0.192000	1.10e-01	1.45e-04
Neuronal System	326	3.89e-10	3.56e-09	0.2080	2.80e-02	-0.207000	3.84e-01	1.38e-10
Chemokine receptors bind chemokines	22	2.63e-01	3.22e-01	0.2080	9.19e-02	0.187000	4.56e-01	1.29e-01
Inhibition of replication initiation of damaged DNA by RB1/E2F1	13	4.25e-01	4.83e-01	0.2080	2.07e-01	-0.012700	1.96e-01	9.37e-01
Plasma lipoprotein clearance	29	1.36e-01	1.80e-01	0.2070	1.94e-01	-0.072600	7.02e-02	4.99e-01
Translation of Structural Proteins	29	1.56e-01	2.03e-01	0.2070	-1.40e-02	-0.207000	8.96e-01	5.38e-02
Base-Excision Repair, AP Site Formation	35	8.56e-02	1.20e-01	0.2070	-1.59e-01	0.132000	1.03e-01	1.77e-01
Metabolism of lipids	643	1.22e-17	2.42e-16	0.2060	-3.95e-02	-0.202000	8.72e-02	1.67e-18
Metabolism of nitric oxide: NOS3 activation and regulation	15	4.01e-01	4.60e-01	0.2060	-5.92e-02	-0.197000	6.91e-01	1.86e-01
RNA Polymerase II Transcription	1234	7.75e-31	3.34e-29	0.2060	-1.80e-01	-0.098400	8.96e-27	5.31e-09
Glycerophospholipid biosynthesis	110	1.74e-03	3.61e-03	0.2050	-1.38e-01	-0.152000	1.24e-02	5.81e-03
Pyruvate metabolism	28	1.99e-01	2.54e-01	0.2040	-1.65e-01	-0.120000	1.30e-01	2.70e-01
Signaling by NOTCH4	81	4.55e-03	8.62e-03	0.2040	-1.93e-01	0.067300	2.67e-03	2.95e-01
Chaperonin-mediated protein folding	83	8.32e-03	1.51e-02	0.2040	-1.73e-01	-0.109000	6.50e-03	8.62e-02
Sensory processing of sound	62	1.56e-02	2.65e-02	0.2040	8.63e-02	-0.185000	2.40e-01	1.18e-02
Generic Transcription Pathway	1116	2.74e-27	1.00e-25	0.2030	-1.70e-01	-0.111000	6.46e-22	2.99e-10
Mitotic Metaphase and Anaphase	229	4.59e-07	2.18e-06	0.2030	-1.99e-01	0.040400	2.22e-07	2.92e-01
Purine salvage	12	4.55e-01	5.12e-01	0.2020	7.01e-02	-0.190000	6.74e-01	2.55e-01
FGFR3 mutant receptor activation	10	5.53e-01	6.09e-01	0.2020	1.97e-01	0.045400	2.81e-01	8.04e-01
Signaling by activated point mutants of FGFR3	10	5.53e-01	6.09e-01	0.2020	1.97e-01	0.045400	2.81e-01	8.04e-01
Defective HDR through Homologous Recombination (HRR) due to BRCA1 loss-of-function	24	2.57e-01	3.15e-01	0.2010	1.79e-01	0.092900	1.30e-01	4.31e-01
Defective HDR through Homologous Recombination (HRR) due to PALB2 loss of function	24	2.57e-01	3.15e-01	0.2010	1.79e-01	0.092900	1.30e-01	4.31e-01
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function	24	2.57e-01	3.15e-01	0.2010	1.79e-01	0.092900	1.30e-01	4.31e-01
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function	24	2.57e-01	3.15e-01	0.2010	1.79e-01	0.092900	1.30e-01	4.31e-01
Diseases of DNA Double-Strand Break Repair	24	2.57e-01	3.15e-01	0.2010	1.79e-01	0.092900	1.30e-01	4.31e-01
Mitotic Anaphase	228	6.05e-07	2.80e-06	0.2010	-1.97e-01	0.039800	2.84e-07	3.00e-01
Transmission across Chemical Synapses	212	1.91e-06	7.82e-06	0.2010	2.83e-02	-0.199000	4.77e-01	5.83e-07
TRAF6-mediated induction of TAK1 complex within TLR4 complex	16	4.13e-01	4.72e-01	0.2010	-1.42e-01	-0.142000	3.25e-01	3.27e-01
Defective Intrinsic Pathway for Apoptosis	22	2.94e-01	3.55e-01	0.2000	-1.74e-01	-0.099600	1.59e-01	4.19e-01
SLC-mediated transmembrane transport	196	5.87e-06	2.13e-05	0.1990	4.05e-02	-0.195000	3.28e-01	2.60e-06
IL-6-type cytokine receptor ligand interactions	16	3.54e-01	4.15e-01	0.1980	1.52e-01	-0.127000	2.91e-01	3.79e-01
Termination of translesion DNA synthesis	32	1.68e-01	2.18e-01	0.1980	7.01e-02	0.185000	4.93e-01	6.97e-02
GABA receptor activation	45	7.46e-02	1.06e-01	0.1970	-2.17e-02	-0.196000	8.02e-01	2.27e-02
Early Phase of HIV Life Cycle	13	4.53e-01	5.10e-01	0.1970	-1.92e-01	0.043800	2.31e-01	7.84e-01
IRAK4 deficiency (TLR2/4)	15	4.44e-01	5.00e-01	0.1970	8.73e-02	0.176000	5.58e-01	2.38e-01
Telomere Maintenance	84	6.86e-03	1.26e-02	0.1960	-2.67e-02	0.194000	6.72e-01	2.10e-03
Initiation of Nuclear Envelope (NE) Reformation	19	3.59e-01	4.20e-01	0.1950	-1.81e-01	-0.073000	1.72e-01	5.82e-01
G2/M Transition	181	1.76e-05	5.73e-05	0.1950	-1.80e-01	0.073800	2.92e-05	8.67e-02
GPCR downstream signalling	420	2.62e-11	2.95e-10	0.1950	3.28e-02	-0.192000	2.48e-01	1.48e-11
Binding and Uptake of Ligands by Scavenger Receptors	31	1.90e-01	2.43e-01	0.1940	1.81e-01	0.070700	8.09e-02	4.96e-01
Signaling by GPCR	474	1.38e-12	1.80e-11	0.1940	3.01e-02	-0.192000	2.62e-01	7.40e-13
Protein folding	89	8.20e-03	1.49e-02	0.1940	-1.87e-01	-0.052600	2.33e-03	3.91e-01
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein	76	1.88e-02	3.11e-02	0.1940	-9.25e-02	-0.170000	1.63e-01	1.02e-02
CASP8 activity is inhibited	10	5.56e-01	6.11e-01	0.1930	4.07e-02	-0.189000	8.24e-01	3.00e-01
Dimerization of procaspase-8	10	5.56e-01	6.11e-01	0.1930	4.07e-02	-0.189000	8.24e-01	3.00e-01
Regulation by c-FLIP	10	5.56e-01	6.11e-01	0.1930	4.07e-02	-0.189000	8.24e-01	3.00e-01
Metabolism of proteins	1731	1.62e-36	8.49e-35	0.1930	-1.44e-01	-0.128000	1.33e-23	5.62e-19
mTORC1-mediated signalling	24	2.86e-01	3.47e-01	0.1910	-5.51e-02	-0.182000	6.40e-01	1.22e-01
Transcriptional Regulation by TP53	356	1.29e-08	8.39e-08	0.1900	-1.80e-01	-0.061900	5.14e-09	4.48e-02
Nervous system development	522	8.27e-12	9.77e-11	0.1900	-1.19e-01	-0.149000	3.47e-06	5.53e-09
Mitotic G2-G2/M phases	183	2.48e-05	7.69e-05	0.1900	-1.74e-01	0.076600	4.85e-05	7.39e-02
FGFR2 mutant receptor activation	29	1.78e-01	2.30e-01	0.1900	-1.43e-01	0.126000	1.84e-01	2.42e-01
Cell Cycle Checkpoints	260	2.55e-07	1.27e-06	0.1890	-1.46e-01	0.121000	5.16e-05	8.03e-04
Mitochondrial calcium ion transport	22	3.34e-01	3.96e-01	0.1880	-1.70e-01	-0.082200	1.68e-01	5.04e-01
SHC-mediated cascade:FGFR2	19	3.32e-01	3.94e-01	0.1880	1.26e-01	-0.139000	3.41e-01	2.95e-01
Norepinephrine Neurotransmitter Release Cycle	16	4.44e-01	5.00e-01	0.1870	-1.82e-01	-0.045500	2.08e-01	7.53e-01
Disease	1437	1.81e-29	6.97e-28	0.1870	-9.45e-02	-0.162000	1.73e-09	6.57e-25
BBSome-mediated cargo-targeting to cilium	21	3.56e-01	4.17e-01	0.1870	-7.95e-02	-0.169000	5.28e-01	1.79e-01
ADORA2B mediated anti-inflammatory cytokines production	81	1.23e-02	2.16e-02	0.1870	3.66e-02	-0.183000	5.69e-01	4.42e-03
Processing of SMDT1	15	4.51e-01	5.08e-01	0.1860	-1.86e-01	0.013600	2.13e-01	9.27e-01
Activation of HOX genes during differentiation	81	1.76e-02	2.94e-02	0.1860	-1.80e-01	-0.047000	5.08e-03	4.64e-01
Activation of anterior HOX genes in hindbrain development during early embryogenesis	81	1.76e-02	2.94e-02	0.1860	-1.80e-01	-0.047000	5.08e-03	4.64e-01
Signaling by NOTCH	193	1.05e-04	2.84e-04	0.1860	-1.55e-01	-0.102000	2.01e-04	1.42e-02
Signaling by FGFR2 in disease	39	1.44e-01	1.90e-01	0.1850	-1.81e-01	-0.036300	5.05e-02	6.95e-01
Glyoxylate metabolism and glycine degradation	25	2.92e-01	3.53e-01	0.1840	-1.79e-01	-0.042800	1.21e-01	7.11e-01
DNA Damage/Telomere Stress Induced Senescence	51	8.34e-02	1.17e-01	0.1840	-1.77e-01	-0.050000	2.86e-02	5.36e-01
Formation of the beta-catenin:TCF transactivating complex	52	8.92e-02	1.24e-01	0.1840	-1.19e-01	-0.140000	1.38e-01	8.01e-02
Neurotransmitter release cycle	47	1.11e-01	1.51e-01	0.1830	-8.60e-02	-0.162000	3.08e-01	5.50e-02
Amino acid transport across the plasma membrane	29	2.40e-01	2.99e-01	0.1830	-2.85e-02	-0.181000	7.91e-01	9.19e-02
Response of Mtb to phagocytosis	22	3.50e-01	4.12e-01	0.1830	-5.97e-02	-0.173000	6.28e-01	1.60e-01
Cellular Senescence	152	8.17e-04	1.84e-03	0.1830	-1.66e-01	-0.077000	4.13e-04	1.01e-01
Neutrophil degranulation	406	3.72e-09	2.77e-08	0.1820	-3.08e-02	-0.179000	2.86e-01	5.29e-10
Mitochondrial tRNA aminoacylation	21	3.80e-01	4.39e-01	0.1820	-8.30e-02	-0.162000	5.10e-01	2.00e-01
Intrinsic Pathway for Apoptosis	53	6.79e-02	9.76e-02	0.1810	2.14e-02	-0.180000	7.88e-01	2.32e-02
Global Genome Nucleotide Excision Repair (GG-NER)	84	1.09e-02	1.93e-02	0.1810	-1.50e-01	0.102000	1.78e-02	1.04e-01
RMTs methylate histone arginines	42	1.21e-01	1.61e-01	0.1810	-1.81e-01	0.015200	4.29e-02	8.65e-01
Basigin interactions	23	3.12e-01	3.74e-01	0.1810	2.53e-02	-0.179000	8.34e-01	1.37e-01
Translesion Synthesis by POLH	18	3.83e-01	4.42e-01	0.1810	-1.52e-01	0.096900	2.63e-01	4.77e-01
Cardiac conduction	107	3.57e-03	6.85e-03	0.1800	9.28e-02	-0.154000	9.71e-02	5.88e-03
Sema4D in semaphorin signaling	24	3.29e-01	3.93e-01	0.1800	-5.34e-02	-0.172000	6.51e-01	1.45e-01
Phospholipase C-mediated cascade; FGFR2	14	5.42e-01	6.00e-01	0.1780	1.38e-01	0.113000	3.70e-01	4.66e-01
Beta-oxidation of very long chain fatty acids	10	6.35e-01	6.85e-01	0.1780	1.71e-01	0.050700	3.50e-01	7.81e-01
Developmental Biology	843	2.54e-16	4.43e-15	0.1780	-8.61e-02	-0.155000	2.07e-05	1.55e-14
Formation of Senescence-Associated Heterochromatin Foci (SAHF)	16	4.95e-01	5.53e-01	0.1770	-8.16e-02	-0.157000	5.72e-01	2.76e-01
Extension of Telomeres	51	1.12e-01	1.52e-01	0.1770	1.24e-01	0.126000	1.26e-01	1.19e-01
ABC-family proteins mediated transport	97	7.92e-03	1.44e-02	0.1770	-1.64e-01	0.064600	5.15e-03	2.72e-01
Post-chaperonin tubulin folding pathway	20	3.88e-01	4.47e-01	0.1760	-5.37e-03	0.176000	9.67e-01	1.72e-01
Dectin-2 family	14	5.47e-01	6.05e-01	0.1760	1.46e-01	0.099400	3.45e-01	5.20e-01
Glycogen storage diseases	14	5.42e-01	6.00e-01	0.1760	1.60e-01	0.073600	2.99e-01	6.33e-01
Activation of kainate receptors upon glutamate binding	24	3.62e-01	4.23e-01	0.1760	-1.21e-01	-0.128000	3.07e-01	2.79e-01
Axon guidance	500	1.60e-09	1.28e-08	0.1730	-1.12e-01	-0.132000	1.62e-05	4.32e-07
SHC-mediated cascade:FGFR4	16	4.55e-01	5.12e-01	0.1730	1.15e-01	-0.129000	4.28e-01	3.71e-01
Activation of SMO	18	4.78e-01	5.35e-01	0.1730	-1.28e-01	-0.115000	3.45e-01	3.97e-01
Diseases of programmed cell death	61	5.11e-02	7.61e-02	0.1720	-1.32e-01	0.110000	7.37e-02	1.37e-01
RIPK1-mediated regulated necrosis	27	3.30e-01	3.93e-01	0.1720	-1.47e-01	-0.090000	1.87e-01	4.18e-01
Regulation of necroptotic cell death	27	3.30e-01	3.93e-01	0.1720	-1.47e-01	-0.090000	1.87e-01	4.18e-01
Post-translational modification: synthesis of GPI-anchored proteins	63	5.57e-02	8.20e-02	0.1720	1.70e-01	-0.026700	1.97e-02	7.14e-01
Oxidative Stress Induced Senescence	82	2.85e-02	4.53e-02	0.1720	-1.70e-01	-0.022300	7.68e-03	7.26e-01
FRS-mediated FGFR4 signaling	18	4.62e-01	5.18e-01	0.1710	-3.23e-02	-0.168000	8.12e-01	2.16e-01
FRS-mediated FGFR2 signaling	21	3.94e-01	4.52e-01	0.1710	-7.09e-04	-0.171000	9.96e-01	1.74e-01
Interleukin-37 signaling	21	3.79e-01	4.39e-01	0.1710	4.17e-02	-0.166000	7.41e-01	1.88e-01
Transcriptional regulation of testis differentiation	11	5.92e-01	6.44e-01	0.1710	8.81e-02	-0.146000	6.13e-01	4.00e-01
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	13	5.95e-01	6.47e-01	0.1710	-1.17e-01	-0.124000	4.64e-01	4.39e-01
Mitotic G1 phase and G1/S transition	147	9.65e-04	2.13e-03	0.1700	-9.14e-02	0.144000	5.56e-02	2.62e-03
Peroxisomal protein import	59	7.12e-02	1.02e-01	0.1700	2.69e-02	-0.168000	7.21e-01	2.58e-02
G alpha (s) signalling events	92	1.54e-02	2.62e-02	0.1700	4.28e-02	-0.164000	4.78e-01	6.43e-03
Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane	10	6.74e-01	7.20e-01	0.1670	-5.88e-02	-0.156000	7.48e-01	3.93e-01
Adrenaline,noradrenaline inhibits insulin secretion	23	3.88e-01	4.47e-01	0.1660	-1.29e-02	-0.166000	9.15e-01	1.69e-01
Infection with Mycobacterium tuberculosis	24	3.84e-01	4.44e-01	0.1650	-3.16e-02	-0.162000	7.89e-01	1.69e-01
Nucleotide salvage	21	4.31e-01	4.89e-01	0.1650	1.63e-01	0.023200	1.95e-01	8.54e-01
Phase II - Conjugation of compounds	75	5.11e-02	7.61e-02	0.1650	3.08e-02	0.162000	6.44e-01	1.52e-02
Regulation of Complement cascade	25	3.34e-01	3.96e-01	0.1640	-1.47e-01	0.073000	2.02e-01	5.27e-01
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	25	3.47e-01	4.09e-01	0.1640	4.33e-02	-0.158000	7.08e-01	1.72e-01
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	14	5.40e-01	5.99e-01	0.1630	1.12e-01	-0.119000	4.67e-01	4.42e-01
Aspartate and asparagine metabolism	10	6.94e-01	7.36e-01	0.1630	1.27e-01	0.102000	4.87e-01	5.77e-01
Recognition of DNA damage by PCNA-containing replication complex	30	2.71e-01	3.30e-01	0.1630	-1.02e-01	0.127000	3.34e-01	2.29e-01
Base Excision Repair	63	7.81e-02	1.11e-01	0.1630	-1.24e-02	0.162000	8.65e-01	2.59e-02
Incretin synthesis, secretion, and inactivation	16	5.51e-01	6.08e-01	0.1620	-1.50e-01	-0.061600	2.99e-01	6.69e-01
S Phase	160	1.10e-03	2.41e-03	0.1620	-8.21e-02	0.140000	7.30e-02	2.30e-03
Branched-chain amino acid catabolism	21	4.30e-01	4.88e-01	0.1620	1.38e-02	-0.161000	9.13e-01	2.01e-01
Vitamin D (calciferol) metabolism	10	6.56e-01	7.05e-01	0.1610	7.08e-02	-0.145000	6.98e-01	4.27e-01
Telomere C-strand synthesis initiation	13	5.78e-01	6.31e-01	0.1610	8.13e-02	-0.139000	6.12e-01	3.87e-01
Class B/2 (Secretin family receptors)	70	5.68e-02	8.34e-02	0.1610	5.07e-02	-0.152000	4.63e-01	2.76e-02
Formation of tubulin folding intermediates by CCT/TriC	23	4.38e-01	4.96e-01	0.1600	-1.41e-01	-0.075900	2.41e-01	5.29e-01
Phospholipase C-mediated cascade; FGFR3	11	6.81e-01	7.25e-01	0.1600	1.11e-01	0.115000	5.25e-01	5.09e-01
Smooth Muscle Contraction	32	2.62e-01	3.21e-01	0.1590	1.05e-01	-0.120000	3.04e-01	2.40e-01
cGMP effects	14	5.60e-01	6.14e-01	0.1580	1.11e-01	-0.113000	4.73e-01	4.63e-01
Pre-NOTCH Expression and Processing	70	8.96e-02	1.25e-01	0.1580	-9.47e-02	-0.127000	1.71e-01	6.66e-02
Signaling by Hedgehog	132	7.68e-03	1.40e-02	0.1580	-1.57e-01	-0.015800	1.81e-03	7.54e-01
Phase 0 - rapid depolarisation	28	3.61e-01	4.22e-01	0.1560	1.56e-01	0.014000	1.54e-01	8.98e-01
Visual phototransduction	70	6.90e-02	9.87e-02	0.1560	4.02e-02	-0.150000	5.61e-01	2.96e-02
M Phase	370	1.70e-06	6.98e-06	0.1540	-1.53e-01	0.013800	3.94e-07	6.49e-01
Muscle contraction	159	2.29e-03	4.60e-03	0.1530	9.71e-02	-0.118000	3.46e-02	1.02e-02
The phototransduction cascade	26	4.04e-01	4.63e-01	0.1530	-9.93e-03	-0.152000	9.30e-01	1.78e-01
Apoptosis	169	4.71e-03	8.88e-03	0.1520	-9.73e-02	-0.117000	2.90e-02	8.59e-03
Programmed Cell Death	195	1.99e-03	4.06e-03	0.1520	-8.13e-02	-0.129000	5.01e-02	1.94e-03
Transport of inorganic cations/anions and amino acids/oligopeptides	90	4.90e-02	7.33e-02	0.1510	-2.23e-02	-0.149000	7.15e-01	1.42e-02
Transcriptional Regulation by VENTX	38	2.71e-01	3.30e-01	0.1500	-1.50e-01	0.007890	1.10e-01	9.33e-01
Recycling of bile acids and salts	13	6.63e-01	7.10e-01	0.1500	1.35e-01	0.065300	3.99e-01	6.83e-01
Serotonin Neurotransmitter Release Cycle	17	5.82e-01	6.35e-01	0.1490	-1.43e-01	-0.041800	3.08e-01	7.66e-01
Sema4D induced cell migration and growth-cone collapse	20	5.40e-01	5.99e-01	0.1480	-6.69e-02	-0.132000	6.05e-01	3.05e-01
G0 and Early G1	27	4.42e-01	5.00e-01	0.1480	1.14e-01	0.095000	3.06e-01	3.93e-01
Prostacyclin signalling through prostacyclin receptor	15	6.26e-01	6.77e-01	0.1480	-1.39e-01	-0.049400	3.50e-01	7.40e-01
The canonical retinoid cycle in rods (twilight vision)	16	6.11e-01	6.62e-01	0.1470	5.69e-02	0.136000	6.94e-01	3.46e-01
TP53 Regulates Transcription of Death Receptors and Ligands	11	6.76e-01	7.21e-01	0.1470	1.13e-01	-0.093800	5.15e-01	5.90e-01
Voltage gated Potassium channels	32	3.26e-01	3.90e-01	0.1470	6.63e-02	-0.131000	5.16e-01	1.99e-01
Plasma lipoprotein assembly, remodeling, and clearance	55	1.43e-01	1.88e-01	0.1470	1.12e-01	-0.094600	1.50e-01	2.25e-01
Glutamate Neurotransmitter Release Cycle	23	5.05e-01	5.63e-01	0.1470	-1.19e-01	-0.085000	3.21e-01	4.80e-01
Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol	20	5.53e-01	6.09e-01	0.1470	-1.18e-01	-0.086600	3.60e-01	5.02e-01
Transport of small molecules	598	4.33e-09	3.14e-08	0.1470	1.29e-02	-0.146000	5.90e-01	1.01e-09
Peroxisomal lipid metabolism	27	3.90e-01	4.49e-01	0.1460	9.05e-02	-0.114000	4.16e-01	3.05e-01
Homology Directed Repair	111	4.04e-02	6.18e-02	0.1440	6.39e-02	0.129000	2.45e-01	1.89e-02
Mitotic Spindle Checkpoint	109	2.66e-02	4.27e-02	0.1440	-1.31e-01	0.059000	1.79e-02	2.87e-01
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA)	105	4.46e-02	6.76e-02	0.1440	3.78e-02	0.139000	5.03e-01	1.41e-02
Transcription of E2F targets under negative control by DREAM complex	19	5.85e-01	6.39e-01	0.1430	9.89e-02	0.104000	4.56e-01	4.34e-01
E2F mediated regulation of DNA replication	22	5.35e-01	5.94e-01	0.1420	5.83e-02	0.130000	6.36e-01	2.93e-01
Caspase activation via Death Receptors in the presence of ligand	15	6.09e-01	6.60e-01	0.1420	8.98e-02	-0.110000	5.47e-01	4.62e-01
HDR through Single Strand Annealing (SSA)	37	3.63e-01	4.24e-01	0.1410	1.16e-01	0.079200	2.21e-01	4.04e-01
Processing of DNA double-strand break ends	72	9.61e-02	1.33e-01	0.1410	-1.05e-01	0.093700	1.24e-01	1.69e-01
Collagen chain trimerization	37	3.06e-01	3.69e-01	0.1400	1.25e-01	-0.063500	1.87e-01	5.04e-01
Killing mechanisms	11	7.05e-01	7.45e-01	0.1400	1.27e-01	-0.060200	4.67e-01	7.30e-01
WNT5:FZD7-mediated leishmania damping	11	7.05e-01	7.45e-01	0.1400	1.27e-01	-0.060200	4.67e-01	7.30e-01
TP53 Regulates Metabolic Genes	85	9.11e-02	1.26e-01	0.1400	-1.36e-01	-0.033000	3.04e-02	5.99e-01
Gamma carboxylation, hypusine formation and arylsulfatase activation	36	3.33e-01	3.95e-01	0.1400	2.98e-02	-0.136000	7.57e-01	1.57e-01
Removal of the Flap Intermediate from the C-strand	17	6.06e-01	6.59e-01	0.1390	2.08e-03	-0.139000	9.88e-01	3.20e-01
Regulation of TP53 Activity through Association with Co-factors	12	6.89e-01	7.31e-01	0.1390	5.41e-02	-0.128000	7.45e-01	4.43e-01
Complement cascade	31	3.73e-01	4.34e-01	0.1390	-1.04e-01	0.092600	3.18e-01	3.72e-01
RHO GTPases Activate Formins	118	4.49e-02	6.81e-02	0.1390	-1.01e-01	-0.095100	5.84e-02	7.42e-02
Constitutive Signaling by NOTCH1 HD Domain Mutants	15	6.58e-01	7.06e-01	0.1380	-2.83e-02	-0.135000	8.49e-01	3.64e-01
Signaling by NOTCH1 HD Domain Mutants in Cancer	15	6.58e-01	7.06e-01	0.1380	-2.83e-02	-0.135000	8.49e-01	3.64e-01
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway	16	6.08e-01	6.60e-01	0.1380	-6.88e-02	0.120000	6.34e-01	4.07e-01
Signaling by Retinoic Acid	37	3.60e-01	4.20e-01	0.1380	-1.35e-01	-0.029700	1.56e-01	7.55e-01
Protein localization	158	9.55e-03	1.71e-02	0.1370	-1.31e-01	0.037600	4.34e-03	4.15e-01
TP53 Regulates Transcription of Cell Death Genes	43	3.33e-01	3.95e-01	0.1340	-1.25e-01	-0.049200	1.56e-01	5.77e-01
G alpha (i) signalling events	194	4.58e-03	8.65e-03	0.1340	2.06e-02	-0.133000	6.20e-01	1.45e-03
Inactivation, recovery and regulation of the phototransduction cascade	25	5.27e-01	5.87e-01	0.1340	-4.42e-02	-0.127000	7.02e-01	2.74e-01
Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon	17	6.11e-01	6.62e-01	0.1330	-6.34e-02	0.117000	6.51e-01	4.02e-01
Cyclin D associated events in G1	45	3.31e-01	3.94e-01	0.1330	-6.83e-02	-0.114000	4.28e-01	1.85e-01
G1 Phase	45	3.31e-01	3.94e-01	0.1330	-6.83e-02	-0.114000	4.28e-01	1.85e-01
Dual Incision in GG-NER	41	3.31e-01	3.94e-01	0.1320	-1.62e-02	0.131000	8.58e-01	1.46e-01
Transcriptional regulation of pluripotent stem cells	30	4.43e-01	5.00e-01	0.1310	3.36e-02	-0.127000	7.50e-01	2.29e-01
Synthesis of bile acids and bile salts	30	4.89e-01	5.46e-01	0.1310	-5.86e-02	-0.117000	5.79e-01	2.69e-01
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal	92	9.34e-02	1.29e-01	0.1300	-1.30e-01	0.004050	3.07e-02	9.47e-01
Amplification of signal from the kinetochores	92	9.34e-02	1.29e-01	0.1300	-1.30e-01	0.004050	3.07e-02	9.47e-01
Common Pathway of Fibrin Clot Formation	14	6.81e-01	7.25e-01	0.1300	5.60e-02	-0.117000	7.17e-01	4.47e-01
Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)	14	7.22e-01	7.61e-01	0.1300	-8.37e-02	-0.099500	5.88e-01	5.19e-01
Resolution of Sister Chromatid Cohesion	105	7.97e-02	1.13e-01	0.1290	-1.26e-01	-0.028400	2.58e-02	6.15e-01
Ion channel transport	152	1.60e-02	2.72e-02	0.1290	7.76e-02	-0.103000	9.86e-02	2.83e-02
Aggrephagy	21	5.66e-01	6.19e-01	0.1290	-7.50e-02	0.104000	5.52e-01	4.08e-01
Triglyceride metabolism	26	5.31e-01	5.91e-01	0.1280	-9.47e-03	-0.127000	9.33e-01	2.61e-01
Metabolic disorders of biological oxidation enzymes	28	5.27e-01	5.87e-01	0.1270	1.17e-01	0.049700	2.83e-01	6.49e-01
Arachidonic acid metabolism	37	3.77e-01	4.38e-01	0.1270	-6.51e-02	0.109000	4.93e-01	2.50e-01
Regulation of FZD by ubiquitination	21	6.14e-01	6.65e-01	0.1270	-3.52e-02	-0.122000	7.80e-01	3.33e-01
POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation	13	7.34e-01	7.72e-01	0.1270	1.26e-01	0.013100	4.32e-01	9.35e-01
Regulation of TP53 Activity through Phosphorylation	91	1.21e-01	1.61e-01	0.1270	-1.24e-01	-0.026200	4.12e-02	6.65e-01
Amino acids regulate mTORC1	51	3.08e-01	3.71e-01	0.1260	-1.24e-01	-0.023200	1.27e-01	7.74e-01
Acyl chain remodelling of PG	11	7.87e-01	8.18e-01	0.1260	-1.02e-01	-0.072500	5.56e-01	6.77e-01
Telomere Extension By Telomerase	23	5.90e-01	6.43e-01	0.1250	-1.24e-01	-0.018500	3.05e-01	8.78e-01
EML4 and NUDC in mitotic spindle formation	96	1.14e-01	1.54e-01	0.1250	-1.22e-01	-0.025100	3.85e-02	6.71e-01
Aberrant regulation of mitotic cell cycle due to RB1 defects	36	4.64e-01	5.20e-01	0.1210	2.65e-02	0.118000	7.83e-01	2.19e-01
Xenobiotics	14	7.20e-01	7.59e-01	0.1200	1.05e-01	-0.058800	4.98e-01	7.03e-01
ROS and RNS production in phagocytes	31	5.45e-01	6.03e-01	0.1190	6.53e-02	0.099400	5.29e-01	3.38e-01
Sensory Perception	173	1.97e-02	3.25e-02	0.1180	5.70e-02	-0.104000	1.96e-01	1.84e-02
Chaperone Mediated Autophagy	17	7.23e-01	7.61e-01	0.1170	-9.89e-02	-0.063200	4.80e-01	6.52e-01
TRAF6 mediated NF-kB activation	23	6.48e-01	6.98e-01	0.1170	-8.65e-02	-0.078900	4.73e-01	5.12e-01
Apoptosis induced DNA fragmentation	12	7.68e-01	8.01e-01	0.1170	-4.54e-02	0.108000	7.85e-01	5.19e-01
Fertilization	15	7.41e-01	7.78e-01	0.1170	1.91e-02	0.115000	8.98e-01	4.40e-01
Metabolism of vitamins and cofactors	171	2.38e-02	3.86e-02	0.1160	7.39e-02	-0.088800	9.53e-02	4.50e-02
Nicotinamide salvaging	18	6.88e-01	7.31e-01	0.1150	1.13e-01	-0.022400	4.06e-01	8.70e-01
Nucleotide catabolism	31	5.71e-01	6.25e-01	0.1150	8.42e-02	0.077900	4.17e-01	4.53e-01
Na+/Cl- dependent neurotransmitter transporters	11	7.90e-01	8.20e-01	0.1140	6.39e-02	-0.094600	7.13e-01	5.87e-01
Biosynthesis of specialized proresolving mediators (SPMs)	14	7.44e-01	7.80e-01	0.1140	-5.87e-02	0.097500	7.04e-01	5.28e-01
RA biosynthesis pathway	17	7.46e-01	7.82e-01	0.1120	6.25e-02	0.092600	6.55e-01	5.09e-01
Transcriptional regulation of granulopoiesis	50	4.25e-01	4.84e-01	0.1110	-6.11e-02	-0.092900	4.55e-01	2.56e-01
Biological oxidations	150	6.39e-02	9.23e-02	0.1110	2.43e-03	0.111000	9.59e-01	1.93e-02
Synthesis of PC	26	6.28e-01	6.78e-01	0.1110	-2.00e-02	-0.109000	8.60e-01	3.37e-01
ERBB2 Activates PTK6 Signaling	11	8.35e-01	8.57e-01	0.1090	-5.86e-02	-0.091800	7.36e-01	5.98e-01
G2/M DNA damage checkpoint	69	2.79e-01	3.38e-01	0.1080	-1.03e-01	0.033600	1.41e-01	6.29e-01
Formation of Fibrin Clot (Clotting Cascade)	24	6.76e-01	7.21e-01	0.1080	-9.80e-02	-0.044700	4.06e-01	7.05e-01
Apoptotic factor-mediated response	19	7.40e-01	7.77e-01	0.1070	-8.40e-02	-0.066900	5.26e-01	6.14e-01
Activation of G protein gated Potassium channels	23	6.54e-01	7.03e-01	0.1070	-9.88e-02	0.041300	4.12e-01	7.31e-01
G protein gated Potassium channels	23	6.54e-01	7.03e-01	0.1070	-9.88e-02	0.041300	4.12e-01	7.31e-01
Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits	23	6.54e-01	7.03e-01	0.1070	-9.88e-02	0.041300	4.12e-01	7.31e-01
Nitric oxide stimulates guanylate cyclase	18	7.18e-01	7.57e-01	0.1070	4.39e-02	-0.097400	7.47e-01	4.75e-01
Class C/3 (Metabotropic glutamate/pheromone receptors)	13	7.98e-01	8.25e-01	0.1060	-1.19e-02	0.105000	9.41e-01	5.10e-01
TP53 Regulates Transcription of Caspase Activators and Caspases	11	8.23e-01	8.48e-01	0.1050	-3.46e-02	0.099400	8.43e-01	5.68e-01
Interconversion of nucleotide di- and triphosphates	29	5.98e-01	6.50e-01	0.1050	-3.74e-02	0.098300	7.27e-01	3.59e-01
Metabolism of porphyrins	22	7.14e-01	7.54e-01	0.1050	5.42e-02	0.089900	6.60e-01	4.66e-01
SUMOylation of DNA methylation proteins	16	7.54e-01	7.90e-01	0.1050	-9.65e-02	0.040500	5.04e-01	7.79e-01
FGFR3 ligand binding and activation	11	8.29e-01	8.53e-01	0.1040	1.02e-01	-0.022000	5.59e-01	9.00e-01
FGFR3c ligand binding and activation	11	8.29e-01	8.53e-01	0.1040	1.02e-01	-0.022000	5.59e-01	9.00e-01
Pyroptosis	24	6.60e-01	7.08e-01	0.1030	5.60e-02	-0.086200	6.35e-01	4.65e-01
Eicosanoid ligand-binding receptors	12	8.23e-01	8.48e-01	0.1020	-1.02e-01	0.012500	5.42e-01	9.40e-01
Regulation of PLK1 Activity at G2/M Transition	87	2.53e-01	3.12e-01	0.1020	-1.02e-01	0.001150	9.89e-02	9.85e-01
Regulated Necrosis	51	4.78e-01	5.35e-01	0.1020	-5.13e-02	-0.088300	5.26e-01	2.75e-01
Downregulation of ERBB2 signaling	27	6.80e-01	7.25e-01	0.1020	-5.57e-02	-0.084900	6.16e-01	4.45e-01
Cytosolic sulfonation of small molecules	21	7.01e-01	7.42e-01	0.1010	6.75e-02	-0.075600	5.92e-01	5.48e-01
Transferrin endocytosis and recycling	30	6.43e-01	6.93e-01	0.1010	9.66e-02	0.030700	3.60e-01	7.71e-01
Tryptophan catabolism	12	8.45e-01	8.67e-01	0.1010	6.39e-02	0.078200	7.01e-01	6.39e-01
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1	16	7.97e-01	8.25e-01	0.1010	8.57e-02	0.053400	5.53e-01	7.12e-01
Termination of O-glycan biosynthesis	17	7.56e-01	7.92e-01	0.1000	5.85e-02	-0.081100	6.76e-01	5.63e-01
Stimuli-sensing channels	84	2.54e-01	3.13e-01	0.1000	5.48e-02	-0.083600	3.85e-01	1.85e-01
Sealing of the nuclear envelope (NE) by ESCRT-III	29	6.28e-01	6.78e-01	0.0992	4.85e-02	-0.086500	6.51e-01	4.20e-01
Striated Muscle Contraction	26	7.08e-01	7.48e-01	0.0980	5.59e-02	0.080500	6.22e-01	4.77e-01
Metabolism of water-soluble vitamins and cofactors	117	1.62e-01	2.12e-01	0.0973	6.44e-02	-0.072900	2.28e-01	1.73e-01
Peptide ligand-binding receptors	100	2.75e-01	3.35e-01	0.0960	8.71e-02	0.040500	1.32e-01	4.84e-01
Olfactory Signaling Pathway	21	7.66e-01	7.99e-01	0.0956	4.75e-02	0.082900	7.06e-01	5.11e-01
Cell Cycle, Mitotic	512	6.83e-04	1.56e-03	0.0954	-9.02e-02	0.031100	4.71e-04	2.27e-01
Pre-NOTCH Transcription and Translation	54	4.99e-01	5.57e-01	0.0954	-3.51e-02	-0.088700	6.55e-01	2.60e-01
TNFs bind their physiological receptors	19	7.71e-01	8.03e-01	0.0950	-1.17e-03	0.095000	9.93e-01	4.74e-01
Diseases associated with the TLR signaling cascade	27	6.89e-01	7.31e-01	0.0940	-9.22e-02	0.018400	4.07e-01	8.69e-01
Diseases of Immune System	27	6.89e-01	7.31e-01	0.0940	-9.22e-02	0.018400	4.07e-01	8.69e-01
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	76	3.52e-01	4.14e-01	0.0936	9.11e-02	-0.021600	1.70e-01	7.45e-01
Downregulation of ERBB2:ERBB3 signaling	13	8.50e-01	8.71e-01	0.0932	-2.52e-02	-0.089700	8.75e-01	5.75e-01
Phospholipase C-mediated cascade: FGFR1	13	8.35e-01	8.57e-01	0.0929	-8.51e-02	0.037200	5.95e-01	8.16e-01
Sensory perception of sweet, bitter, and umami (glutamate) taste	19	7.96e-01	8.25e-01	0.0926	-8.29e-02	-0.041200	5.32e-01	7.56e-01
TP53 Regulates Transcription of Cell Cycle Genes	48	5.64e-01	6.18e-01	0.0911	-2.52e-02	-0.087600	7.63e-01	2.94e-01
Insulin receptor recycling	24	7.64e-01	7.98e-01	0.0904	6.42e-02	0.063600	5.86e-01	5.90e-01
Cytochrome P450 - arranged by substrate type	42	5.74e-01	6.27e-01	0.0898	7.25e-02	-0.053000	4.16e-01	5.52e-01
Plasma lipoprotein remodeling	22	7.48e-01	7.84e-01	0.0896	5.19e-02	-0.073000	6.73e-01	5.53e-01
AURKA Activation by TPX2	72	4.12e-01	4.72e-01	0.0878	-8.25e-02	0.030000	2.26e-01	6.60e-01
LGI-ADAM interactions	11	8.71e-01	8.90e-01	0.0872	6.96e-02	-0.052600	6.89e-01	7.63e-01
Organelle biogenesis and maintenance	272	6.12e-02	8.94e-02	0.0868	-6.94e-02	-0.052100	4.88e-02	1.39e-01
Fatty acid metabolism	146	1.67e-01	2.17e-01	0.0865	6.41e-02	-0.058100	1.81e-01	2.25e-01
Cell Cycle	636	6.30e-04	1.46e-03	0.0860	-8.01e-02	0.031500	5.57e-04	1.74e-01
Maturation of nucleoprotein	11	8.83e-01	8.98e-01	0.0860	6.35e-03	-0.085700	9.71e-01	6.22e-01
Diseases of mitotic cell cycle	38	6.73e-01	7.19e-01	0.0847	1.74e-02	0.082900	8.52e-01	3.77e-01
Intrinsic Pathway of Fibrin Clot Formation	14	8.51e-01	8.72e-01	0.0842	7.55e-02	-0.037300	6.25e-01	8.09e-01
DNA Damage Bypass	47	6.11e-01	6.62e-01	0.0830	-8.29e-02	0.004000	3.25e-01	9.62e-01
Acyl chain remodelling of PC	19	8.06e-01	8.32e-01	0.0830	-5.25e-02	0.064300	6.92e-01	6.27e-01
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain	13	8.78e-01	8.95e-01	0.0820	8.16e-02	0.008720	6.11e-01	9.57e-01
Acetylcholine Neurotransmitter Release Cycle	15	8.71e-01	8.90e-01	0.0817	-6.39e-02	-0.051000	6.68e-01	7.32e-01
Pregnenolone biosynthesis	10	9.02e-01	9.14e-01	0.0816	8.06e-02	-0.012400	6.59e-01	9.46e-01
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template	38	7.05e-01	7.46e-01	0.0803	2.59e-02	0.076000	7.82e-01	4.18e-01
NOTCH3 Activation and Transmission of Signal to the Nucleus	25	7.80e-01	8.11e-01	0.0780	4.26e-02	-0.065300	7.12e-01	5.72e-01
Advanced glycosylation endproduct receptor signaling	11	8.98e-01	9.12e-01	0.0773	4.03e-02	-0.065900	8.17e-01	7.05e-01
Generation of second messenger molecules	27	7.98e-01	8.25e-01	0.0765	7.25e-02	0.024400	5.14e-01	8.26e-01
Inwardly rectifying K+ channels	28	7.66e-01	7.99e-01	0.0761	-5.93e-02	0.047700	5.87e-01	6.62e-01
Loss of Nlp from mitotic centrosomes	69	5.48e-01	6.05e-01	0.0749	-7.40e-02	0.011900	2.88e-01	8.65e-01
Loss of proteins required for interphase microtubule organization from the centrosome	69	5.48e-01	6.05e-01	0.0749	-7.40e-02	0.011900	2.88e-01	8.65e-01
MASTL Facilitates Mitotic Progression	10	9.25e-01	9.35e-01	0.0732	1.52e-02	0.071600	9.34e-01	6.95e-01
DNA Repair	297	7.92e-02	1.12e-01	0.0726	-6.10e-02	0.039400	7.02e-02	2.43e-01
Sensory perception of taste	24	8.18e-01	8.44e-01	0.0718	-6.35e-02	0.033700	5.90e-01	7.75e-01
TRP channels	18	8.60e-01	8.80e-01	0.0714	4.51e-02	-0.055300	7.40e-01	6.85e-01
Other interleukin signaling	22	8.49e-01	8.71e-01	0.0705	-7.04e-02	-0.004390	5.68e-01	9.72e-01
GPCR ligand binding	261	1.21e-01	1.61e-01	0.0705	4.38e-02	-0.055200	2.23e-01	1.24e-01
Metabolism of steroid hormones	28	7.99e-01	8.26e-01	0.0699	5.86e-02	-0.038200	5.92e-01	7.26e-01
GABA synthesis, release, reuptake and degradation	18	8.78e-01	8.95e-01	0.0692	1.82e-04	-0.069200	9.99e-01	6.11e-01
Potassium Channels	81	5.57e-01	6.11e-01	0.0689	3.52e-03	-0.068800	9.56e-01	2.84e-01
POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation	10	9.26e-01	9.36e-01	0.0681	-5.19e-02	0.044100	7.76e-01	8.09e-01
Nucleotide-like (purinergic) receptors	12	9.27e-01	9.36e-01	0.0659	6.44e-02	0.014000	6.99e-01	9.33e-01
Metabolism of folate and pterines	16	9.04e-01	9.15e-01	0.0630	5.97e-02	-0.020300	6.80e-01	8.88e-01
Mitotic Prometaphase	186	3.52e-01	4.14e-01	0.0610	-6.10e-02	0.001350	1.51e-01	9.75e-01
Interleukin-10 signaling	32	8.37e-01	8.59e-01	0.0603	6.00e-02	-0.005160	5.57e-01	9.60e-01
Meiotic synapsis	49	7.85e-01	8.16e-01	0.0586	-5.66e-02	-0.015100	4.93e-01	8.55e-01
Metabolism	1856	4.20e-04	1.00e-03	0.0570	-5.01e-02	-0.027000	3.24e-04	5.24e-02
Class A/1 (Rhodopsin-like receptors)	178	4.43e-01	5.00e-01	0.0530	4.49e-02	-0.028300	3.01e-01	5.15e-01
Amyloid fiber formation	59	7.88e-01	8.18e-01	0.0527	9.52e-03	0.051800	8.99e-01	4.91e-01
Suppression of phagosomal maturation	13	9.46e-01	9.53e-01	0.0519	-1.13e-02	0.050700	9.44e-01	7.52e-01
NRIF signals cell death from the nucleus	16	9.40e-01	9.48e-01	0.0486	-3.83e-02	0.029800	7.91e-01	8.36e-01
Phase I - Functionalization of compounds	71	7.61e-01	7.96e-01	0.0483	-3.16e-02	0.036500	6.45e-01	5.94e-01
DNA Double-Strand Break Repair	140	6.63e-01	7.10e-01	0.0461	2.52e-02	0.038600	6.06e-01	4.30e-01
Reproduction	90	7.59e-01	7.93e-01	0.0458	8.07e-03	0.045100	8.95e-01	4.59e-01
Trafficking and processing of endosomal TLR	11	9.69e-01	9.73e-01	0.0458	-2.64e-02	-0.037500	8.80e-01	8.30e-01
Keratinization	46	8.82e-01	8.98e-01	0.0434	4.23e-02	0.009620	6.20e-01	9.10e-01
Processive synthesis on the C-strand of the telomere	19	9.44e-01	9.51e-01	0.0428	2.98e-02	-0.030600	8.22e-01	8.17e-01
Regulation of BACH1 activity	11	9.73e-01	9.76e-01	0.0414	8.60e-03	0.040500	9.61e-01	8.16e-01
Vitamin B5 (pantothenate) metabolism	17	9.60e-01	9.65e-01	0.0414	1.90e-02	0.036700	8.92e-01	7.93e-01
Anchoring of the basal body to the plasma membrane	97	7.98e-01	8.25e-01	0.0411	2.23e-02	0.034500	7.04e-01	5.57e-01
Glucagon-type ligand receptors	22	9.44e-01	9.51e-01	0.0408	1.19e-02	-0.039000	9.23e-01	7.52e-01
FGFR1 ligand binding and activation	12	9.74e-01	9.76e-01	0.0401	-2.96e-02	-0.027100	8.59e-01	8.71e-01
Diseases associated with N-glycosylation of proteins	17	9.59e-01	9.65e-01	0.0390	1.34e-02	-0.036600	9.24e-01	7.94e-01
Bile acid and bile salt metabolism	37	9.14e-01	9.25e-01	0.0387	1.78e-02	-0.034400	8.52e-01	7.18e-01
Cilium Assembly	181	6.84e-01	7.27e-01	0.0366	8.87e-03	-0.035500	8.37e-01	4.09e-01
Acyl chain remodelling of PE	19	9.65e-01	9.70e-01	0.0363	1.45e-02	0.033200	9.13e-01	8.02e-01
Iron uptake and transport	55	8.99e-01	9.12e-01	0.0347	3.17e-02	-0.014100	6.84e-01	8.57e-01
Centrosome maturation	81	8.75e-01	8.93e-01	0.0320	-1.25e-02	0.029500	8.46e-01	6.46e-01
Recruitment of mitotic centrosome proteins and complexes	81	8.75e-01	8.93e-01	0.0320	-1.25e-02	0.029500	8.46e-01	6.46e-01
Meiosis	75	8.97e-01	9.11e-01	0.0316	5.86e-03	0.031000	9.30e-01	6.42e-01
Metabolism of nucleotides	90	8.86e-01	9.01e-01	0.0297	-2.46e-03	0.029600	9.68e-01	6.28e-01
Recruitment of NuMA to mitotic centrosomes	80	9.12e-01	9.23e-01	0.0268	-2.46e-02	0.010600	7.03e-01	8.69e-01
Lysine catabolism	12	9.87e-01	9.87e-01	0.0260	5.58e-03	-0.025400	9.73e-01	8.79e-01
Acyl chain remodelling of PS	15	9.85e-01	9.86e-01	0.0247	1.24e-02	-0.021300	9.34e-01	8.86e-01
Transcriptional Regulation by E2F6	34	9.75e-01	9.76e-01	0.0233	-1.12e-02	-0.020400	9.10e-01	8.36e-01
Carboxyterminal post-translational modifications of tubulin	37	9.73e-01	9.76e-01	0.0223	-3.69e-03	-0.022000	9.69e-01	8.17e-01

---

Detailed Gene set reports

CLEC7A (Dectin-1) induces NFAT activation

CLEC7A (Dectin-1) induces NFAT activation

metric	value
setSize	11
pMANOVA	3.38e-06
p.adjustMANOVA	1.31e-05
s.dist	0.897
s.KO	-0.308
s.drug	-0.842
p.KO	0.077
p.drug	1.3e-06

Top 20 genes

Gene	KO	drug
ITPR1	-11523	-11275
NFATC1	-9218	-9228
NFATC3	-8816	-9311
ITPR2	-7642	-10382
NFATC2	-11381	-6299
PPP3CB	-8974	-7138
PPP3R1	-5334	-9996

Click HERE to show all gene set members

All member genes

	KO	drug
AHCYL1	5721	-10813
CALM1	11329	-6948
ITPR1	-11523	-11275
ITPR2	-7642	-10382
ITPR3	969	-10878
NFATC1	-9218	-9228
NFATC2	-11381	-6299
NFATC3	-8816	-9311
PPP3CA	10840	-10652
PPP3CB	-8974	-7138
PPP3R1	-5334	-9996

---

---

Cohesin Loading onto Chromatin

Cohesin Loading onto Chromatin

metric	value
setSize	10
pMANOVA	1.94e-05
p.adjustMANOVA	6.18e-05
s.dist	0.865
s.KO	-0.196
s.drug	-0.842
p.KO	0.283
p.drug	3.98e-06

Top 20 genes

Gene	KO	drug
PDS5A	-11384	-10144
RAD21	-8210	-10188
MAU2	-8939	-8256
STAG2	-6812	-10112
PDS5B	-5114	-8962
WAPL	-2614	-10812

Click HERE to show all gene set members

All member genes

	KO	drug
MAU2	-8939	-8256
NIPBL	4834	-10197
PDS5A	-11384	-10144
PDS5B	-5114	-8962
RAD21	-8210	-10188
SMC1A	1268	-9163
SMC3	9009	-7428
STAG1	10689	-8263
STAG2	-6812	-10112
WAPL	-2614	-10812

---

---

MET activates RAP1 and RAC1

MET activates RAP1 and RAC1

metric	value
setSize	11
pMANOVA	1.26e-05
p.adjustMANOVA	4.27e-05
s.dist	0.856
s.KO	-0.399
s.drug	-0.758
p.KO	0.022
p.drug	1.35e-05

Top 20 genes

Gene	KO	drug
CRKL	-11456	-9981
CRK	-11328	-8779
RAPGEF1	-9306	-9048
RAP1B	-8213	-8902
GRB2	-6137	-10524
GAB1	-6660	-8223
RAC1	-7472	-3724
HGF	-5157	-4177
RAP1A	-1904	-6372

Click HERE to show all gene set members

All member genes

	KO	drug
CRK	-11328	-8779
CRKL	-11456	-9981
DOCK7	10605	-10745
GAB1	-6660	-8223
GRB2	-6137	-10524
HGF	-5157	-4177
MET	10796	-11047
RAC1	-7472	-3724
RAP1A	-1904	-6372
RAP1B	-8213	-8902
RAPGEF1	-9306	-9048

---

---

Syndecan interactions

Syndecan interactions

metric	value
setSize	19
pMANOVA	5.07e-10
p.adjustMANOVA	4.45e-09
s.dist	0.844
s.KO	0.216
s.drug	-0.816
p.KO	0.104
p.drug	7.21e-10

Top 20 genes

Gene	KO	drug
ITGB3	12688	-11286
SDC4	12322	-10633
PRKCA	12366	-10396
ITGB5	12503	-10104
ITGB4	12465	-8452
THBS1	12626	-7518
ITGA2	8062	-11213
ACTN1	8122	-10816
SDC1	12230	-7104
SDC3	12401	-6760
ITGAV	144	-11011

Click HERE to show all gene set members

All member genes

	KO	drug
ACTN1	8122	-10816
CASK	-5732	-8641
FGF2	-5091	-5205
ITGA2	8062	-11213
ITGA6	-7384	-11184
ITGAV	144	-11011
ITGB1	-3655	-11215
ITGB3	12688	-11286
ITGB4	12465	-8452
ITGB5	12503	-10104
PRKCA	12366	-10396
SDC1	12230	-7104
SDC2	-6754	-5737
SDC3	12401	-6760
SDC4	12322	-10633
TGFB1	-3526	-8816
THBS1	12626	-7518
TNC	-10537	-10838
TRAPPC4	-10355	-4660

---

---

Peptide chain elongation

Peptide chain elongation

metric	value
setSize	87
pMANOVA	2.79e-43
p.adjustMANOVA	3.4e-41
s.dist	0.83
s.KO	-0.422
s.drug	0.715
p.KO	9.35e-12
p.drug	8.26e-31

Top 20 genes

Gene	KO	drug
RPL22L1	-10448	12221
RPL9	-9659	12806
RPS17	-10534	11631
RPL34	-9357	12996
RPL12	-9329	12992
RPL26L1	-9387	12770
RPS13	-9450	12652
RPS25	-9371	12690
RPL37A	-9347	12675
RPS18	-9122	12984
RPL17	-8989	12909
RPL31	-8781	13131
RPS6	-9225	12405
RPS15A	-8754	12989
RPL36	-8818	12868
FAU	-8610	13102
RPL26	-8797	12658
RPLP2	-8225	12999
RPL11	-8529	12382
RPL35	-8027	13097

Click HERE to show all gene set members

All member genes

	KO	drug
EEF1A1	-9758	-7439
EEF2	-6416	-8810
FAU	-8610	13102
RPL10	-3821	1597
RPL10A	-9707	-8212
RPL11	-8529	12382
RPL12	-9329	12992
RPL13	-3469	12598
RPL13A	-6854	6955
RPL14	-6386	13137
RPL15	-786	12153
RPL17	-8989	12909
RPL18	-6672	12800
RPL18A	-6976	11926
RPL19	3924	12911
RPL21	-6322	5141
RPL22	-5554	9520
RPL22L1	-10448	12221
RPL23	5769	12922
RPL23A	11361	-5257
RPL24	-4591	12995
RPL26	-8797	12658
RPL26L1	-9387	12770
RPL27	6735	11625
RPL27A	-7818	13051
RPL28	-5809	12962
RPL29	-4515	12915
RPL3	-6827	-4535
RPL30	-3907	11096
RPL31	-8781	13131
RPL32	-5028	12983
RPL34	-9357	12996
RPL35	-8027	13097
RPL35A	-1449	12789
RPL36	-8818	12868
RPL36A	-4480	13009
RPL36AL	-8216	12702
RPL37	-4624	13134
RPL37A	-9347	12675
RPL38	1558	13140
RPL39	-6168	11962
RPL39L	-6608	-6269
RPL3L	-510	7904
RPL4	11351	12558
RPL41	-4616	-6074
RPL5	4679	12075
RPL6	-6903	12730
RPL7	-3327	-8789
RPL7A	-6163	11708
RPL8	-7572	10323
RPL9	-9659	12806
RPLP0	-1504	-7331
RPLP1	9026	12731
RPLP2	-8225	12999
RPS10	-8384	10665
RPS11	-7725	12935
RPS12	-7872	11600
RPS13	-9450	12652
RPS14	-1180	12428
RPS15	-7430	12908
RPS15A	-8754	12989
RPS16	-3844	12941
RPS17	-10534	11631
RPS18	-9122	12984
RPS19	-7633	12888
RPS2	-10222	8916
RPS20	-4961	13095
RPS21	-3001	13022
RPS23	6940	11907
RPS24	2369	13034
RPS25	-9371	12690
RPS26	-2615	13114
RPS27	651	11270
RPS27A	5357	6464
RPS27L	7330	12750
RPS28	2716	12485
RPS29	-652	9078
RPS3	-7756	12135
RPS3A	-9170	5257
RPS4X	-8542	12239
RPS5	-6283	-7965
RPS6	-9225	12405
RPS7	5142	12976
RPS8	-5812	12745
RPS9	-8815	10189
RPSA	292	11576
UBA52	-6807	11639

---

---

Viral mRNA Translation

Viral mRNA Translation

metric	value
setSize	87
pMANOVA	3.07e-43
p.adjustMANOVA	3.46e-41
s.dist	0.83
s.KO	-0.42
s.drug	0.715
p.KO	1.17e-11
p.drug	7.1e-31

Top 20 genes

Gene	KO	drug
RPL22L1	-10448	12221
RPL9	-9659	12806
RPS17	-10534	11631
RPL34	-9357	12996
RPL12	-9329	12992
RPL26L1	-9387	12770
RPS13	-9450	12652
RPS25	-9371	12690
RPL37A	-9347	12675
RPS18	-9122	12984
RPL17	-8989	12909
RPL31	-8781	13131
RPS6	-9225	12405
RPS15A	-8754	12989
RPL36	-8818	12868
FAU	-8610	13102
RPL26	-8797	12658
RPLP2	-8225	12999
RPL11	-8529	12382
RPL35	-8027	13097

Click HERE to show all gene set members

All member genes

	KO	drug
DNAJC3	-2895	-7549
FAU	-8610	13102
GRSF1	-11152	-7843
RPL10	-3821	1597
RPL10A	-9707	-8212
RPL11	-8529	12382
RPL12	-9329	12992
RPL13	-3469	12598
RPL13A	-6854	6955
RPL14	-6386	13137
RPL15	-786	12153
RPL17	-8989	12909
RPL18	-6672	12800
RPL18A	-6976	11926
RPL19	3924	12911
RPL21	-6322	5141
RPL22	-5554	9520
RPL22L1	-10448	12221
RPL23	5769	12922
RPL23A	11361	-5257
RPL24	-4591	12995
RPL26	-8797	12658
RPL26L1	-9387	12770
RPL27	6735	11625
RPL27A	-7818	13051
RPL28	-5809	12962
RPL29	-4515	12915
RPL3	-6827	-4535
RPL30	-3907	11096
RPL31	-8781	13131
RPL32	-5028	12983
RPL34	-9357	12996
RPL35	-8027	13097
RPL35A	-1449	12789
RPL36	-8818	12868
RPL36A	-4480	13009
RPL36AL	-8216	12702
RPL37	-4624	13134
RPL37A	-9347	12675
RPL38	1558	13140
RPL39	-6168	11962
RPL39L	-6608	-6269
RPL3L	-510	7904
RPL4	11351	12558
RPL41	-4616	-6074
RPL5	4679	12075
RPL6	-6903	12730
RPL7	-3327	-8789
RPL7A	-6163	11708
RPL8	-7572	10323
RPL9	-9659	12806
RPLP0	-1504	-7331
RPLP1	9026	12731
RPLP2	-8225	12999
RPS10	-8384	10665
RPS11	-7725	12935
RPS12	-7872	11600
RPS13	-9450	12652
RPS14	-1180	12428
RPS15	-7430	12908
RPS15A	-8754	12989
RPS16	-3844	12941
RPS17	-10534	11631
RPS18	-9122	12984
RPS19	-7633	12888
RPS2	-10222	8916
RPS20	-4961	13095
RPS21	-3001	13022
RPS23	6940	11907
RPS24	2369	13034
RPS25	-9371	12690
RPS26	-2615	13114
RPS27	651	11270
RPS27A	5357	6464
RPS27L	7330	12750
RPS28	2716	12485
RPS29	-652	9078
RPS3	-7756	12135
RPS3A	-9170	5257
RPS4X	-8542	12239
RPS5	-6283	-7965
RPS6	-9225	12405
RPS7	5142	12976
RPS8	-5812	12745
RPS9	-8815	10189
RPSA	292	11576
UBA52	-6807	11639

---

---

APC truncation mutants have impaired AXIN binding

APC truncation mutants have impaired AXIN binding

metric	value
setSize	14
pMANOVA	1.34e-06
p.adjustMANOVA	5.64e-06
s.dist	0.828
s.KO	-0.348
s.drug	-0.752
p.KO	0.0243
p.drug	1.1e-06

Top 20 genes

Gene	KO	drug
PPP2R5D	-11383	-11113
PPP2CB	-11374	-10028
CSNK1A1	-9043	-10837
AXIN1	-11360	-7258
AMER1	-7397	-8126
PPP2R5A	-4776	-9580
PPP2R1A	-9193	-4828
PPP2R5B	-8731	-4219
PPP2CA	-3124	-7225
PPP2R5E	-847	-10491

Click HERE to show all gene set members

All member genes

	KO	drug
AMER1	-7397	-8126
APC	7962	-10237
AXIN1	-11360	-7258
CSNK1A1	-9043	-10837
GSK3B	7016	-10755
PPP2CA	-3124	-7225
PPP2CB	-11374	-10028
PPP2R1A	-9193	-4828
PPP2R1B	6255	-5465
PPP2R5A	-4776	-9580
PPP2R5B	-8731	-4219
PPP2R5C	5890	-5302
PPP2R5D	-11383	-11113
PPP2R5E	-847	-10491

---

---

AXIN missense mutants destabilize the destruction complex

AXIN missense mutants destabilize the destruction complex

metric	value
setSize	14
pMANOVA	1.34e-06
p.adjustMANOVA	5.64e-06
s.dist	0.828
s.KO	-0.348
s.drug	-0.752
p.KO	0.0243
p.drug	1.1e-06

Top 20 genes

Gene	KO	drug
PPP2R5D	-11383	-11113
PPP2CB	-11374	-10028
CSNK1A1	-9043	-10837
AXIN1	-11360	-7258
AMER1	-7397	-8126
PPP2R5A	-4776	-9580
PPP2R1A	-9193	-4828
PPP2R5B	-8731	-4219
PPP2CA	-3124	-7225
PPP2R5E	-847	-10491

Click HERE to show all gene set members

All member genes

	KO	drug
AMER1	-7397	-8126
APC	7962	-10237
AXIN1	-11360	-7258
CSNK1A1	-9043	-10837
GSK3B	7016	-10755
PPP2CA	-3124	-7225
PPP2CB	-11374	-10028
PPP2R1A	-9193	-4828
PPP2R1B	6255	-5465
PPP2R5A	-4776	-9580
PPP2R5B	-8731	-4219
PPP2R5C	5890	-5302
PPP2R5D	-11383	-11113
PPP2R5E	-847	-10491

---

---

Signaling by AMER1 mutants

Signaling by AMER1 mutants

metric	value
setSize	14
pMANOVA	1.34e-06
p.adjustMANOVA	5.64e-06
s.dist	0.828
s.KO	-0.348
s.drug	-0.752
p.KO	0.0243
p.drug	1.1e-06

Top 20 genes

Gene	KO	drug
PPP2R5D	-11383	-11113
PPP2CB	-11374	-10028
CSNK1A1	-9043	-10837
AXIN1	-11360	-7258
AMER1	-7397	-8126
PPP2R5A	-4776	-9580
PPP2R1A	-9193	-4828
PPP2R5B	-8731	-4219
PPP2CA	-3124	-7225
PPP2R5E	-847	-10491

Click HERE to show all gene set members

All member genes

	KO	drug
AMER1	-7397	-8126
APC	7962	-10237
AXIN1	-11360	-7258
CSNK1A1	-9043	-10837
GSK3B	7016	-10755
PPP2CA	-3124	-7225
PPP2CB	-11374	-10028
PPP2R1A	-9193	-4828
PPP2R1B	6255	-5465
PPP2R5A	-4776	-9580
PPP2R5B	-8731	-4219
PPP2R5C	5890	-5302
PPP2R5D	-11383	-11113
PPP2R5E	-847	-10491

---

---

Signaling by APC mutants

Signaling by APC mutants

metric	value
setSize	14
pMANOVA	1.34e-06
p.adjustMANOVA	5.64e-06
s.dist	0.828
s.KO	-0.348
s.drug	-0.752
p.KO	0.0243
p.drug	1.1e-06

Top 20 genes

Gene	KO	drug
PPP2R5D	-11383	-11113
PPP2CB	-11374	-10028
CSNK1A1	-9043	-10837
AXIN1	-11360	-7258
AMER1	-7397	-8126
PPP2R5A	-4776	-9580
PPP2R1A	-9193	-4828
PPP2R5B	-8731	-4219
PPP2CA	-3124	-7225
PPP2R5E	-847	-10491

Click HERE to show all gene set members

All member genes

	KO	drug
AMER1	-7397	-8126
APC	7962	-10237
AXIN1	-11360	-7258
CSNK1A1	-9043	-10837
GSK3B	7016	-10755
PPP2CA	-3124	-7225
PPP2CB	-11374	-10028
PPP2R1A	-9193	-4828
PPP2R1B	6255	-5465
PPP2R5A	-4776	-9580
PPP2R5B	-8731	-4219
PPP2R5C	5890	-5302
PPP2R5D	-11383	-11113
PPP2R5E	-847	-10491

---

---

Signaling by AXIN mutants

Signaling by AXIN mutants

metric	value
setSize	14
pMANOVA	1.34e-06
p.adjustMANOVA	5.64e-06
s.dist	0.828
s.KO	-0.348
s.drug	-0.752
p.KO	0.0243
p.drug	1.1e-06

Top 20 genes

Gene	KO	drug
PPP2R5D	-11383	-11113
PPP2CB	-11374	-10028
CSNK1A1	-9043	-10837
AXIN1	-11360	-7258
AMER1	-7397	-8126
PPP2R5A	-4776	-9580
PPP2R1A	-9193	-4828
PPP2R5B	-8731	-4219
PPP2CA	-3124	-7225
PPP2R5E	-847	-10491

Click HERE to show all gene set members

All member genes

	KO	drug
AMER1	-7397	-8126
APC	7962	-10237
AXIN1	-11360	-7258
CSNK1A1	-9043	-10837
GSK3B	7016	-10755
PPP2CA	-3124	-7225
PPP2CB	-11374	-10028
PPP2R1A	-9193	-4828
PPP2R1B	6255	-5465
PPP2R5A	-4776	-9580
PPP2R5B	-8731	-4219
PPP2R5C	5890	-5302
PPP2R5D	-11383	-11113
PPP2R5E	-847	-10491

---

---

Truncations of AMER1 destabilize the destruction complex

Truncations of AMER1 destabilize the destruction complex

metric	value
setSize	14
pMANOVA	1.34e-06
p.adjustMANOVA	5.64e-06
s.dist	0.828
s.KO	-0.348
s.drug	-0.752
p.KO	0.0243
p.drug	1.1e-06

Top 20 genes

Gene	KO	drug
PPP2R5D	-11383	-11113
PPP2CB	-11374	-10028
CSNK1A1	-9043	-10837
AXIN1	-11360	-7258
AMER1	-7397	-8126
PPP2R5A	-4776	-9580
PPP2R1A	-9193	-4828
PPP2R5B	-8731	-4219
PPP2CA	-3124	-7225
PPP2R5E	-847	-10491

Click HERE to show all gene set members

All member genes

	KO	drug
AMER1	-7397	-8126
APC	7962	-10237
AXIN1	-11360	-7258
CSNK1A1	-9043	-10837
GSK3B	7016	-10755
PPP2CA	-3124	-7225
PPP2CB	-11374	-10028
PPP2R1A	-9193	-4828
PPP2R1B	6255	-5465
PPP2R5A	-4776	-9580
PPP2R5B	-8731	-4219
PPP2R5C	5890	-5302
PPP2R5D	-11383	-11113
PPP2R5E	-847	-10491

---

---

Laminin interactions

Laminin interactions

metric	value
setSize	23
pMANOVA	1.23e-11
p.adjustMANOVA	1.39e-10
s.dist	0.827
s.KO	0.269
s.drug	-0.782
p.KO	0.0258
p.drug	8.23e-11

Top 20 genes

Gene	KO	drug
LAMC1	12854	-11227
LAMB2	12607	-10832
LAMA5	12583	-10447
ITGA1	12258	-10552
LAMA1	12802	-10091
ITGA3	12831	-9596
NID1	9752	-11078
ITGB4	12465	-8452
ITGA7	12807	-7517
ITGA2	8062	-11213
LAMB3	7018	-11255
LAMC2	10786	-6533
COL18A1	10348	-6371
LAMC3	11660	-2369
ITGAV	144	-11011

Click HERE to show all gene set members

All member genes

	KO	drug
COL18A1	10348	-6371
HSPG2	-9046	-9768
ITGA1	12258	-10552
ITGA2	8062	-11213
ITGA3	12831	-9596
ITGA6	-7384	-11184
ITGA7	12807	-7517
ITGAV	144	-11011
ITGB1	-3655	-11215
ITGB4	12465	-8452
LAMA1	12802	-10091
LAMA2	-8729	-4165
LAMA3	-11238	4464
LAMA4	-7403	-10348
LAMA5	12583	-10447
LAMB1	-9087	-10329
LAMB2	12607	-10832
LAMB3	7018	-11255
LAMC1	12854	-11227
LAMC2	10786	-6533
LAMC3	11660	-2369
NID1	9752	-11078
NID2	-11453	-7027

---

---

ERKs are inactivated

ERKs are inactivated

metric	value
setSize	13
pMANOVA	4.26e-06
p.adjustMANOVA	1.6e-05
s.dist	0.821
s.KO	-0.333
s.drug	-0.751
p.KO	0.0374
p.drug	2.76e-06

Top 20 genes

Gene	KO	drug
PPP2R5D	-11383	-11113
PPP2CB	-11374	-10028
MAPK1	-9173	-10906
MAPK3	-9742	-9271
VRK3	-8775	-7133
DUSP7	-4800	-10041
PPP2R1A	-9193	-4828
MAPK7	-7980	-4568
PPP2CA	-3124	-7225

Click HERE to show all gene set members

All member genes

	KO	drug
DUSP3	11933	-9367
DUSP4	2520	-11183
DUSP6	10590	-5904
DUSP7	-4800	-10041
MAPK1	-9173	-10906
MAPK3	-9742	-9271
MAPK7	-7980	-4568
PPP2CA	-3124	-7225
PPP2CB	-11374	-10028
PPP2R1A	-9193	-4828
PPP2R1B	6255	-5465
PPP2R5D	-11383	-11113
VRK3	-8775	-7133

---

---

Receptor Mediated Mitophagy

Receptor Mediated Mitophagy

metric	value
setSize	11
pMANOVA	2.63e-05
p.adjustMANOVA	8.1e-05
s.dist	0.819
s.KO	-0.776
s.drug	-0.263
p.KO	8.3e-06
p.drug	0.131

Top 20 genes

Gene	KO	drug
CSNK2A1	-10604	-10586
CSNK2A2	-9949	-10332
SRC	-11388	-7284
ULK1	-10494	-7342
ATG5	-7565	-7228
PGAM5	-10817	-4475
ATG12	-4585	-5690
MAP1LC3B	-9817	-1760

Click HERE to show all gene set members

All member genes

	KO	drug
ATG12	-4585	-5690
ATG5	-7565	-7228
CSNK2A1	-10604	-10586
CSNK2A2	-9949	-10332
CSNK2B	-9249	12011
FUNDC1	-3096	9106
MAP1LC3A	-9431	8671
MAP1LC3B	-9817	-1760
PGAM5	-10817	-4475
SRC	-11388	-7284
ULK1	-10494	-7342

---

---

S33 mutants of beta-catenin aren’t phosphorylated

S33 mutants of beta-catenin aren’t phosphorylated

metric	value
setSize	15
pMANOVA	7.71e-07
p.adjustMANOVA	3.45e-06
s.dist	0.811
s.KO	-0.26
s.drug	-0.768
p.KO	0.0808
p.drug	2.62e-07

Top 20 genes

Gene	KO	drug
PPP2R5D	-11383	-11113
PPP2CB	-11374	-10028
CSNK1A1	-9043	-10837
AXIN1	-11360	-7258
AMER1	-7397	-8126
PPP2R5A	-4776	-9580
PPP2R1A	-9193	-4828
PPP2R5B	-8731	-4219
PPP2CA	-3124	-7225
PPP2R5E	-847	-10491

Click HERE to show all gene set members

All member genes

	KO	drug
AMER1	-7397	-8126
APC	7962	-10237
AXIN1	-11360	-7258
CSNK1A1	-9043	-10837
CTNNB1	12434	-11116
GSK3B	7016	-10755
PPP2CA	-3124	-7225
PPP2CB	-11374	-10028
PPP2R1A	-9193	-4828
PPP2R1B	6255	-5465
PPP2R5A	-4776	-9580
PPP2R5B	-8731	-4219
PPP2R5C	5890	-5302
PPP2R5D	-11383	-11113
PPP2R5E	-847	-10491

---

---

S37 mutants of beta-catenin aren’t phosphorylated

S37 mutants of beta-catenin aren’t phosphorylated

metric	value
setSize	15
pMANOVA	7.71e-07
p.adjustMANOVA	3.45e-06
s.dist	0.811
s.KO	-0.26
s.drug	-0.768
p.KO	0.0808
p.drug	2.62e-07

Top 20 genes

Gene	KO	drug
PPP2R5D	-11383	-11113
PPP2CB	-11374	-10028
CSNK1A1	-9043	-10837
AXIN1	-11360	-7258
AMER1	-7397	-8126
PPP2R5A	-4776	-9580
PPP2R1A	-9193	-4828
PPP2R5B	-8731	-4219
PPP2CA	-3124	-7225
PPP2R5E	-847	-10491

Click HERE to show all gene set members

All member genes

	KO	drug
AMER1	-7397	-8126
APC	7962	-10237
AXIN1	-11360	-7258
CSNK1A1	-9043	-10837
CTNNB1	12434	-11116
GSK3B	7016	-10755
PPP2CA	-3124	-7225
PPP2CB	-11374	-10028
PPP2R1A	-9193	-4828
PPP2R1B	6255	-5465
PPP2R5A	-4776	-9580
PPP2R5B	-8731	-4219
PPP2R5C	5890	-5302
PPP2R5D	-11383	-11113
PPP2R5E	-847	-10491

---

---

S45 mutants of beta-catenin aren’t phosphorylated

S45 mutants of beta-catenin aren’t phosphorylated

metric	value
setSize	15
pMANOVA	7.71e-07
p.adjustMANOVA	3.45e-06
s.dist	0.811
s.KO	-0.26
s.drug	-0.768
p.KO	0.0808
p.drug	2.62e-07

Top 20 genes

Gene	KO	drug
PPP2R5D	-11383	-11113
PPP2CB	-11374	-10028
CSNK1A1	-9043	-10837
AXIN1	-11360	-7258
AMER1	-7397	-8126
PPP2R5A	-4776	-9580
PPP2R1A	-9193	-4828
PPP2R5B	-8731	-4219
PPP2CA	-3124	-7225
PPP2R5E	-847	-10491

Click HERE to show all gene set members

All member genes

	KO	drug
AMER1	-7397	-8126
APC	7962	-10237
AXIN1	-11360	-7258
CSNK1A1	-9043	-10837
CTNNB1	12434	-11116
GSK3B	7016	-10755
PPP2CA	-3124	-7225
PPP2CB	-11374	-10028
PPP2R1A	-9193	-4828
PPP2R1B	6255	-5465
PPP2R5A	-4776	-9580
PPP2R5B	-8731	-4219
PPP2R5C	5890	-5302
PPP2R5D	-11383	-11113
PPP2R5E	-847	-10491

---

---

Signaling by CTNNB1 phospho-site mutants

Signaling by CTNNB1 phospho-site mutants

metric	value
setSize	15
pMANOVA	7.71e-07
p.adjustMANOVA	3.45e-06
s.dist	0.811
s.KO	-0.26
s.drug	-0.768
p.KO	0.0808
p.drug	2.62e-07

Top 20 genes

Gene	KO	drug
PPP2R5D	-11383	-11113
PPP2CB	-11374	-10028
CSNK1A1	-9043	-10837
AXIN1	-11360	-7258
AMER1	-7397	-8126
PPP2R5A	-4776	-9580
PPP2R1A	-9193	-4828
PPP2R5B	-8731	-4219
PPP2CA	-3124	-7225
PPP2R5E	-847	-10491

Click HERE to show all gene set members

All member genes

	KO	drug
AMER1	-7397	-8126
APC	7962	-10237
AXIN1	-11360	-7258
CSNK1A1	-9043	-10837
CTNNB1	12434	-11116
GSK3B	7016	-10755
PPP2CA	-3124	-7225
PPP2CB	-11374	-10028
PPP2R1A	-9193	-4828
PPP2R1B	6255	-5465
PPP2R5A	-4776	-9580
PPP2R5B	-8731	-4219
PPP2R5C	5890	-5302
PPP2R5D	-11383	-11113
PPP2R5E	-847	-10491

---

---

Signaling by GSK3beta mutants

Signaling by GSK3beta mutants

metric	value
setSize	15
pMANOVA	7.71e-07
p.adjustMANOVA	3.45e-06
s.dist	0.811
s.KO	-0.26
s.drug	-0.768
p.KO	0.0808
p.drug	2.62e-07

Top 20 genes

Gene	KO	drug
PPP2R5D	-11383	-11113
PPP2CB	-11374	-10028
CSNK1A1	-9043	-10837
AXIN1	-11360	-7258
AMER1	-7397	-8126
PPP2R5A	-4776	-9580
PPP2R1A	-9193	-4828
PPP2R5B	-8731	-4219
PPP2CA	-3124	-7225
PPP2R5E	-847	-10491

Click HERE to show all gene set members

All member genes

	KO	drug
AMER1	-7397	-8126
APC	7962	-10237
AXIN1	-11360	-7258
CSNK1A1	-9043	-10837
CTNNB1	12434	-11116
GSK3B	7016	-10755
PPP2CA	-3124	-7225
PPP2CB	-11374	-10028
PPP2R1A	-9193	-4828
PPP2R1B	6255	-5465
PPP2R5A	-4776	-9580
PPP2R5B	-8731	-4219
PPP2R5C	5890	-5302
PPP2R5D	-11383	-11113
PPP2R5E	-847	-10491

---

---

T41 mutants of beta-catenin aren’t phosphorylated

T41 mutants of beta-catenin aren’t phosphorylated

metric	value
setSize	15
pMANOVA	7.71e-07
p.adjustMANOVA	3.45e-06
s.dist	0.811
s.KO	-0.26
s.drug	-0.768
p.KO	0.0808
p.drug	2.62e-07

Top 20 genes

Gene	KO	drug
PPP2R5D	-11383	-11113
PPP2CB	-11374	-10028
CSNK1A1	-9043	-10837
AXIN1	-11360	-7258
AMER1	-7397	-8126
PPP2R5A	-4776	-9580
PPP2R1A	-9193	-4828
PPP2R5B	-8731	-4219
PPP2CA	-3124	-7225
PPP2R5E	-847	-10491

Click HERE to show all gene set members

All member genes

	KO	drug
AMER1	-7397	-8126
APC	7962	-10237
AXIN1	-11360	-7258
CSNK1A1	-9043	-10837
CTNNB1	12434	-11116
GSK3B	7016	-10755
PPP2CA	-3124	-7225
PPP2CB	-11374	-10028
PPP2R1A	-9193	-4828
PPP2R1B	6255	-5465
PPP2R5A	-4776	-9580
PPP2R5B	-8731	-4219
PPP2R5C	5890	-5302
PPP2R5D	-11383	-11113
PPP2R5E	-847	-10491

---

---

Mucopolysaccharidoses

Mucopolysaccharidoses

metric	value
setSize	11
pMANOVA	1.36e-05
p.adjustMANOVA	4.58e-05
s.dist	0.799
s.KO	0.756
s.drug	-0.258
p.KO	1.41e-05
p.drug	0.138

Top 20 genes

Gene	KO	drug
GNS	11099	-11125
GLB1	10162	-9240
ARSB	12086	-7494
IDS	8178	-10132
GALNS	11751	-6370
NAGLU	12163	-5299
HGSNAT	6442	-3959

Click HERE to show all gene set members

All member genes

	KO	drug
ARSB	12086	-7494
GALNS	11751	-6370
GLB1	10162	-9240
GNS	11099	-11125
GUSB	9430	8910
HGSNAT	6442	-3959
HYAL1	4794	556
IDS	8178	-10132
IDUA	11538	11620
NAGLU	12163	-5299
SGSH	11466	8231

---

---

Defective EXT1 causes exostoses 1, TRPS2 and CHDS

Defective EXT1 causes exostoses 1, TRPS2 and CHDS

metric	value
setSize	13
pMANOVA	1.43e-06
p.adjustMANOVA	5.93e-06
s.dist	0.799
s.KO	0.358
s.drug	-0.714
p.KO	0.0255
p.drug	8.23e-06

Top 20 genes

Gene	KO	drug
AGRN	12518	-11205
SDC4	12322	-10633
EXT2	11023	-9224
GPC4	11190	-8942
SDC1	12230	-7104
SDC3	12401	-6760
EXT1	10114	-6275
GPC5	7673	-3135
GPC1	1951	-7922

Click HERE to show all gene set members

All member genes

	KO	drug
AGRN	12518	-11205
EXT1	10114	-6275
EXT2	11023	-9224
GPC1	1951	-7922
GPC2	-3913	-3279
GPC4	11190	-8942
GPC5	7673	-3135
GPC6	-6095	-11229
HSPG2	-9046	-9768
SDC1	12230	-7104
SDC2	-6754	-5737
SDC3	12401	-6760
SDC4	12322	-10633

---

---

Defective EXT2 causes exostoses 2

Defective EXT2 causes exostoses 2

metric	value
setSize	13
pMANOVA	1.43e-06
p.adjustMANOVA	5.93e-06
s.dist	0.799
s.KO	0.358
s.drug	-0.714
p.KO	0.0255
p.drug	8.23e-06

Top 20 genes

Gene	KO	drug
AGRN	12518	-11205
SDC4	12322	-10633
EXT2	11023	-9224
GPC4	11190	-8942
SDC1	12230	-7104
SDC3	12401	-6760
EXT1	10114	-6275
GPC5	7673	-3135
GPC1	1951	-7922

Click HERE to show all gene set members

All member genes

	KO	drug
AGRN	12518	-11205
EXT1	10114	-6275
EXT2	11023	-9224
GPC1	1951	-7922
GPC2	-3913	-3279
GPC4	11190	-8942
GPC5	7673	-3135
GPC6	-6095	-11229
HSPG2	-9046	-9768
SDC1	12230	-7104
SDC2	-6754	-5737
SDC3	12401	-6760
SDC4	12322	-10633

---

---

Establishment of Sister Chromatid Cohesion

Establishment of Sister Chromatid Cohesion

metric	value
setSize	11
pMANOVA	5.26e-05
p.adjustMANOVA	0.000153
s.dist	0.795
s.KO	-0.298
s.drug	-0.737
p.KO	0.0865
p.drug	2.3e-05

Top 20 genes

Gene	KO	drug
PDS5A	-11384	-10144
RAD21	-8210	-10188
ESCO1	-7849	-9245
STAG2	-6812	-10112
PDS5B	-5114	-8962
WAPL	-2614	-10812
ESCO2	-5830	-3862
CDCA5	-5906	-564

Click HERE to show all gene set members

All member genes

	KO	drug
CDCA5	-5906	-564
ESCO1	-7849	-9245
ESCO2	-5830	-3862
PDS5A	-11384	-10144
PDS5B	-5114	-8962
RAD21	-8210	-10188
SMC1A	1268	-9163
SMC3	9009	-7428
STAG1	10689	-8263
STAG2	-6812	-10112
WAPL	-2614	-10812

---

---

Eukaryotic Translation Termination

Eukaryotic Translation Termination

metric	value
setSize	91
pMANOVA	2.19e-41
p.adjustMANOVA	1.89e-39
s.dist	0.794
s.KO	-0.402
s.drug	0.684
p.KO	3.27e-11
p.drug	1.32e-29

Top 20 genes

Gene	KO	drug
RPL22L1	-10448	12221
RPL9	-9659	12806
RPS17	-10534	11631
RPL34	-9357	12996
RPL12	-9329	12992
RPL26L1	-9387	12770
RPS13	-9450	12652
RPS25	-9371	12690
RPL37A	-9347	12675
RPS18	-9122	12984
RPL17	-8989	12909
RPL31	-8781	13131
RPS6	-9225	12405
RPS15A	-8754	12989
RPL36	-8818	12868
FAU	-8610	13102
RPL26	-8797	12658
RPLP2	-8225	12999
RPL11	-8529	12382
RPL35	-8027	13097

Click HERE to show all gene set members

All member genes

	KO	drug
APEH	9298	-8571
ETF1	-5515	-9496
FAU	-8610	13102
GSPT1	-11018	-10260
GSPT2	-5509	-6727
N6AMT1	7099	10581
RPL10	-3821	1597
RPL10A	-9707	-8212
RPL11	-8529	12382
RPL12	-9329	12992
RPL13	-3469	12598
RPL13A	-6854	6955
RPL14	-6386	13137
RPL15	-786	12153
RPL17	-8989	12909
RPL18	-6672	12800
RPL18A	-6976	11926
RPL19	3924	12911
RPL21	-6322	5141
RPL22	-5554	9520
RPL22L1	-10448	12221
RPL23	5769	12922
RPL23A	11361	-5257
RPL24	-4591	12995
RPL26	-8797	12658
RPL26L1	-9387	12770
RPL27	6735	11625
RPL27A	-7818	13051
RPL28	-5809	12962
RPL29	-4515	12915
RPL3	-6827	-4535
RPL30	-3907	11096
RPL31	-8781	13131
RPL32	-5028	12983
RPL34	-9357	12996
RPL35	-8027	13097
RPL35A	-1449	12789
RPL36	-8818	12868
RPL36A	-4480	13009
RPL36AL	-8216	12702
RPL37	-4624	13134
RPL37A	-9347	12675
RPL38	1558	13140
RPL39	-6168	11962
RPL39L	-6608	-6269
RPL3L	-510	7904
RPL4	11351	12558
RPL41	-4616	-6074
RPL5	4679	12075
RPL6	-6903	12730
RPL7	-3327	-8789
RPL7A	-6163	11708
RPL8	-7572	10323
RPL9	-9659	12806
RPLP0	-1504	-7331
RPLP1	9026	12731
RPLP2	-8225	12999
RPS10	-8384	10665
RPS11	-7725	12935
RPS12	-7872	11600
RPS13	-9450	12652
RPS14	-1180	12428
RPS15	-7430	12908
RPS15A	-8754	12989
RPS16	-3844	12941
RPS17	-10534	11631
RPS18	-9122	12984
RPS19	-7633	12888
RPS2	-10222	8916
RPS20	-4961	13095
RPS21	-3001	13022
RPS23	6940	11907
RPS24	2369	13034
RPS25	-9371	12690
RPS26	-2615	13114
RPS27	651	11270
RPS27A	5357	6464
RPS27L	7330	12750
RPS28	2716	12485
RPS29	-652	9078
RPS3	-7756	12135
RPS3A	-9170	5257
RPS4X	-8542	12239
RPS5	-6283	-7965
RPS6	-9225	12405
RPS7	5142	12976
RPS8	-5812	12745
RPS9	-8815	10189
RPSA	292	11576
TRMT112	-5741	13057
UBA52	-6807	11639

---

---

Eukaryotic Translation Elongation

Eukaryotic Translation Elongation

metric	value
setSize	92
pMANOVA	1.82e-41
p.adjustMANOVA	1.67e-39
s.dist	0.79
s.KO	-0.412
s.drug	0.674
p.KO	8.16e-12
p.drug	4.97e-29

Top 20 genes

Gene	KO	drug
RPL22L1	-10448	12221
RPL9	-9659	12806
RPS17	-10534	11631
RPL34	-9357	12996
RPL12	-9329	12992
RPL26L1	-9387	12770
RPS13	-9450	12652
RPS25	-9371	12690
RPL37A	-9347	12675
RPS18	-9122	12984
RPL17	-8989	12909
RPL31	-8781	13131
RPS6	-9225	12405
RPS15A	-8754	12989
RPL36	-8818	12868
FAU	-8610	13102
RPL26	-8797	12658
RPLP2	-8225	12999
RPL11	-8529	12382
RPL35	-8027	13097

Click HERE to show all gene set members

All member genes

	KO	drug
EEF1A1	-9758	-7439
EEF1A1P5	-2416	-8237
EEF1A2	11418	-3448
EEF1B2	-9424	8464
EEF1D	-2336	11036
EEF1G	-7846	-5785
EEF2	-6416	-8810
FAU	-8610	13102
RPL10	-3821	1597
RPL10A	-9707	-8212
RPL11	-8529	12382
RPL12	-9329	12992
RPL13	-3469	12598
RPL13A	-6854	6955
RPL14	-6386	13137
RPL15	-786	12153
RPL17	-8989	12909
RPL18	-6672	12800
RPL18A	-6976	11926
RPL19	3924	12911
RPL21	-6322	5141
RPL22	-5554	9520
RPL22L1	-10448	12221
RPL23	5769	12922
RPL23A	11361	-5257
RPL24	-4591	12995
RPL26	-8797	12658
RPL26L1	-9387	12770
RPL27	6735	11625
RPL27A	-7818	13051
RPL28	-5809	12962
RPL29	-4515	12915
RPL3	-6827	-4535
RPL30	-3907	11096
RPL31	-8781	13131
RPL32	-5028	12983
RPL34	-9357	12996
RPL35	-8027	13097
RPL35A	-1449	12789
RPL36	-8818	12868
RPL36A	-4480	13009
RPL36AL	-8216	12702
RPL37	-4624	13134
RPL37A	-9347	12675
RPL38	1558	13140
RPL39	-6168	11962
RPL39L	-6608	-6269
RPL3L	-510	7904
RPL4	11351	12558
RPL41	-4616	-6074
RPL5	4679	12075
RPL6	-6903	12730
RPL7	-3327	-8789
RPL7A	-6163	11708
RPL8	-7572	10323
RPL9	-9659	12806
RPLP0	-1504	-7331
RPLP1	9026	12731
RPLP2	-8225	12999
RPS10	-8384	10665
RPS11	-7725	12935
RPS12	-7872	11600
RPS13	-9450	12652
RPS14	-1180	12428
RPS15	-7430	12908
RPS15A	-8754	12989
RPS16	-3844	12941
RPS17	-10534	11631
RPS18	-9122	12984
RPS19	-7633	12888
RPS2	-10222	8916
RPS20	-4961	13095
RPS21	-3001	13022
RPS23	6940	11907
RPS24	2369	13034
RPS25	-9371	12690
RPS26	-2615	13114
RPS27	651	11270
RPS27A	5357	6464
RPS27L	7330	12750
RPS28	2716	12485
RPS29	-652	9078
RPS3	-7756	12135
RPS3A	-9170	5257
RPS4X	-8542	12239
RPS5	-6283	-7965
RPS6	-9225	12405
RPS7	5142	12976
RPS8	-5812	12745
RPS9	-8815	10189
RPSA	292	11576
UBA52	-6807	11639

---

---

Formation of a pool of free 40S subunits

Formation of a pool of free 40S subunits

metric	value
setSize	99
pMANOVA	1.26e-44
p.adjustMANOVA	1.68e-42
s.dist	0.789
s.KO	-0.444
s.drug	0.652
p.KO	2.03e-14
p.drug	3.21e-29

Top 20 genes

Gene	KO	drug
RPL22L1	-10448	12221
RPL9	-9659	12806
RPS17	-10534	11631
RPL34	-9357	12996
RPL12	-9329	12992
RPL26L1	-9387	12770
RPS13	-9450	12652
RPS25	-9371	12690
RPL37A	-9347	12675
RPS18	-9122	12984
RPL17	-8989	12909
RPL31	-8781	13131
RPS6	-9225	12405
RPS15A	-8754	12989
RPL36	-8818	12868
FAU	-8610	13102
RPL26	-8797	12658
RPLP2	-8225	12999
RPL11	-8529	12382
RPL35	-8027	13097

Click HERE to show all gene set members

All member genes

	KO	drug
EIF1AX	-5479	11112
EIF3A	-5233	-9195
EIF3B	-4779	-8277
EIF3C	-8843	11244
EIF3D	-10400	-7621
EIF3E	-9070	10545
EIF3F	-1343	-5879
EIF3G	-7655	4326
EIF3H	-8110	-1879
EIF3I	-7897	12235
EIF3J	-4825	-4367
EIF3K	-2668	9951
EIF3L	-9160	-8016
EIF3M	-10718	9044
FAU	-8610	13102
RPL10	-3821	1597
RPL10A	-9707	-8212
RPL11	-8529	12382
RPL12	-9329	12992
RPL13	-3469	12598
RPL13A	-6854	6955
RPL14	-6386	13137
RPL15	-786	12153
RPL17	-8989	12909
RPL18	-6672	12800
RPL18A	-6976	11926
RPL19	3924	12911
RPL21	-6322	5141
RPL22	-5554	9520
RPL22L1	-10448	12221
RPL23	5769	12922
RPL23A	11361	-5257
RPL24	-4591	12995
RPL26	-8797	12658
RPL26L1	-9387	12770
RPL27	6735	11625
RPL27A	-7818	13051
RPL28	-5809	12962
RPL29	-4515	12915
RPL3	-6827	-4535
RPL30	-3907	11096
RPL31	-8781	13131
RPL32	-5028	12983
RPL34	-9357	12996
RPL35	-8027	13097
RPL35A	-1449	12789
RPL36	-8818	12868
RPL36A	-4480	13009
RPL36AL	-8216	12702
RPL37	-4624	13134
RPL37A	-9347	12675
RPL38	1558	13140
RPL39	-6168	11962
RPL39L	-6608	-6269
RPL3L	-510	7904
RPL4	11351	12558
RPL41	-4616	-6074
RPL5	4679	12075
RPL6	-6903	12730
RPL7	-3327	-8789
RPL7A	-6163	11708
RPL8	-7572	10323
RPL9	-9659	12806
RPLP0	-1504	-7331
RPLP1	9026	12731
RPLP2	-8225	12999
RPS10	-8384	10665
RPS11	-7725	12935
RPS12	-7872	11600
RPS13	-9450	12652
RPS14	-1180	12428
RPS15	-7430	12908
RPS15A	-8754	12989
RPS16	-3844	12941
RPS17	-10534	11631
RPS18	-9122	12984
RPS19	-7633	12888
RPS2	-10222	8916
RPS20	-4961	13095
RPS21	-3001	13022
RPS23	6940	11907
RPS24	2369	13034
RPS25	-9371	12690
RPS26	-2615	13114
RPS27	651	11270
RPS27A	5357	6464
RPS27L	7330	12750
RPS28	2716	12485
RPS29	-652	9078
RPS3	-7756	12135
RPS3A	-9170	5257
RPS4X	-8542	12239
RPS5	-6283	-7965
RPS6	-9225	12405
RPS7	5142	12976
RPS8	-5812	12745
RPS9	-8815	10189
RPSA	292	11576
UBA52	-6807	11639

---

---

Signaling by Hippo

Signaling by Hippo

metric	value
setSize	20
pMANOVA	1.9e-08
p.adjustMANOVA	1.19e-07
s.dist	0.781
s.KO	-0.162
s.drug	-0.764
p.KO	0.209
p.drug	3.23e-09

Top 20 genes

Gene	KO	drug
STK4	-10071	-9177
AMOTL2	-9439	-9139
AMOTL1	-7699	-11147
CASP3	-10552	-8110
LATS1	-8149	-10122
DVL2	-9629	-6902
YAP1	-5571	-10960
MOB1B	-7457	-8165
STK3	-6242	-7825
SAV1	-3497	-9467
NPHP4	-2565	-6207

Click HERE to show all gene set members

All member genes

	KO	drug
AMOT	7703	-10465
AMOTL1	-7699	-11147
AMOTL2	-9439	-9139
CASP3	-10552	-8110
DVL2	-9629	-6902
LATS1	-8149	-10122
LATS2	11787	-9234
MOB1A	2732	-9207
MOB1B	-7457	-8165
NPHP4	-2565	-6207
SAV1	-3497	-9467
STK3	-6242	-7825
STK4	-10071	-9177
TJP1	11775	-10865
TJP2	6248	-10022
WWC1	2910	-5030
WWTR1	10572	-10736
YAP1	-5571	-10960
YWHAB	11096	-6543
YWHAE	-10212	1399

---

---

Synthesis of PIPs at the early endosome membrane

Synthesis of PIPs at the early endosome membrane

metric	value
setSize	16
pMANOVA	1.36e-06
p.adjustMANOVA	5.69e-06
s.dist	0.773
s.KO	-0.298
s.drug	-0.713
p.KO	0.0391
p.drug	7.87e-07

Top 20 genes

Gene	KO	drug
MTMR12	-10618	-11138
PIKFYVE	-10388	-10306
VAC14	-9751	-7774
PIK3C3	-8170	-7865
INPP4A	-6949	-8897
MTMR2	-6094	-9336
PIK3C2A	-5604	-9519
INPP5F	-6267	-8385
PI4K2A	-7282	-6755
MTMR4	-4934	-8877
MTM1	-4584	-7808
PI4K2B	-4371	-7468

Click HERE to show all gene set members

All member genes

	KO	drug
FIG4	10135	-5525
INPP4A	-6949	-8897
INPP4B	7799	1151
INPP5F	-6267	-8385
MTM1	-4584	-7808
MTMR10	9939	-6395
MTMR12	-10618	-11138
MTMR2	-6094	-9336
MTMR4	-4934	-8877
PI4K2A	-7282	-6755
PI4K2B	-4371	-7468
PIK3C2A	-5604	-9519
PIK3C3	-8170	-7865
PIK3R4	9611	-9422
PIKFYVE	-10388	-10306
VAC14	-9751	-7774

---

---

Synthesis of PIPs at the late endosome membrane

Synthesis of PIPs at the late endosome membrane

metric	value
setSize	11
pMANOVA	0.000109
p.adjustMANOVA	0.000294
s.dist	0.771
s.KO	-0.383
s.drug	-0.67
p.KO	0.0278
p.drug	0.00012

Top 20 genes

Gene	KO	drug
PIKFYVE	-10388	-10306
MTMR9	-9350	-8112
VAC14	-9751	-7774
PIK3C3	-8170	-7865
MTMR2	-6094	-9336
PIK3C2A	-5604	-9519
MTMR4	-4934	-8877
MTM1	-4584	-7808

Click HERE to show all gene set members

All member genes

	KO	drug
FIG4	10135	-5525
MTM1	-4584	-7808
MTMR2	-6094	-9336
MTMR4	-4934	-8877
MTMR7	-5015	4886
MTMR9	-9350	-8112
PIK3C2A	-5604	-9519
PIK3C3	-8170	-7865
PIK3R4	9611	-9422
PIKFYVE	-10388	-10306
VAC14	-9751	-7774

---

---

HDMs demethylate histones

HDMs demethylate histones

metric	value
setSize	22
pMANOVA	1.14e-08
p.adjustMANOVA	7.46e-08
s.dist	0.771
s.KO	-0.358
s.drug	-0.683
p.KO	0.00361
p.drug	2.94e-08

Top 20 genes

Gene	KO	drug
KDM7A	-11295	-10173
KDM1B	-9446	-10808
KDM1A	-10032	-9331
KDM6A	-9651	-8938
KDM2A	-11020	-7679
KDM2B	-10344	-8038
KDM4B	-6893	-10083
KDM5C	-7030	-9378
PHF8	-8404	-7628
KDM3A	-9030	-6941
PHF2	-10182	-5776
JMJD6	-6552	-8458
KDM4C	-2464	-10800
KDM6B	-2868	-8061
KDM4D	-364	-5384

Click HERE to show all gene set members

All member genes

	KO	drug
ARID5B	686.0	-6056.0
H3C1	-1179.0	2773.0
H3C15	2532.5	7678.5
JMJD6	-6552.0	-8458.0
KDM1A	-10032.0	-9331.0
KDM1B	-9446.0	-10808.0
KDM2A	-11020.0	-7679.0
KDM2B	-10344.0	-8038.0
KDM3A	-9030.0	-6941.0
KDM3B	11164.0	-9930.0
KDM4A	9104.0	-8480.0
KDM4B	-6893.0	-10083.0
KDM4C	-2464.0	-10800.0
KDM4D	-364.0	-5384.0
KDM5A	7125.0	-10180.0
KDM5B	4544.0	-11091.0
KDM5C	-7030.0	-9378.0
KDM6A	-9651.0	-8938.0
KDM6B	-2868.0	-8061.0
KDM7A	-11295.0	-10173.0
PHF2	-10182.0	-5776.0
PHF8	-8404.0	-7628.0

---

---

Unwinding of DNA

Unwinding of DNA

metric	value
setSize	12
pMANOVA	5.5e-05
p.adjustMANOVA	0.00016
s.dist	0.77
s.KO	0.603
s.drug	0.479
p.KO	0.000299
p.drug	0.00402

Top 20 genes

Gene	KO	drug
MCM3	12292	11486
GINS2	11246	12341
MCM8	11436	11881
MCM5	11258	11775
CDC45	10231	12211
GINS3	9481	10673
GINS1	11040	5509
GINS4	11290	5284
MCM4	12194	780

Click HERE to show all gene set members

All member genes

	KO	drug
CDC45	10231	12211
GINS1	11040	5509
GINS2	11246	12341
GINS3	9481	10673
GINS4	11290	5284
MCM2	12294	-4587
MCM3	12292	11486
MCM4	12194	780
MCM5	11258	11775
MCM6	-9260	-5270
MCM7	-6963	9667
MCM8	11436	11881

---

---

Activation of RAC1

Activation of RAC1

metric	value
setSize	13
pMANOVA	2.04e-05
p.adjustMANOVA	6.47e-05
s.dist	0.77
s.KO	-0.34
s.drug	-0.69
p.KO	0.0336
p.drug	1.63e-05

Top 20 genes

Gene	KO	drug
PAK1	-11464	-9735
SLIT2	-11365	-9218
NCK1	-9577	-9993
SOS1	-7259	-9921
NCK2	-10111	-6626
PAK2	-6371	-10285
PAK4	-8948	-6862
ROBO1	-4716	-10678
RAC1	-7472	-3724

Click HERE to show all gene set members

All member genes

	KO	drug
NCK1	-9577	-9993
NCK2	-10111	-6626
PAK1	-11464	-9735
PAK2	-6371	-10285
PAK3	9899	-7417
PAK4	-8948	-6862
PAK5	10389	-4026
PAK6	1878	388
RAC1	-7472	-3724
ROBO1	-4716	-10678
SLIT2	-11365	-9218
SOS1	-7259	-9921
SOS2	9761	-9317

---

---

Selenocysteine synthesis

Selenocysteine synthesis

metric	value
setSize	91
pMANOVA	1.38e-38
p.adjustMANOVA	8.77e-37
s.dist	0.768
s.KO	-0.355
s.drug	0.681
p.KO	4.6e-09
p.drug	2.66e-29

Top 20 genes

Gene	KO	drug
RPL22L1	-10448	12221
RPL9	-9659	12806
RPS17	-10534	11631
RPL34	-9357	12996
RPL12	-9329	12992
RPL26L1	-9387	12770
RPS13	-9450	12652
RPS25	-9371	12690
RPL37A	-9347	12675
RPS18	-9122	12984
RPL17	-8989	12909
RPL31	-8781	13131
RPS6	-9225	12405
RPS15A	-8754	12989
RPL36	-8818	12868
FAU	-8610	13102
RPL26	-8797	12658
RPLP2	-8225	12999
RPL11	-8529	12382
RPL35	-8027	13097

Click HERE to show all gene set members

All member genes

	KO	drug
EEFSEC	11184	-3492
FAU	-8610	13102
PSTK	5756	9314
RPL10	-3821	1597
RPL10A	-9707	-8212
RPL11	-8529	12382
RPL12	-9329	12992
RPL13	-3469	12598
RPL13A	-6854	6955
RPL14	-6386	13137
RPL15	-786	12153
RPL17	-8989	12909
RPL18	-6672	12800
RPL18A	-6976	11926
RPL19	3924	12911
RPL21	-6322	5141
RPL22	-5554	9520
RPL22L1	-10448	12221
RPL23	5769	12922
RPL23A	11361	-5257
RPL24	-4591	12995
RPL26	-8797	12658
RPL26L1	-9387	12770
RPL27	6735	11625
RPL27A	-7818	13051
RPL28	-5809	12962
RPL29	-4515	12915
RPL3	-6827	-4535
RPL30	-3907	11096
RPL31	-8781	13131
RPL32	-5028	12983
RPL34	-9357	12996
RPL35	-8027	13097
RPL35A	-1449	12789
RPL36	-8818	12868
RPL36A	-4480	13009
RPL36AL	-8216	12702
RPL37	-4624	13134
RPL37A	-9347	12675
RPL38	1558	13140
RPL39	-6168	11962
RPL39L	-6608	-6269
RPL3L	-510	7904
RPL4	11351	12558
RPL41	-4616	-6074
RPL5	4679	12075
RPL6	-6903	12730
RPL7	-3327	-8789
RPL7A	-6163	11708
RPL8	-7572	10323
RPL9	-9659	12806
RPLP0	-1504	-7331
RPLP1	9026	12731
RPLP2	-8225	12999
RPS10	-8384	10665
RPS11	-7725	12935
RPS12	-7872	11600
RPS13	-9450	12652
RPS14	-1180	12428
RPS15	-7430	12908
RPS15A	-8754	12989
RPS16	-3844	12941
RPS17	-10534	11631
RPS18	-9122	12984
RPS19	-7633	12888
RPS2	-10222	8916
RPS20	-4961	13095
RPS21	-3001	13022
RPS23	6940	11907
RPS24	2369	13034
RPS25	-9371	12690
RPS26	-2615	13114
RPS27	651	11270
RPS27A	5357	6464
RPS27L	7330	12750
RPS28	2716	12485
RPS29	-652	9078
RPS3	-7756	12135
RPS3A	-9170	5257
RPS4X	-8542	12239
RPS5	-6283	-7965
RPS6	-9225	12405
RPS7	5142	12976
RPS8	-5812	12745
RPS9	-8815	10189
RPSA	292	11576
SARS1	10748	-9421
SECISBP2	11207	-6517
SEPHS2	8103	-351
SEPSECS	-6443	-5096
UBA52	-6807	11639

---

---

Cell-extracellular matrix interactions

Cell-extracellular matrix interactions

metric	value
setSize	16
pMANOVA	2.2e-06
p.adjustMANOVA	8.89e-06
s.dist	0.766
s.KO	-0.418
s.drug	-0.642
p.KO	0.00377
p.drug	8.63e-06

Top 20 genes

Gene	KO	drug
FLNC	-11176	-11224
FLNA	-11044	-11244
FERMT2	-9974	-11051
PARVB	-9605	-8758
PXN	-9307	-8111
LIMS1	-6324	-10598
VASP	-9209	-6573
ILK	-8271	-6696
ITGB1	-3655	-11215
LIMS2	-5134	-4517
PARVA	-2258	-6707

Click HERE to show all gene set members

All member genes

	KO	drug
ACTN1	8122	-10816
ARHGEF6	10171	-7583
FBLIM1	12771	-9890
FERMT2	-9974	-11051
FLNA	-11044	-11244
FLNC	-11176	-11224
ILK	-8271	-6696
ITGB1	-3655	-11215
LIMS1	-6324	-10598
LIMS2	-5134	-4517
PARVA	-2258	-6707
PARVB	-9605	-8758
PXN	-9307	-8111
RSU1	-5575	5754
TESK1	-10587	8733
VASP	-9209	-6573

---

---

MET activates PTK2 signaling

MET activates PTK2 signaling

metric	value
setSize	18
pMANOVA	6.8e-08
p.adjustMANOVA	3.72e-07
s.dist	0.765
s.KO	0.155
s.drug	-0.749
p.KO	0.256
p.drug	3.71e-08

Top 20 genes

Gene	KO	drug
LAMC1	12854	-11227
LAMB2	12607	-10832
LAMA5	12583	-10447
LAMA1	12802	-10091
ITGA3	12831	-9596
MET	10796	-11047
ITGA2	8062	-11213
LAMB3	7018	-11255
LAMC2	10786	-6533
LAMC3	11660	-2369

Click HERE to show all gene set members

All member genes

	KO	drug
HGF	-5157	-4177
ITGA2	8062	-11213
ITGA3	12831	-9596
ITGB1	-3655	-11215
LAMA1	12802	-10091
LAMA2	-8729	-4165
LAMA3	-11238	4464
LAMA4	-7403	-10348
LAMA5	12583	-10447
LAMB1	-9087	-10329
LAMB2	12607	-10832
LAMB3	7018	-11255
LAMC1	12854	-11227
LAMC2	10786	-6533
LAMC3	11660	-2369
MET	10796	-11047
PTK2	-9167	-10148
SRC	-11388	-7284

---

---

Signaling by PDGFRA extracellular domain mutants

Signaling by PDGFRA extracellular domain mutants

metric	value
setSize	12
pMANOVA	4.81e-05
p.adjustMANOVA	0.000141
s.dist	0.763
s.KO	-0.263
s.drug	-0.716
p.KO	0.114
p.drug	1.74e-05

Top 20 genes

Gene	KO	drug
PDGFRA	-11424	-11082
PIK3CB	-9217	-10250
STAT1	-8311	-10243
SOS1	-7259	-9921
GRB2	-6137	-10524
PIK3CA	-5426	-9599
PIK3R2	-6506	-5848
NRAS	-3309	-9724

Click HERE to show all gene set members

All member genes

	KO	drug
GRB2	-6137	-10524
HRAS	-8054	12320
KRAS	12719	-8619
NRAS	-3309	-9724
PDGFRA	-11424	-11082
PIK3CA	-5426	-9599
PIK3CB	-9217	-10250
PIK3R1	10169	-9568
PIK3R2	-6506	-5848
SOS1	-7259	-9921
STAT1	-8311	-10243
STAT3	12160	-10670

---

---

Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants

Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants

metric	value
setSize	12
pMANOVA	4.81e-05
p.adjustMANOVA	0.000141
s.dist	0.763
s.KO	-0.263
s.drug	-0.716
p.KO	0.114
p.drug	1.74e-05

Top 20 genes

Gene	KO	drug
PDGFRA	-11424	-11082
PIK3CB	-9217	-10250
STAT1	-8311	-10243
SOS1	-7259	-9921
GRB2	-6137	-10524
PIK3CA	-5426	-9599
PIK3R2	-6506	-5848
NRAS	-3309	-9724

Click HERE to show all gene set members

All member genes

	KO	drug
GRB2	-6137	-10524
HRAS	-8054	12320
KRAS	12719	-8619
NRAS	-3309	-9724
PDGFRA	-11424	-11082
PIK3CA	-5426	-9599
PIK3CB	-9217	-10250
PIK3R1	10169	-9568
PIK3R2	-6506	-5848
SOS1	-7259	-9921
STAT1	-8311	-10243
STAT3	12160	-10670

---

---

Beta-catenin phosphorylation cascade

Beta-catenin phosphorylation cascade

metric	value
setSize	17
pMANOVA	8.19e-07
p.adjustMANOVA	3.66e-06
s.dist	0.762
s.KO	-0.273
s.drug	-0.711
p.KO	0.0512
p.drug	3.79e-07

Top 20 genes

Gene	KO	drug
PPP2R5D	-11383	-11113
PPP2CB	-11374	-10028
CSNK1A1	-9043	-10837
AXIN1	-11360	-7258
AMER1	-7397	-8126
PPP2R5A	-4776	-9580
PPP2R1A	-9193	-4828
PPP2R5B	-8731	-4219
PPP2CA	-3124	-7225
FRAT2	-7878	-2844
PPP2R5E	-847	-10491

Click HERE to show all gene set members

All member genes

	KO	drug
AMER1	-7397	-8126
APC	7962	-10237
AXIN1	-11360	-7258
CSNK1A1	-9043	-10837
CTNNB1	12434	-11116
FRAT1	208	-2333
FRAT2	-7878	-2844
GSK3B	7016	-10755
PPP2CA	-3124	-7225
PPP2CB	-11374	-10028
PPP2R1A	-9193	-4828
PPP2R1B	6255	-5465
PPP2R5A	-4776	-9580
PPP2R5B	-8731	-4219
PPP2R5C	5890	-5302
PPP2R5D	-11383	-11113
PPP2R5E	-847	-10491

---

---

tRNA processing in the mitochondrion

tRNA processing in the mitochondrion

metric	value
setSize	20
pMANOVA	6.21e-08
p.adjustMANOVA	3.42e-07
s.dist	0.755
s.KO	0.16
s.drug	0.738
p.KO	0.216
p.drug	1.09e-08

Top 20 genes

Gene	KO	drug
MT-CO1	9067	13178
MT-ATP8	9404	12604
MT-CO2	8603	13180
MT-ATP6	8420	13018
MT-CO3	8245	13176
MT-ND3	6571	13181
MT-CYB	5991	13184
MT-ND1	5209	13177
MT-ND6	4676	13045
MT-ND5	4289	13012
HSD17B10	2620	11931
MT-ND4L	2132	13172
MT-ND4	566	13174

Click HERE to show all gene set members

All member genes

	KO	drug
ELAC2	-9745	-1209
HSD17B10	2620	11931
MT-ATP6	8420	13018
MT-ATP8	9404	12604
MT-CO1	9067	13178
MT-CO2	8603	13180
MT-CO3	8245	13176
MT-CYB	5991	13184
MT-ND1	5209	13177
MT-ND2	-1457	13183
MT-ND3	6571	13181
MT-ND4	566	13174
MT-ND4L	2132	13172
MT-ND5	4289	13012
MT-ND6	4676	13045
MT-RNR1	-5225	13169
MT-RNR2	-1383	13168
PRORP	-2649	-8367
TRMT10C	-106	3998
TRNT1	-2728	-3540

---

---

Response of EIF2AK4 (GCN2) to amino acid deficiency

Response of EIF2AK4 (GCN2) to amino acid deficiency

metric	value
setSize	99
pMANOVA	6.6e-41
p.adjustMANOVA	5.37e-39
s.dist	0.755
s.KO	-0.423
s.drug	0.625
p.KO	3.36e-13
p.drug	5.07e-27

Top 20 genes

Gene	KO	drug
ASNS	-10878	12349
RPL22L1	-10448	12221
RPL9	-9659	12806
RPS17	-10534	11631
RPL34	-9357	12996
RPL12	-9329	12992
RPL26L1	-9387	12770
RPS13	-9450	12652
RPS25	-9371	12690
RPL37A	-9347	12675
RPS18	-9122	12984
RPL17	-8989	12909
RPL31	-8781	13131
RPS6	-9225	12405
RPS15A	-8754	12989
RPL36	-8818	12868
FAU	-8610	13102
RPL26	-8797	12658
RPLP2	-8225	12999
RPL11	-8529	12382

Click HERE to show all gene set members

All member genes

	KO	drug
ASNS	-10878	12349
ATF2	-8942	-9289
ATF3	-4081	-4353
ATF4	-6768	11948
CEBPB	-7116	12656
CEBPG	-9940	6581
DDIT3	-9395	10987
EIF2AK4	10865	-7766
EIF2S1	-8950	-8774
EIF2S2	-10653	-6089
EIF2S3	-10174	-5022
FAU	-8610	13102
GCN1	10665	-8257
IMPACT	-1732	-8127
RPL10	-3821	1597
RPL10A	-9707	-8212
RPL11	-8529	12382
RPL12	-9329	12992
RPL13	-3469	12598
RPL13A	-6854	6955
RPL14	-6386	13137
RPL15	-786	12153
RPL17	-8989	12909
RPL18	-6672	12800
RPL18A	-6976	11926
RPL19	3924	12911
RPL21	-6322	5141
RPL22	-5554	9520
RPL22L1	-10448	12221
RPL23	5769	12922
RPL23A	11361	-5257
RPL24	-4591	12995
RPL26	-8797	12658
RPL26L1	-9387	12770
RPL27	6735	11625
RPL27A	-7818	13051
RPL28	-5809	12962
RPL29	-4515	12915
RPL3	-6827	-4535
RPL30	-3907	11096
RPL31	-8781	13131
RPL32	-5028	12983
RPL34	-9357	12996
RPL35	-8027	13097
RPL35A	-1449	12789
RPL36	-8818	12868
RPL36A	-4480	13009
RPL36AL	-8216	12702
RPL37	-4624	13134
RPL37A	-9347	12675
RPL38	1558	13140
RPL39	-6168	11962
RPL39L	-6608	-6269
RPL3L	-510	7904
RPL4	11351	12558
RPL41	-4616	-6074
RPL5	4679	12075
RPL6	-6903	12730
RPL7	-3327	-8789
RPL7A	-6163	11708
RPL8	-7572	10323
RPL9	-9659	12806
RPLP0	-1504	-7331
RPLP1	9026	12731
RPLP2	-8225	12999
RPS10	-8384	10665
RPS11	-7725	12935
RPS12	-7872	11600
RPS13	-9450	12652
RPS14	-1180	12428
RPS15	-7430	12908
RPS15A	-8754	12989
RPS16	-3844	12941
RPS17	-10534	11631
RPS18	-9122	12984
RPS19	-7633	12888
RPS2	-10222	8916
RPS20	-4961	13095
RPS21	-3001	13022
RPS23	6940	11907
RPS24	2369	13034
RPS25	-9371	12690
RPS26	-2615	13114
RPS27	651	11270
RPS27A	5357	6464
RPS27L	7330	12750
RPS28	2716	12485
RPS29	-652	9078
RPS3	-7756	12135
RPS3A	-9170	5257
RPS4X	-8542	12239
RPS5	-6283	-7965
RPS6	-9225	12405
RPS7	5142	12976
RPS8	-5812	12745
RPS9	-8815	10189
RPSA	292	11576
TRIB3	-3221	-5552
UBA52	-6807	11639

---

---

ERK/MAPK targets

ERK/MAPK targets

metric	value
setSize	22
pMANOVA	2.93e-08
p.adjustMANOVA	1.77e-07
s.dist	0.751
s.KO	-0.352
s.drug	-0.663
p.KO	0.00427
p.drug	7.08e-08

Top 20 genes

Gene	KO	drug
PPP2R5D	-11383	-11113
PPP2CB	-11374	-10028
MAPK1	-9173	-10906
MAPK3	-9742	-9271
RPS6KA3	-8355	-9502
RPS6KA2	-8378	-9101
MAPK14	-9586	-7538
RPS6KA5	-8869	-7063
VRK3	-8775	-7133
DUSP7	-4800	-10041
PPP2R1A	-9193	-4828
ELK1	-10880	-3893
MAPK7	-7980	-4568
MEF2C	-8056	-4261
MEF2A	-4972	-5692
PPP2CA	-3124	-7225

Click HERE to show all gene set members

All member genes

	KO	drug
DUSP3	11933	-9367
DUSP4	2520	-11183
DUSP6	10590	-5904
DUSP7	-4800	-10041
ELK1	-10880	-3893
MAPK1	-9173	-10906
MAPK11	10678	4248
MAPK14	-9586	-7538
MAPK3	-9742	-9271
MAPK7	-7980	-4568
MEF2A	-4972	-5692
MEF2C	-8056	-4261
PPP2CA	-3124	-7225
PPP2CB	-11374	-10028
PPP2R1A	-9193	-4828
PPP2R1B	6255	-5465
PPP2R5D	-11383	-11113
RPS6KA1	12818	-7761
RPS6KA2	-8378	-9101
RPS6KA3	-8355	-9502
RPS6KA5	-8869	-7063
VRK3	-8775	-7133

---

---

Non-integrin membrane-ECM interactions

Non-integrin membrane-ECM interactions

metric	value
setSize	41
pMANOVA	1.27e-16
p.adjustMANOVA	2.25e-15
s.dist	0.751
s.KO	0.2
s.drug	-0.724
p.KO	0.0268
p.drug	1e-15

Top 20 genes

Gene	KO	drug
LAMC1	12854	-11227
ITGB3	12688	-11286
PDGFB	12741	-11178
AGRN	12518	-11205
LAMB2	12607	-10832
LAMA5	12583	-10447
SDC4	12322	-10633
LAMA1	12802	-10091
PRKCA	12366	-10396
ITGB5	12503	-10104
ITGB4	12465	-8452
DDR1	12660	-8206
THBS1	12626	-7518
PDGFA	12623	-7408
ITGA2	8062	-11213
ACTN1	8122	-10816
SDC1	12230	-7104
SDC3	12401	-6760
LAMB3	7018	-11255
LAMC2	10786	-6533

Click HERE to show all gene set members

All member genes

	KO	drug
ACTN1	8122	-10816
AGRN	12518	-11205
CASK	-5732	-8641
DAG1	6148	-8573
DDR1	12660	-8206
DDR2	-9960	-7915
DMD	-237	910
FGF2	-5091	-5205
HSPG2	-9046	-9768
ITGA2	8062	-11213
ITGA6	-7384	-11184
ITGAV	144	-11011
ITGB1	-3655	-11215
ITGB3	12688	-11286
ITGB4	12465	-8452
ITGB5	12503	-10104
LAMA1	12802	-10091
LAMA2	-8729	-4165
LAMA3	-11238	4464
LAMA4	-7403	-10348
LAMA5	12583	-10447
LAMB1	-9087	-10329
LAMB2	12607	-10832
LAMB3	7018	-11255
LAMC1	12854	-11227
LAMC2	10786	-6533
LAMC3	11660	-2369
NRXN1	-7510	141
NTN4	-8804	-7703
PDGFA	12623	-7408
PDGFB	12741	-11178
PRKCA	12366	-10396
SDC1	12230	-7104
SDC2	-6754	-5737
SDC3	12401	-6760
SDC4	12322	-10633
TGFB1	-3526	-8816
THBS1	12626	-7518
TNC	-10537	-10838
TRAPPC4	-10355	-4660
TTR	-212	1928

---

---

Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)

Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)

metric	value
setSize	93
pMANOVA	6.86e-38
p.adjustMANOVA	4.02e-36
s.dist	0.749
s.KO	-0.424
s.drug	0.617
p.KO	1.55e-12
p.drug	6.83e-25

Top 20 genes

Gene	KO	drug
RPL22L1	-10448	12221
RPL9	-9659	12806
RPS17	-10534	11631
RPL34	-9357	12996
RPL12	-9329	12992
RPL26L1	-9387	12770
RPS13	-9450	12652
RPS25	-9371	12690
RPL37A	-9347	12675
RPS18	-9122	12984
RPL17	-8989	12909
RPL31	-8781	13131
RPS6	-9225	12405
RPS15A	-8754	12989
RPL36	-8818	12868
FAU	-8610	13102
RPL26	-8797	12658
RPLP2	-8225	12999
RPL11	-8529	12382
RPL35	-8027	13097

Click HERE to show all gene set members

All member genes

	KO	drug
EIF4G1	9159	-10287
ETF1	-5515	-9496
FAU	-8610	13102
GSPT1	-11018	-10260
GSPT2	-5509	-6727
NCBP1	-7784	-5234
NCBP2	-6378	-6281
PABPC1	-7033	-10406
RPL10	-3821	1597
RPL10A	-9707	-8212
RPL11	-8529	12382
RPL12	-9329	12992
RPL13	-3469	12598
RPL13A	-6854	6955
RPL14	-6386	13137
RPL15	-786	12153
RPL17	-8989	12909
RPL18	-6672	12800
RPL18A	-6976	11926
RPL19	3924	12911
RPL21	-6322	5141
RPL22	-5554	9520
RPL22L1	-10448	12221
RPL23	5769	12922
RPL23A	11361	-5257
RPL24	-4591	12995
RPL26	-8797	12658
RPL26L1	-9387	12770
RPL27	6735	11625
RPL27A	-7818	13051
RPL28	-5809	12962
RPL29	-4515	12915
RPL3	-6827	-4535
RPL30	-3907	11096
RPL31	-8781	13131
RPL32	-5028	12983
RPL34	-9357	12996
RPL35	-8027	13097
RPL35A	-1449	12789
RPL36	-8818	12868
RPL36A	-4480	13009
RPL36AL	-8216	12702
RPL37	-4624	13134
RPL37A	-9347	12675
RPL38	1558	13140
RPL39	-6168	11962
RPL39L	-6608	-6269
RPL3L	-510	7904
RPL4	11351	12558
RPL41	-4616	-6074
RPL5	4679	12075
RPL6	-6903	12730
RPL7	-3327	-8789
RPL7A	-6163	11708
RPL8	-7572	10323
RPL9	-9659	12806
RPLP0	-1504	-7331
RPLP1	9026	12731
RPLP2	-8225	12999
RPS10	-8384	10665
RPS11	-7725	12935
RPS12	-7872	11600
RPS13	-9450	12652
RPS14	-1180	12428
RPS15	-7430	12908
RPS15A	-8754	12989
RPS16	-3844	12941
RPS17	-10534	11631
RPS18	-9122	12984
RPS19	-7633	12888
RPS2	-10222	8916
RPS20	-4961	13095
RPS21	-3001	13022
RPS23	6940	11907
RPS24	2369	13034
RPS25	-9371	12690
RPS26	-2615	13114
RPS27	651	11270
RPS27A	5357	6464
RPS27L	7330	12750
RPS28	2716	12485
RPS29	-652	9078
RPS3	-7756	12135
RPS3A	-9170	5257
RPS4X	-8542	12239
RPS5	-6283	-7965
RPS6	-9225	12405
RPS7	5142	12976
RPS8	-5812	12745
RPS9	-8815	10189
RPSA	292	11576
UBA52	-6807	11639
UPF1	-10419	-10092

---

---

Complex I biogenesis

Complex I biogenesis

metric	value
setSize	57
pMANOVA	8.21e-22
p.adjustMANOVA	2.23e-20
s.dist	0.74
s.KO	-0.123
s.drug	0.729
p.KO	0.109
p.drug	1.49e-21

Top 20 genes

Gene	KO	drug
NDUFA6	-10640	12901
NDUFB10	-9687	12582
NDUFA8	-8774	12900
NDUFS3	-8653	12725
NDUFB9	-8544	12805
NDUFS8	-7989	12773
NDUFB6	-8238	12165
NDUFAB1	-10558	8746
NDUFV2	-6865	13148
NDUFC1	-7186	12437
NDUFAF4	-8760	9608
NDUFS5	-6394	13145
NDUFV3	-6779	12304
NDUFB11	-7090	11583
NDUFA1	-6222	13127
TMEM126B	-8036	9815
NDUFS6	-6327	12108
NDUFA5	-6593	11094
NDUFAF2	-5167	12574
ECSIT	-6333	10114

Click HERE to show all gene set members

All member genes

	KO	drug
ACAD9	12457	11377
COA1	11438	12298
ECSIT	-6333	10114
MT-ND1	5209	13177
MT-ND2	-1457	13183
MT-ND3	6571	13181
MT-ND4	566	13174
MT-ND5	4289	13012
MT-ND6	4676	13045
NDUFA1	-6222	13127
NDUFA10	-7241	-4285
NDUFA11	9807	12851
NDUFA12	6720	13048
NDUFA13	-4424	12971
NDUFA2	5937	13125
NDUFA3	-4508	13084
NDUFA5	-6593	11094
NDUFA6	-10640	12901
NDUFA7	8872	13143
NDUFA8	-8774	12900
NDUFA9	2605	10360
NDUFAB1	-10558	8746
NDUFAF1	2883	9463
NDUFAF2	-5167	12574
NDUFAF3	10175	13112
NDUFAF4	-8760	9608
NDUFAF5	-3460	9719
NDUFAF6	-5625	10508
NDUFAF7	6751	8883
NDUFB1	8092	13163
NDUFB10	-9687	12582
NDUFB11	-7090	11583
NDUFB2	11367	12511
NDUFB3	1661	12046
NDUFB4	8888	13008
NDUFB5	-3244	-5075
NDUFB6	-8238	12165
NDUFB7	-4205	12444
NDUFB8	8367	13039
NDUFB9	-8544	12805
NDUFC1	-7186	12437
NDUFC2	-5184	11409
NDUFS1	-9609	-7041
NDUFS2	3967	-10068
NDUFS3	-8653	12725
NDUFS4	6388	3949
NDUFS5	-6394	13145
NDUFS6	-6327	12108
NDUFS7	5531	12411
NDUFS8	-7989	12773
NDUFV1	-5404	8980
NDUFV2	-6865	13148
NDUFV3	-6779	12304
NUBPL	8039	-8010
TIMMDC1	9211	-3329
TMEM126B	-8036	9815
TMEM186	-8187	5086

---

---

Defective B4GALT7 causes EDS, progeroid type

Defective B4GALT7 causes EDS, progeroid type

metric	value
setSize	18
pMANOVA	1.1e-07
p.adjustMANOVA	5.83e-07
s.dist	0.739
s.KO	0.371
s.drug	-0.639
p.KO	0.00644
p.drug	2.71e-06

Top 20 genes

Gene	KO	drug
CSPG4	12459	-11273
AGRN	12518	-11205
SDC4	12322	-10633
GPC4	11190	-8942
SDC1	12230	-7104
SDC3	12401	-6760
B4GALT7	10562	-4980
BCAN	12079	-4013
GPC5	7673	-3135
BGN	11953	-1313
GPC1	1951	-7922
NCAN	3533	-1773
CSPG5	545	-3163

Click HERE to show all gene set members

All member genes

	KO	drug
AGRN	12518	-11205
B4GALT7	10562	-4980
BCAN	12079	-4013
BGN	11953	-1313
CSPG4	12459	-11273
CSPG5	545	-3163
GPC1	1951	-7922
GPC2	-3913	-3279
GPC4	11190	-8942
GPC5	7673	-3135
GPC6	-6095	-11229
HSPG2	-9046	-9768
NCAN	3533	-1773
SDC1	12230	-7104
SDC2	-6754	-5737
SDC3	12401	-6760
SDC4	12322	-10633
VCAN	-1861	-11263

---

---

Formation of the ternary complex, and subsequently, the 43S complex

Formation of the ternary complex, and subsequently, the 43S complex

metric	value
setSize	50
pMANOVA	7.28e-20
p.adjustMANOVA	1.67e-18
s.dist	0.731
s.KO	-0.501
s.drug	0.532
p.KO	8.83e-10
p.drug	7.23e-11

Top 20 genes

Gene	KO	drug
RPS17	-10534	11631
RPS13	-9450	12652
RPS25	-9371	12690
RPS18	-9122	12984
RPS6	-9225	12405
RPS15A	-8754	12989
FAU	-8610	13102
RPS4X	-8542	12239
RPS11	-7725	12935
EIF3C	-8843	11244
RPS19	-7633	12888
EIF3M	-10718	9044
EIF3I	-7897	12235
RPS15	-7430	12908
EIF3E	-9070	10545
RPS3	-7756	12135
RPS12	-7872	11600
RPS2	-10222	8916
RPS9	-8815	10189
RPS10	-8384	10665

Click HERE to show all gene set members

All member genes

	KO	drug
EIF1AX	-5479	11112
EIF2S1	-8950	-8774
EIF2S2	-10653	-6089
EIF2S3	-10174	-5022
EIF3A	-5233	-9195
EIF3B	-4779	-8277
EIF3C	-8843	11244
EIF3D	-10400	-7621
EIF3E	-9070	10545
EIF3F	-1343	-5879
EIF3G	-7655	4326
EIF3H	-8110	-1879
EIF3I	-7897	12235
EIF3J	-4825	-4367
EIF3K	-2668	9951
EIF3L	-9160	-8016
EIF3M	-10718	9044
FAU	-8610	13102
RPS10	-8384	10665
RPS11	-7725	12935
RPS12	-7872	11600
RPS13	-9450	12652
RPS14	-1180	12428
RPS15	-7430	12908
RPS15A	-8754	12989
RPS16	-3844	12941
RPS17	-10534	11631
RPS18	-9122	12984
RPS19	-7633	12888
RPS2	-10222	8916
RPS20	-4961	13095
RPS21	-3001	13022
RPS23	6940	11907
RPS24	2369	13034
RPS25	-9371	12690
RPS26	-2615	13114
RPS27	651	11270
RPS27A	5357	6464
RPS27L	7330	12750
RPS28	2716	12485
RPS29	-652	9078
RPS3	-7756	12135
RPS3A	-9170	5257
RPS4X	-8542	12239
RPS5	-6283	-7965
RPS6	-9225	12405
RPS7	5142	12976
RPS8	-5812	12745
RPS9	-8815	10189
RPSA	292	11576

---

---

Signaling by PDGFR in disease

Signaling by PDGFR in disease

metric	value
setSize	19
pMANOVA	5.53e-07
p.adjustMANOVA	2.59e-06
s.dist	0.726
s.KO	-0.198
s.drug	-0.698
p.KO	0.135
p.drug	1.36e-07

Top 20 genes

Gene	KO	drug
PDGFRA	-11424	-11082
PIK3CB	-9217	-10250
STAT1	-8311	-10243
SOS1	-7259	-9921
GRB2	-6137	-10524
PIK3CA	-5426	-9599
STRN	-4990	-10079
FIP1L1	-10927	-4497
WDR48	-6426	-7065
PIK3R2	-6506	-5848
NRAS	-3309	-9724
GOLGA4	-1644	-10261
KDR	-650	-4500

Click HERE to show all gene set members

All member genes

	KO	drug
ETV6	10751	-5574
FIP1L1	-10927	-4497
GOLGA4	-1644	-10261
GRB2	-6137	-10524
HRAS	-8054	12320
KANK1	11265	-8486
KDR	-650	-4500
KRAS	12719	-8619
NRAS	-3309	-9724
PDGFRA	-11424	-11082
PIK3CA	-5426	-9599
PIK3CB	-9217	-10250
PIK3R1	10169	-9568
PIK3R2	-6506	-5848
SOS1	-7259	-9921
STAT1	-8311	-10243
STAT3	12160	-10670
STRN	-4990	-10079
WDR48	-6426	-7065

---

---

MET promotes cell motility

MET promotes cell motility

metric	value
setSize	29
pMANOVA	1.04e-10
p.adjustMANOVA	1.03e-09
s.dist	0.725
s.KO	-0.011
s.drug	-0.725
p.KO	0.919
p.drug	1.37e-11

Top 20 genes

Gene	KO	drug
CRKL	-11456	-9981
CRK	-11328	-8779
LAMB1	-9087	-10329
PTK2	-9167	-10148
RAPGEF1	-9306	-9048
SRC	-11388	-7284
LAMA4	-7403	-10348
RAP1B	-8213	-8902
GRB2	-6137	-10524
GAB1	-6660	-8223
ITGB1	-3655	-11215
LAMA2	-8729	-4165
RAC1	-7472	-3724
HGF	-5157	-4177
RAP1A	-1904	-6372

Click HERE to show all gene set members

All member genes

	KO	drug
CRK	-11328	-8779
CRKL	-11456	-9981
DOCK7	10605	-10745
GAB1	-6660	-8223
GRB2	-6137	-10524
HGF	-5157	-4177
ITGA2	8062	-11213
ITGA3	12831	-9596
ITGB1	-3655	-11215
LAMA1	12802	-10091
LAMA2	-8729	-4165
LAMA3	-11238	4464
LAMA4	-7403	-10348
LAMA5	12583	-10447
LAMB1	-9087	-10329
LAMB2	12607	-10832
LAMB3	7018	-11255
LAMC1	12854	-11227
LAMC2	10786	-6533
LAMC3	11660	-2369
MET	10796	-11047
PTK2	-9167	-10148
RAC1	-7472	-3724
RAP1A	-1904	-6372
RAP1B	-8213	-8902
RAPGEF1	-9306	-9048
SRC	-11388	-7284
TNS3	11628	-8857
TNS4	9700	3510

---

---

Here is the session info with all the versions of packages used.

sessionInfo()

## R version 4.2.0 (2022-04-22)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 20.04.4 LTS
## 
## Matrix products: default
## BLAS:   /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.9.0
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.9.0
## 
## locale:
##  [1] LC_CTYPE=en_US.UTF-8       LC_NUMERIC=C              
##  [3] LC_TIME=en_US.UTF-8        LC_COLLATE=en_US.UTF-8    
##  [5] LC_MONETARY=en_US.UTF-8    LC_MESSAGES=en_US.UTF-8   
##  [7] LC_PAPER=en_US.UTF-8       LC_NAME=C                 
##  [9] LC_ADDRESS=C               LC_TELEPHONE=C            
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C       
## 
## attached base packages:
## [1] parallel  stats4    stats     graphics  grDevices utils     datasets 
## [8] methods   base     
## 
## other attached packages:
##  [1] pkgload_1.2.4               GGally_2.1.2               
##  [3] gtools_3.9.2                echarts4r_0.4.3            
##  [5] beeswarm_0.4.0              vioplot_0.3.7              
##  [7] sm_2.2-5.7                  kableExtra_1.3.4           
##  [9] topconfects_1.8.0           limma_3.48.3               
## [11] eulerr_6.1.1                mitch_1.4.1                
## [13] MASS_7.3-56                 fgsea_1.18.0               
## [15] gplots_3.1.1                DESeq2_1.32.0              
## [17] SummarizedExperiment_1.22.0 Biobase_2.52.0             
## [19] MatrixGenerics_1.4.3        matrixStats_0.61.0         
## [21] GenomicRanges_1.44.0        GenomeInfoDb_1.28.4        
## [23] IRanges_2.26.0              S4Vectors_0.30.2           
## [25] BiocGenerics_0.38.0         reshape2_1.4.4             
## [27] forcats_0.5.1               stringr_1.4.0              
## [29] dplyr_1.0.8                 purrr_0.3.4                
## [31] readr_2.1.2                 tidyr_1.2.0                
## [33] tibble_3.1.6                ggplot2_3.3.5              
## [35] tidyverse_1.3.1             zoo_1.8-9                  
## 
## loaded via a namespace (and not attached):
##   [1] readxl_1.3.1           backports_1.4.1        fastmatch_1.1-3       
##   [4] systemfonts_1.0.4      plyr_1.8.6             polylabelr_0.2.0      
##   [7] splines_4.2.0          BiocParallel_1.26.2    digest_0.6.29         
##  [10] htmltools_0.5.2        fansi_1.0.2            magrittr_2.0.2        
##  [13] memoise_2.0.1          tzdb_0.2.0             Biostrings_2.60.2     
##  [16] annotate_1.70.0        modelr_0.1.8           svglite_2.1.0         
##  [19] colorspace_2.0-3       blob_1.2.2             rvest_1.0.2           
##  [22] haven_2.4.3            xfun_0.30              crayon_1.5.0          
##  [25] RCurl_1.98-1.6         jsonlite_1.8.0         genefilter_1.74.1     
##  [28] survival_3.3-1         glue_1.6.2             polyclip_1.10-0       
##  [31] gtable_0.3.0           zlibbioc_1.38.0        XVector_0.32.0        
##  [34] webshot_0.5.2          DelayedArray_0.18.0    scales_1.1.1          
##  [37] DBI_1.1.2              Rcpp_1.0.8.2           viridisLite_0.4.0     
##  [40] xtable_1.8-4           bit_4.0.4              htmlwidgets_1.5.4     
##  [43] httr_1.4.2             RColorBrewer_1.1-2     ellipsis_0.3.2        
##  [46] farver_2.1.0           pkgconfig_2.0.3        reshape_0.8.8         
##  [49] XML_3.99-0.9           sass_0.4.0             dbplyr_2.1.1          
##  [52] locfit_1.5-9.5         utf8_1.2.2             labeling_0.4.2        
##  [55] tidyselect_1.1.2       rlang_1.0.2            later_1.3.0           
##  [58] AnnotationDbi_1.54.1   munsell_0.5.0          cellranger_1.1.0      
##  [61] tools_4.2.0            cachem_1.0.6           cli_3.2.0             
##  [64] generics_0.1.2         RSQLite_2.2.10         broom_0.7.12          
##  [67] evaluate_0.15          fastmap_1.1.0          yaml_2.3.5            
##  [70] knitr_1.37             bit64_4.0.5            fs_1.5.2              
##  [73] caTools_1.18.2         KEGGREST_1.32.0        mime_0.12             
##  [76] xml2_1.3.3             compiler_4.2.0         rstudioapi_0.13       
##  [79] png_0.1-7              reprex_2.0.1           geneplotter_1.70.0    
##  [82] bslib_0.3.1            stringi_1.7.6          highr_0.9             
##  [85] desc_1.4.1             lattice_0.20-45        Matrix_1.4-1          
##  [88] vctrs_0.3.8            pillar_1.7.0           lifecycle_1.0.1       
##  [91] jquerylib_0.1.4        data.table_1.14.2      bitops_1.0-7          
##  [94] httpuv_1.6.5           R6_2.5.1               promises_1.2.0.1      
##  [97] KernSmooth_2.23-20     gridExtra_2.3          assertthat_0.2.1      
## [100] rprojroot_2.0.2        withr_2.5.0            GenomeInfoDbData_1.2.6
## [103] hms_1.1.1              grid_4.2.0             rmarkdown_2.13        
## [106] shiny_1.7.1            lubridate_1.8.0

END of report